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Despite recent advances in oncology, metastatic disease remains the major cause of 
cancer-related death. The cascade of events involved in this process includes invasion of 
surrounding tissue, intravasation into the blood or lymph vasculature, survival in the 
circulation and extravasation and colonization of distant tissue. Each of these steps involves 
crosstalk between tumour cells and hematopoietic cells, including lymphocytes and different 
cell types of myeloid origin. Whereas most T cell subsets and NK cells contribute to tumour 
control, tumour-associated macrophages in most of the cases promote progression and 
metastasis. 
Using a model of spontaneous metastasis from resected, syngeneic tumours, I have 
investigated the impact of several cell types and interventions on formation and progression 
of metastasis. 
The first chapter describes that depleting tumour-associated macrophages with an inhibitor of 
colony stimulating factor 1 receptor (CSF1R) unexpectedly promotes metastasis. CSF1R 
blockade indirectly diminishes the number of circulating NK cells due to a paucity of myeloid 
cells that trans-present the survival factor IL-15 to NK cells. CSF1R blockade also abolishes 
the anti-metastatic effect of agonistic anti-CD40 therapy. 
The second chapter describes that combination of agonistic anti-CD40 antibodies with 
immune checkpoint blockade (anti-CTLA-4 plus anti-PD-1) did not further improve the 
anti-metastatic effect of anti-CD40. Monotherapy with agonistic anti-CD27 antibodies, which 
bypasses the CD70-signal provided by activated dendritic cells, did not impact on the 
development or progression of spontaneous metastasis.  
The third chapter shows that the tumour-derived, proinflammatory factor prostaglandin E2 
promotes metastasis. Our results suggest that prostaglandin E2 may be an interesting 
therapeutic target. 
Finally, I show in the fourth chapter that the adhesion molecule ALCAM contributes to 
development of metastasis as Alcam-/- mice develop less metastases than Alcam+/+ mice. 
The results presented in this dissertation provide further evidence for immune-mediated 





Trotz der jüngsten Fortschritte im Bereich der Onkologie stellen Metastasen weiterhin die 
Haupttodesursache für Krebskranke dar. In diesem Prozess kommt es zur folgenden Kette 
von Ereignissen: die Invasion der Krebszellen in umliegendes Gewebe, das Eindringen in 
Blut- oder Lymphgefässe, ihr Überleben im Kreislauf, Extravasation, und Kolonisation in 
entfernten Organen. Jeder dieser Schritte umfasst die Kommunikation zwischen Krebs- und 
hämatopoetischen Zellen, einschließlich der Lymphozyten und verschiedener Zellen 
myeloischen Ursprungs. Während die Mehrheit der Untergruppen von T-Zellen und NK-
Zellen zur Tumorkontrolle beitragen, unterstützen die Tumor-assoziierten Makrophagen die 
Krebsentwicklung und fördern Metastasen.  
Unter Verwendung eines nach Resektion von syngenen Tumoren entstehenden spontanen 
Metastasenmodels untersuchte ich die Wirkung mehrerer Zelltypen und Interventionen auf 
die Bildung und Progression der Metastasen. 
Im ersten Kapitel wird gezeigt, dass eine Verringerung der Tumor-assoziierten Makrophagen 
mithilfe eines Inhibitors des kolonienstimulierenden Faktor 1 Rezeptors (CSF1R) die 
Metastasenbildung unerwartet unterstützt. Das Blockieren von CSF1R vermindert indirekt die 
Anzahl der zirkulierenden NK-Zellen aufgrund des Mangels an myeloiden Zellen, die NK-
Zellen den Überlebensfaktor IL-15 trans-präsentieren. Das Blockieren von CSF1R hebt 
ausserdem die anti-metastatische Wirkung der agonistischen anti-CD40 Therapie auf.  
Das zweite Kapitel thematisiert, dass die Kombination agonistischer anti-CD40 Antikörper 
mit Immun-Checkpoint Blockade (anti-CTLA-4 plus anti-PD-1 Antikörper) die anti-
metastatische Wirkung nicht verbessert. Die Monotherapie mit agonistischen Antikörpern 
anti-CD27, welche das von aktivierten dendritischen Zellen zugelieferte Signal CD70 
umgeht, beeinflusste die Entwicklung oder das Fortschreiten der spontanen Metastasen nicht. 
Das dritte Kapitel zeigt, dass der tumorassoziierte proentzündliche Faktor Prostaglandin E2 
Metastasen fördert. Unsere Ergebnisse weisen darauf hin, dass Prostaglandin E2 ein 
interessantes therapeutisches Ziel sein könnte. 
Abschliessend zeige ich im vierten Kapitel, dass das Adhäsionsmolekül ALCAM zur 
Entwicklung der Metastasen beiträgt, da Alcam-/- Mäuse weniger Metastasen bilden als 
Alcam+/+ Mäuse. 
Die in dieser Dissertation präsentierten Ergebnisse liefern weitere Hinweise für die 
immunvermittelte Kontrolle von Metastasen und können zur Entwicklung neuer 
Krebstherapien beitragen. 	  
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1.1 Current view on cancer 
Advances in health care vastly increased life expectancy, leaving cancer as one of the main 
threats. In 2012 approximately 14 million new cases have been diagnosed worldwide and this 
statistic is expected to increase over the next decades (1). The number of cancer-related 
mortalities reached 8.2 million, the majority of which were due to metastatic disease (1-3). 
The most common cancer types in women are breast, colorectal, lung, cervix and stomach, 
whereas in men lung, prostate, colorectal, stomach and liver (1, 4). All these cancers are 
prone to form secondary lesions, e.g. bone and lung metastases, some of which can develop 
without symptoms for prolonged time (5, 6). 
Cancer covers a vast spectrum of diseases that lead to dysplastic changes that can arise in 
almost every organ. More than 100 distinct types of this disease have been recognized (7), but 
all share the common trait of uncontrolled cell proliferation. This is caused by accumulation 
of mutations in the genomic and mitochondrial DNA (8-10), leading to deregulation of cell 
death signalling pathways, cell metabolism and elevated expression of normal and mutated, 
constantly active growth factor receptors (7, 11-14). Although uncontrolled proliferation 
characterizes as well benign tumours, malignant cancers in addition can infiltrate adjacent 
tissue (15).  
Solid tumours are composed of cancer cells and stroma, which consists of recruited 
mesenchymal and immune cells of host origin, collectively known as the tumour 
microenvironment. The tumour microenvironment often changes with disease progression 
(16) and contains adipocytes, epithelial cells, fibroblasts, pericytes and endothelial cells as 
well as various immune cells.  Each of these cells types can be further divided into subsets 
playing differential role in cancer development - both restraining the growth of transformed 
cells, as well as supporting tumours by maintenance of nutrient and oxygen supply, 
production of growth factors, removal of the toxic metabolites and protection from 
immunosurveillance (10, 17). 
1.2 The immune system 
The immune system evolved to protect the host against pathogens. Consequently, 
pathogen-associated molecular patterns (PAMPs) and inflammation are essential cues for 
activation of the immune system. 
The immune system can be divided into two complementary branches – the innate and 
	 2 
adaptive part – both of which are involved and collaborate in the defence against pathogens.  
 
 
Figure 1. Components of the innate and adaptive immune system. The innate immune 
system consists of multiple leukocyte populations as well as complement and anti-microbial 
proteins and peptides. Adaptive immunity consists of T cells and B cells, the latter produce 
antibodies. NKT cells, γδ T cells and innate lymphoid cells (ILCs) are on the crossroad 
between the adaptive and innate parts of the immune system.	(Figure adapted from: 18) 
1.2.1 Innate immunity 
The innate branch of immune system is evolutionary more ancient than the adaptive part and 
recognises patterns rather that single epitopes (19, 20). The activation of innate immunity 
forms an immediate defence against pathogens and in addition, paves the way for adaptive 
response (21-23). Epithelial cells but also innate leukocytes such as granulocytes (neutrophils, 
basophils, eosinophils), mast cells, natural killer (NK) cells, macrophages and dendritic cells 
(DCs) mediate innate responses and there is an inherent overlap and, to some degree, 
redundancy between the reactions mediated by these cells.  
The main functions of innate immunity include: 
- Forming a barrier for pathogens to physically block them from penetrating the tissue; 
- Activation of the complement cascade, leading to opsonization and lysis of the 
targets; 
- Killing pathogens though secretion of cytotoxic peptides and proteins; 
- Removal of pathogens by phagocytosis; 
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- Killing own infected cells by induction of apoptosis; 
- Attraction of leukocytes of both innate and adaptive immunity; 
- Activation of the adaptive immune system by antigen presentation and cytokine 
production; 
- Control of the inflammation by secretion of immune-dampening mediators. 
Innate lymphoid cells (ILCs), NK T cells and γδ T cells are on the crossroad between innate 
and adaptive immunity. ILCs belong to the lymphoid lineage of leukocytes, but they lack T 
and B cell receptors (TCR and BCR) and can act in a similar way to both T helper cells and 
NK cells (24-26). The TCR of γδ T cells is generally not specific for antigen-MHC 
complexes, but instead enables recognition of PAMPs (27). In a similar manner, the TCR of 
NK T cells is restricted to a set of lipid antigens, albeit they share many other properties with 
NK cells (28). 
1.2.2 Adaptive immunity 
Usually, the innate response is followed by the adaptive immune response, which consists of 
B and T lymphocytes. Both cell types require binding of a unique cognate antigen to the B 
and T cell receptor (BCR and TCR), respectively. T cells can be divided into CD8+ and CD4+ 
subsets. CD8+ T cells recognise antigens loaded onto major histocompatibility complex 
(MHC) class I. MHC class I is expressed by virtually every nucleated cell in the mammalian 
body and the sensed antigens are peptides derived from cytoplasmic proteins that are 
degraded by the proteasome (29). In addition, exogenous proteins can be presented on MHC 
class I molecules of a population of DCs (30). This enables elimination of transformed cells 
by cytotoxic CD8+ T cell (31, 32). 
The CD4+ T cell TCR recognises peptides presented in the context of MHC class II by 
antigen presenting cells (APCs) and mediate multiple functions depending on their 
polarization (33). On the one hand CD4+ T cells can acquire a cytotoxic phenotype, but on the 
other hand they can differentiate into T regulatory (Treg) or T helper (Th) cells (33). The 
latter were initially denominated as: Th1 (producing IFN-γ and TNF), Th2 (producing IL-4, 
IL-5 and IL-13), Th3 (producing TGF-β) and Th17 (producing IL-17, IL-22) (33-35), but in 
vivo studies unveiled significant plasticity among different Th subsets (33). CD4+ T cells are 
important for producing cytokines crucial to sustaining B as well as CD8+ T cell responses, 
but can also limit the inflammatory reaction (33, 36). CD4+ T cells provide also anti-apoptotic 
signalling and increase the priming capabilities APCs through CD40/CD40L interaction (37, 
38). 
B cells produce a broad spectrum of antibodies that can opsonize the pathogen, initiate the 
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complement cascade or activate effector cells in a process of antibody-dependent 
cell-mediated cytotoxicity (ADCC). B cells produce also cytokines and express MHC class II, 
and thus can serve as APCs (39, 40). 
Finally, adaptive immune system mediates the memory responses. Upon recognition of a 
previously encountered antigen, T and B cells usually mount a faster and stronger response, 
which results in more efficient control of the pathogen (18). 
 1.3 Immune-mediated cancer control 
The immune system can control transformed cells (10, 41) and a link between leukocytes and 
tumour rejection has been made already in the 1940’s (42). 
The importance of the immune system is emphasized by increased incidence of mainly 
virus- and UV-induced cancers in immunosuppressed individuals, for example in organ 
transplant recipients and AIDS patients (10, 41, 43, 44).  
Evading immune control is a crucial step in cancer progression and transformed cells 
developed multiple mechanisms to escape the control of immune system. This is achieved on 
the one hand by avoiding recognition by immune system and on the other by 
tumour-promoting functions of the tumour stroma. 
1.3.1 NK cell-mediated tumour control 
NK cells are evolutionary conserved cytotoxic lymphocytes. They express effector molecules 
including perforin, granzyme, TNF-related apoptosis-inducing ligand (TRAIL) and FasL (45) 
and IFN-γ (46, 47). Unlike CD8+ T cells, their response does not depend on antigen 
presentation in the context of MHC class I, but rather on a fine balance between inhibitory 
and activating receptors. For example, NK cells are functionally inhibited by binding of killer 
cell immunoglobulin (Ig)-like receptors (KIRs) in humans and Ly49 in mice to MHC class I 
on target cells (47, 48). NK cells express also CD94, which recognises HLA-E in humans and 
Qa1 in mice. Upon forming a heterodimer with NKG2A, CD94 dampens NK cell activation 
(48, 49). 
Nevertheless, loss of inhibitory ligands by target cells is not sufficient to stimulate NK cell 
function, and this requires additional signalling through activating receptors (50). For 
example, CD94 can also signal through NKG2C, triggering NK cell stimulation (47, 48). 
NKG2C belongs, together with NKG2D, to a C-type lectin-like receptor family, which is 
expressed as well by other cells of immune system (51). It is binding to a broad spectrum of 
ligands, all of which share structural homology with MHC class I proteins. In humans these 
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are MHC class I polypeptide-related sequence A (MIC-A), MIC-B and a group of retinoic 
acid early transcript 1 proteins (Raet-1) (48, 52). In mice it can bind to members of the 
retinoic acid early inducible-1 (Rae-1) protein family, minor histocompatibility antigen H60 
and murine UL16-binding protein like transcript-1 (MULT-1) (48, 52). Ligands for NKG2D 
are expressed upon transformation or in stress conditions (52, 53). Furthermore, also 
genotoxic stress and activation of DNA damage checkpoint pathway drives upregulation of 
NKG2D ligands, an observation especially relevant in context of genetic instability of tumour 
cells (54). Cancer cells can counteract this mechanism by shedding NKG2D ligands. This has 
been shown in cancer patients, where elevated serum levels of MIC-A and MIC-B can serve 
as diagnostic markers for cancer progression (52). Shedding ligands not only renders tumour 
cells invisible to NK cells, it can also block activation of bystander NK cells, as constant 
stimulation with ligands leads to downregulation of the NKG2D (52). 
Another family of activating receptors belong to the NKp family and include NKp30, NKp44, 
NKp46, NKp80 (48, 55). There is a wide array of NKp ligands, including those encoded by 
viral genes and upregulation of NKp44 has been observed in NK cells infiltrating human 
non-small lung cancer (56). 
A third type of activating receptors is the family signalling lymphocyte activating molecule 
(SLAM)-related receptors. This group includes CD226 (also known as DNAM1 or DNAX), 
which, similarly to NKG2D, is shared between NK cells as well as subset of CD8+ T cells and 
myeloid cells (48, 50, 57). CD226 binds nectins and nectin-like molecules, like CD112 and 
CD155, which expression is induced by cellular stress, including DNA damage. Importantly, 
these ligands were found to be overexpressed in tumour cells derived from various cancers, 
including neuroblastoma and myeloma, where it was directly correlated with their 
susceptibility to NK cell attack (50, 57, 58).  CD226-mediated activation of NK cells requires 
co-activation with another member of this family, the CD224 (2B4). Similar synergism was 
found to be necessary for NKG2D as well as NKp46 (55).  
CD155 is a shared ligand with T cell immunoglobulin and immunoreceptor tyrosine-based 
inhibitory motif domain (TIGIT) and CD96, two inhibitory receptors expressed on both T and 
NK cells  (59). Moreover, TIGIT has also additional ligands and the list of receptors 
controlling NK cell function is expanding, including also other members of the nectin and 
nectin-like protein receptors e.g. class I restricted T cell–associated molecule (CRTAM) (59) 
or CD85j (60).  
NK cells, as well as T cells and subsets of other innate cells express also leukocyte-associated 
immunoglobulin-like receptor 1 (LAIR-1). LAIR-1 binds to collagens and inhibits 
inflammatory response (61, 62). Some tumour cells hijack this mechanism and overexpress 
collagens, in both secreted and membrane-bound form, what is associated with increased 
metastatic potential (61, 62). Collagen can be also deposited in the tumours by 
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tumour-associated fibroblasts, further emphasizing the multifaceted role of stromal cells (63). 
Aside from the canonical activating receptors, in order to recognise tumour cells, NK cells, as 
wells as CD8+ T cells, require the adhesion molecule CD2 (64, 65). The ligand of CD2 is 
CD58, a member of the immunoglobulin superfamily. Tumour cells frequently downregulate 
CD58, which in context of concomitant loss of MHC class I expression, renders them 
insensitive to both cytotoxic T cell and NK cell surveillance (64). 
Finally, NK cells, as well as various myeloid cells, can bind the constant region (Fc) of IgG 
antibodies through CD16 (FcγRIII), which enables antibody-dependent cellular cytotoxicity 
(ADCC) (48, 60, 66). 
Many of the receptors and mechanisms mentioned above are shared between NK and CD8+ T 
cells as well as other subsets of leukocytes.  
Overall, NK cell interaction with other cells can be assigned into four schemes (48):  
a) Ligation of both activating and inhibitory receptors with a healthy cell does not lead 
to lysis; 
b) Tumour cell loses inhibitory receptors, like MHC class I, and as NK cell is being 
stimulated through activating receptors, tumour cell is lysed (“missing self”); 
c) Stress or cellular damage induces stress ligands on a tumour cell, thus overcomes the 
inhibitory signal and NK cell lyses the target cell (“induced self-ligands”); 
d) Tumour-specific antibodies are bound to CD16 on NK cell and NK cells can 






Figure 2. NK cells activity depends on a balance of activating and inhibiting signals. (A) 
NK cell interaction with healthy cell. (B) Tumour cells downregulate MHC class I thus 
cannot provide inhibitory signal. (C) Tumour cells upregulate stress ligands and activate NK 
cell. (D) NK cells kill tumour cell through ADCC. (Figure from: 48) 
 
The abovementioned schedule holds true in the context of homeostasis and an immune 
response against invading pathogens, whereas the situation in the context of cancer is more 
complex. Tumour-infiltrating NK cells are often dysfunctional and enriched in the immature, 
CD56+ CD16- (human) or CD27+ CD11b- (mouse) population, produce less IFN-γ and TNF-α 
and have lower cytolytic potential (56, 60, 67). They also express lower amounts of activating 
receptors NKp30, NKG2D, CD226 as well as CD16, but higher levels of inhibitory NKG2A 
(60, 67).  
NK cell-dysfunction can be partially explained by the effect of tumour-derived prostaglandin 
E2 (PGE2), adenosine, indoleamine 2,3-dioxygenase (IDO), soluble ligand of FAS or 
transforming growth factor TGF-β. Especially the latter is a potent mediator of NK cell 
tolerance (31, 48, 52). TGF-β, PGE2, IDO1 as well as ADAM17, a metalloproteinase 
involved in shedding NKG2D ligands, are overexpressed in human breast cancer (60). PGE2 
inhibits as well CD8+ T cells, but promotes activity of CD4+ Foxp3+ T regulatory cells 
(Tregs) (68). Finally, many tumour-associated immune cells can inhibit the function of NK 
cells (48, 69).  
NK cells survival depends on sustained Jak1/Jak3 and STAT5α/β signalling through 
CD122/common gamma chain (γc/CD132/IL-2Rγ) complex, also called IL-15Rβ/γ (70). 
However, IL-15 binds with a 100-fold higher activity to the trimer of IL-15Rα, IL-15Rβ and γ 
subunits. Macrophages and monocytes, but also fibroblastic and epithelial cell lines, broadly 
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express IL-15Rα, but their homeostasis is not dependent on IL-15. It has been thus suggested 
that IL-15Rα acts as a chaperone, increasing IL-15 half-life and enabling its 
trans-presentation to NK cells (70-73). IL-15 acts also like a chemoattractant for NK cells and 
stimulates their adhesion to vascular endothelium (74). IL-15 is also important for formation 
of memory CD8+ T cells (71). Preclinical studies show that IL-15 overexpression by tumour 
cells supports NK cell function as well NK cell-mediated tumour control (75). 
Tumour-derived factors, like TGF-β, PGE2 or adenosine can also affect the expression of 
IL-15R on NK cells (48).  
1.3.2 CD8+ T cell-mediated tumour control 
CD8+ T cells can eliminate cancer cells in a MHC class I-restricted response (31). Several 
studies have correlated high density of CD8+ T cells infiltrating cancer lesions with beneficial 
prognosis in various cancer types, including breast, ovarian, colon and oesophageal cancer as 
well as malignant melanoma (31, 32). The same has been observed for cancers of viral 
etiology, where virus-derived peptides were presented as neo-antigens (76). Analogously, 
antigenic proteins may result from genetic mutations, potentially expanding the concept of 
neo-antigens to all tumours (76, 77). Moreover, during the complex process of 
dedifferentiation and acquisition of stem cell-like features, including epithelial to 
mesenchymal transition (EMT), tumour cells start expressing proteins and peptides which are 
in normal circumstances absent in the tissue, like cancer/testis antigens (44, 78). The 
mutational load directly correlates with the activity of cytolytic pathways (44), but T cell 
reactivity can be detected also against non-mutated antigens (76). 
Tumour cells counteract recognition by CD8+ T cells by downregulating the expression of 
MHC class I, which could explains the heterogeneous expression of MHC class I often 
observed in patients (29). MHC class I expression can be lost as a result of different 
mechanisms, including mutations in the proteasome (29, 44) or the genes coding the MHC 
class I loading complex (29, 44, 79).  
1.3.3 Role of CD4+ T cells in tumour progression 
The role of tumour-infiltrating CD4+ T cells is more ambiguous. They can perform cytotoxic 
functions upon recognition of an antigen in the context of MHC class II, as was shown in 
patients (76, 80). Furthermore, they can support CD8+ T cell responses by secretion of type I 
cytokines (80). 
However, the immunosuppressive tumour environment affects the pool of antigen presenting 
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cells in tumour lesion and tumour-draining lymph nodes, thus preventing CD4+ T cell 
activation. Tumours affect maturation of lymph node DCs, as depicted by lower levels of 
MHC class II, CD40, CD83 and costimulatory molecules CD80 and CD86 (60, 81). It can be 
caused by elevated levels of tumour-derived IL-10 (81). Furthermore, vascular endothelial 
growth factor (VEGF) produced by tumour cells and tumour-associated macrophages (TAMs) 
stimulates formation of lymphatic vessels, disrupting the regular lymph flow, lymph node 
architecture and in the end DC migration (81). Moreover, the numerous population of MHC 
class II+ TAMs is not inducing CD4+ T cell responses due to poor antigen presentation 
capabilities (21).  
The same conditions disrupt the activation of CD8+ T cells rendering them anergic, but in 
addition the immunomodulatory tumour microenvironment skews CD4+ T cells polarization 
into a regulatory phenotype (35, 60, 81, 82). Tregs are generally characterised by expression 
of high affinity IL-2 receptor α chain (IL-2Rα) and the fork-head transcription factor (Foxp3) 
(35). Their function has been described as immunosuppressive to both CD8+ and cytotoxic 
CD4+ T cells (17, 35, 83). Their presence correlates with weak anti-tumour immune response 
and low infiltration by CD8+ T cells (35). In preclinical studies, selective Treg depletion was 
shown to be sufficient to increase CD8+ T cell density in the tumour stroma (84). 
TAMs attract Tregs through CCL-22 production, but their polarization is also induced by 
TGF-β and PD1/PDL1 interaction (35, 69, 82, 85). Furthermore, TGF-β is a potent induced of 
Treg proliferation (35). Numbers of Tregs in the lymph nodes of cancer patients normalize 
after tumour dissection, underlining the importance of the tumour microenvironment in the 
Treg differentiation (83). 
Nevertheless, it should be noted that in contrast to murine, human FoxP3+ CD4+ T cells can 
be subdivided into immunosuppressive, so bona fide Treg population, as well as another, 
non-immunosuppressive population characterised by low expression of CD45RA marker. 
This can explain discrepancy between different studies in colorectal cancer, which have 
shown inconsistent correlations of Treg infiltration and cancer prognosis (82). 
Furthermore, there are other populations of regulatory CD4+ T cells, like type I T regulatory 
cells coexpressing CD49b and LAG-3 and producing high levels of IL-10 and TGF-β (35, 
86). They have been involved in maintenance of peripheral tolerance (86) and are present in 
some tumour types (35), but their role in tumour development has not been fully delineated. 
1.3.4 Tumour associated macrophages 
Chronic inflammation has been recognised as one of the hallmarks of cancer and is relevant 
during all the stages of cancer progression (10). In majority of tumour types, macrophages 
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constitute the main cell type of immune infiltrate and their presence correlates with poor 
outcome of cancer patients (87-89). However, due to the plethora of macrophage-derived 
interleukins, interferons, growth factors, scavenger receptors and chemoattractant mediators, 
it would be an oversimplification to assign all tumour-infiltrating macrophages into a single 
pro- or antitumorigenic role. 
Macrophages are tissue-resident phagocytes and are important in sustaining tissue 
homeostasis, wound healing and clearance of infections (88). During wound healing, 
tissue-resident and monocyte-derived macrophages play a unique role in tissue regeneration. 
As exemplified by skin repair, in the early phases of injury macrophages stimulate 
inflammatory response, contribute to infection control and stimulate formation of 
extracellular matrix and connective tissue, which is necessary for wound contraction. They 
produce high levels of VEGF-A, contributing to rebuilding of blood vasculature. In the later 
stages their phenotype is changing towards more regulatory one. They limit neutrophil 
activity through TGF-β production, what is necessary for prevention of tissue damage 
induced by neutrophil-derived proteases. TGF-β also supports homeostasis of endothelial 
cells and stimulates differentiation of myofibroblasts (90-92). This shows the plasticity of 
macrophages in various conditions and points that much of the protumorigenic phenotype of 
tumour associated macrophages (TAMs) might be mirroring the function during wound 
healing, referring to the description of cancer as a “wound that never heals” (92). 
Tumours actively stimulate TAMs infiltration, from triggering production of monocytes in the 
bone marrow to their attraction to the tumour lesion (93).  This is achieved by secretion of 
cytokines, like granulocyte- and granulocyte-macrophage-colony stimulating factor (G-CSF 
and GM-CSF) by the tumour cells themselves (99, 100). These upregulate 
retinoic-acid-related orphan receptor 1 (RORC1) signalling in the bone marrow stem cells, 
promoting positive (like e.g. C/EBPb) and suppressing negative regulators of myeloid 
differentiation (like Socs3 and Bcl3). Furthermore, it imprints the commitment to the 
monocyte lineage by triggering IRF8 and PU.1 transcription factors (90, 93, 94). Such CCR2+ 
monocytes migrate towards tumour-derived chemokine gradient, where they differentiate into 
TAMs by downregulating Ly6C and upregulating F4/80 surface markers (95-98). Tumours 
sustain macrophage differentiation and survival by production of macrophage colony 
stimulating factor (M-CSF, CSF1) (90, 93, 96). 
In vitro experiments with bone marrow-derived cells have shown that depending on the 
stimulus, macrophages represent phenotype that can be positioned on a continuum from 
proficient producers of effector molecules (so-called M1, “classically activated”) to a more 
regulatory, immune-dampening phenotype (M2, “alternatively activated” macrophages). The 
classically activated macrophages were initially shown to produce high amounts of IL-12, 
IL-1β, IL-6, TNF, as well as IL-23, ROS and NOs. On the contrary, alternatively activated 
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macrophages are meant to produce high level of potent immunosuppressant IL-10 and low 
IL-12 (99, 100). 
Experiments in murine models show that TAMs express a mixed set of markers characteristic 
for both classically and alternative-activated macrophages. This includes on the one hand 
MHC class II, nitric oxide synthase 2 (NOS2) and inflammatory chemokines, like chemokine 
(C-C motif) ligand 2 (CCL2), CCL5 or interferon-inducible chemokines (C-X-C motif) ligand 
9 (CXCL9), CXCL16 and CXCL10. On the other they express M2 markers like IL-10, 
β-glucan receptor dectin-1 and a galactose-type C-type lectin MGL1 (95). Others have shown 
that TAMs have phenotype of inflammatory CCR-2+ Ly6C+ monocytes that upregulated 
arginase I and mannose receptor CD206 in a TGF-β-dependent manner (97). This stands in 
opposition to the dichotomy proposed earlier between M1 and M2 populations (99). 
Further studies have shown that TAMs can be divided into two transcriptionally distinct 
populations based on their MHC class II expression (21, 101) and further separated based on 
their Ly6C levels (21). Proportions between these subsets change during tumour progression, 
closely mirroring wound-healing and suggesting differential roles during the disease 
progression (21). 
In breast cancer patients, TAMs form clusters in avascular nests of the tumour stroma (89). 
However, studies in murine models shown that TAMs penetrate both normoxic and hypoxic 
areas, albeit in both conditions they exhibit distinct phenotypes - MHC class IIlow TAMs in 
the hypoxic nests produce more VEGF-A than the MHC class IIhigh TAMs in the normoxic 
parts of tumours (21). Formation of new blood vessels is a crucial process in the 
carcinogenesis as it enables overcoming the limited access to oxygen and nutrients and is 
referred as an “angiogenic switch” (10, 89). In addition to production of VEGF-A, TAMs 
produce matrix metalloproteinase 9 (MMP9), which further releases VEGF bound to the 
extracellular matrix (102). Others have shown have that the pro-angiogenic TAMs express as 
well CD13+, a cell membrane-bound protease (103).  
Tumour cells can directly drive TAMs polarization to stimulate neoangiogenesis. Hypoxic 
tumours switch their metabolism towards anaerobic glycolysis, which leads to accumulation 
of lactic acid as a by-product. Lactic acid alone is sufficient to trigger hypoxia inducible 
factor 1α (HIF1α) in TAMs, what orchestrates their polarization and results in VEGF-A 
expression (104). The same is achieved by tumour-derived exosomes (24, 90).  
Furthermore, TAMs produce as well VEGF-C, a crucial molecule for remodelling of 
lymphatic vasculature (85, 105). This has profound implications in the disease progression to 
metastasis  
As in the wound healing process, tumour growth is associated with tissue remodelling. TAMs 
express lysyl oxidase as well as MMP2, MMP7 and above-mentioned MMP9. Cleaving 
extracellular matrix releases growth factors, e.g. heparin-binding epidermal growth factor 
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(HB-EGF), what supports tumour progression and metastasis (90, 98). In addition, growth 
factors provided by TAMs might help tumour cells to escape apoptosis-signalling induced by 
anti-cancer therapy (106). 
TAMs can also complement immune evasion through inhibition of immune reaction by 
suppressing the proliferation and function of T cells (21, 97, 107, 108). This is partially due to 
the effect of macrophage-derived ROS and NOs. Elevated NOs levels in the tumour 
microenvironment can directly nitrate TCRs, preventing antigen recognition by T cells (107). 
Furthermore, TAMs overexpress arginase I, an enzyme processing arginine, as well as IDO, 
which metabolises tryptophan. Both arginine and tryptophan are necessary for sustained T 
cell responses (81, 108). Furthermore, products of arginine cleavage can directly stimulate 
proliferation of tumour cells (21, 100, 109). Expression of arginase I in TAMs is induced by 
TGF-β and tumour-derived prostaglandins, e.g. PGE2 (109). 
TAMs affect T cells also by exposition of programmed death ligand 1 (PD-L1), what is 
sufficient to trigger T cell anergy (110). Moreover, they can skew CD4+ T cell polarization 
towards tumour-beneficial Treg or Th17 phenotype by production of IL-1α, IL-1β, TGF-β 
and IL-6 (34, 93, 111, 112). 
Based on these observations, it has been postulated that depletion of TAMs is sufficient to 
boost the efficacy of T cell activating therapies. Combination of small molecule inhibitor of 
CSF1R with antibody blocking PD-1 and PD-L1, reduced the tumour growth in a model of 
neuroblastoma (113). Similarly beneficial effect was observed by CSF1R inhibition and 
combination of immune checkpoint blockades anti-PD-1 and anti-cytotoxic 
T-lymphocyte-associated protein (CTLA)-4 (114). TAM-targeted therapies were also shown 
to increase CD8+ T cell infiltration in mammary carcinoma models (115) and improved 
outcome of radiation therapy (116). 
However, it should be noted that results of TAMs depletion might be model-dependent. 
Tumours in Ccr2-/- mice or depletion macrophages in a rat tumour model were shown to 
decrease infiltration of both CD4+ and CD8+ T cells, what negatively correlated with the 
survival. This is most probably a result of scarcity of TAMs-derived chemoattractants (87, 
98). 
Moreover, TAMs activated with combination of agonistic anti-CD40 antibody and IL-2 have 
been shown to clear tumours in a NO-dependent fashion (117). They can also play a 
protective role upon IL-12-based therapy (118) and be source of IL-12 and IL-18 for 
lymphocytes (101, 119, 120).  
Furthermore, myeloid compartment of the tumour infiltrate contains a relatively rare 
population of CD103+ cells, which are differentiating from monocytes and share multiple 
macrophage markers, but were shown to be potent activators of CD8+ T cell responses and 
are correlated with longer survival in patients (101). 
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TAMs exhibit vast heterogeneity and high degree of plasticity. They are modulated by tumour 
cells and can significantly contribute to the tumour escape from immune control, but their 
activation can also elicit antitumoral responses. 
1.4.5 Granulocytes in the tumour microenvironment 
Elevated numbers of neutrophils in peripheral blood is a common observation in some cancer 
types (121). Neutrophils migrate into tumour lesions, comprising significant percentage of 
myeloid cells infiltrate. 
Mirroring macrophage polarization, neutrophils change their phenotype during tumour 
development (122, 123). In murine transplantable models, neutrophils were shown to 
accumulate on the peripheries of the tumour foci early during the tumour progression, 
whereas they scattered among the tumour cells in the later stages. This correlates with loss of 
ability to attract CD8+ T cells and produce TNF-α (122). Furthermore, neutrophils are able to 
inhibit NK cell function and produce metalloproteinases and IL-1β, rendering them 
functionally similar to protumorigenic TAMs (124). Some tumours stimulate expansion and 
release of neutrophils by expression of G-CSF, what correlates with poor prognosis (115,124, 
125). 
On the other hand neutrophils might be also relevant in the context of tumour therapy. They 
express FcγRs and were shown to be necessary for antibody mediated xenograft rejection in a 
preclinical model (126). 
Tumour are also frequently infiltrated by eosinophils, what correlates with good prognosis in 
prostate, gastrointestinal, head and neck as well as bladder cancers, but at the same time with 
poor outcome in cervical carcinoma and Hodgkin lymphoma (84). Eosinophils produce 
CCL5, CXCL9 and CXCL10 and thus can attract CD8+ T cells, but can as well secrete 
pro-angiogenic factors and IL-4, which stimulates the protumorigenic polarization of 
macrophages (84, 90, 99). 
 
As depicted tumour immunome is a complex system with many cross-linked pathways 
involving both innate and adaptive branches of the immune system. Multiple other cell types 
influence the protumorigenic inflammation, just to mention ILCs, plasmacytoid dendritic cells 
(pDCs), γδ T cells or mast cells. Their influence vastly depends on the tumour type and stage, 
but they also contribute to the tumour-associated inflammation (24, 81, 111, 127). This is 
necessary for the progression towards the next step in cancer development – formation of 
metastasis. 
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1.4 The role of the immune system in metastasis 
In majority of the cancer types metastatic disease is the main cause of mortality (2, 3, 81, 124, 
128). A recent study comparing patients with and without metastasis revealed that only the 
lowered lymphatic vessel density and reduced expression of genes related to the immune 
cytotoxicity diverges the two populations (129), thus depicting the pivotal role of the immune 
system in control of the metastatic disease. 
The metastatic cascade can be divided into three steps: intravasation, survival in the 
circulation and colonization of the distant organs. Furthermore, there is emerging evidence 
that tumours induce changes in distant organs prior to arrival of metastatic cells. 
1.4.1 Target organs and formation of the pre-metastatic niche 
Cancers often show a specific pattern of metastasis, e.g. prostate cancer to bone, colorectal 
cancer to the liver, and breast cancer to lung, bone and brain (3, 130, 131). This preferential 
metastases can be explained by the “seed and soil” theory, which was put forward by Stephen 
Paget in the late 19th century and postulates that cancer cells (the seed) changes the metastatic 
organ (the soil) to facilitate the tumour outgrowth. Currently, this process is often referred to 
as formation of the pre-metastatic niche (3).  
Using murine transplantable models, it has been shown that tumour-derived factors like 
TGF-β, TNF-α, VEGF-A, serum amyloid A3 (SAA3) and alarmins S100A8/A9 diminish NK 
cell migration and induce inflammation in the metastasis-target organ. This correlates with 
accumulation of myeloid cells that facilitate tumour cell extravasation (2, 3, 132-136). Other 
studies have shown that neutrophils inhibit NK cell-mediated clearance of circulating tumour 
cells (CTCs) (124). Furthermore, accumulation of neutrophils is sufficient to attract 
metastasising melanoma cells, what is explained by neutrophil-stimulated inflammation and 
angiogenesis (137). Pre-metastatic niche can be also founded by immature cells, like 
VEGFR1+ bone marrow progenitors of monocytes (138), what is presumably the outcome of 
cancer-related myelopoiesis (90, 93, 94). 
Systemic changes were also found in tumour-draining lymph nods, what included diminished 
proliferation of immune cells and disorganisation of T and B cell compartments. This is due 
to lowered CCL-21 and IL-7, but also decreased expression of chemokines for monocytes and 
DCs (81, 139). These proteins are produced by fibroblastic reticular cells as well as myeloid 
cells that accumulate in pre-metastatic lymph nodes and correlate with poor patient prognosis 
(139-141). Moreover, inflammatory signalling, like TNF or IL-1β induce CCL-1 expression 
on lymphatic endothelial cells, what can stimulate migration of CCR-8 positive cancer cells 
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(142).  
The impact of protumorigenic inflammation on metastatic seeding is further illustrated by the 
clinical observation of cancer-to-cancer metastasis (2, 3, 131, 143). A whole-genome 
sequencing study performed on multiple metastatic foci in prostate cancer patients revealed 
that metastasis-to-metastasis spread is a common event (131). Preclinical studies have shown 
that this is induced by mediators of inflammation, like IL-6 and IL-8 (144). 
It should be noted as well that multiple differences in the immune cells composition exist 
among different organs already in the absence of tumours.  NK cells purified from different 
organs have varying cytotoxic capabilities (130, 145-148). Tissue resident macrophages and 
monocytes can define pattern of metastatic spread due to their differential phagocytic activity 
(3, 149). It also cannot be excluded that the majority of pre-metastatic changes occur already 
in the presence of CTCs or dormant metastatic cells. 
There may also be anatomic reasons why particular cancer types metastasise to distinct 
organs (2). For example, liver metastasis from colorectal cancer can be explained by the 
blood flow through the portal vein (130). On the contrary, tumour-intrinsic factors, like 
metadherin in breast carcinomas or focal adhesion-kinase by lung carcinoma cells, can define 
the organ specificity (3, 150). Most probably the organ-targeting of metastasis is a results of 
anatomy, formation of a permissive niche and predisposition of tumour cells to be able to 
grow in a defined organ (151). 
1.4.2 Initiation of the metastatic cascade and intravasation of tumour cells 
To be able to metastasise tumour cells must obtain migratory capabilities by expressing 
proteases, integrin receptors, or by migration along the extracellular matrix fibres (3, 152). 
One of the theories explaining the acquisition of invasive phenotype by tumour cells is the 
epithelial-to-mesenchymal transition (EMT). This transdifferentiation program occurs 
normally during the embryonic development, but acquisition of mesenchymal traits may as 
well increase the motility of cancer cells (2, 3). This includes loss of epithelial polarization 
and intercellular adhesion, but also increased resistance to apoptotic signals (2, 3, 153). 
Importantly, EMT is a reversible process, as epithelial traits are beneficial in the outgrowth of 
a metastatic lesion (2). Two of the factors stimulating invasive phenotype and EMT are 
TGF-β and wnt-ligands derived from Tie-2+ TAMs (24, 60, 90, 154), thus linking immune 
cells and tumour transdifferentiation. 
It is a matter of discussion if EMT is sufficient and necessary to stimulate metastasis, as it 
was shown in a murine model that, albeit it contributed to the chemotherapy resistance, EMT 
is not necessary for cancer cells to colonize lungs (155). 
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Acquisition of migratory phenotype alone is insufficient for induction of metastasis, as 
tumour cells need to overcome blood or lymph vessel endothelium (156, 157). Even although 
the vasculature in primary tumours is considered aberrant and dysfunctional (10), immune 
cells are important controllers of tumour cell intravasation. As a matter of fact, vascular 
permeability occurs only in the vicinity of the protumorigenic Tie2+ TAMs, which serve as 
gatekeepers for the metastasising cells. This is mediated by local production of VEGF-A and 
is a result of the tumour-intrinsic inflammatory reaction (157, 158). Similarly, TGF-β or 
MMP-1 produced by TAMs trigger endothelial permeability (3). Systemic absence of 
macrophages in mice lacking CSF-1 diminishes the metastatic capabilities of autochthonous 
mammary carcinomas (159). Others have shown however that targeting TAMs by CSF1R 
inhibition can increase the metastatic burden (160) and similar outcome comes from cessation 
of anti-CCL2 therapy, a treatment developed in order to disrupt monocyte recruitment (161). 
Metastasis may also be promoted by inflammation triggered by conventional therapy, such as 
surgery, radiotherapy or even taking biopsies (68, 162-166). 
1.4.3 Tumour cell survival in the circulation 
Circulating tumour cells (CTCs) can be found in blood of patients with breast, colorectal, 
prostate as well as lung cancer and their increased frequency correlates with poor prognosis 
(167, 168). The typical CTC numbers vary between 1-10 cells per millilitre of peripheral 
blood and they have relatively short survival in the circulation, estimated at around 1-2.5 h (2, 
167, 169). This translates into thousands of cell shed into the circulation, out of which very 
few progress into metastatic lesion. Thus, a very low proportion of CTC actually forms 
metastasis due to death in the circulation, inability to invade the target tissue or to outgrow in 
the parenchyma of the target organ (153, 168). 
Upon extravasation, cancer cells encounter stress conditions, what renders them prone for 
attack from immune cells, especially NK cells (3, 145, 170, 171). NK cell-mediated CTC 
elimination requires close contact and there is evidence that platelets protect CTCs by 
shielding them (3, 172, 173). Thrombocytosis is often observed in cancer patients and it 
correlates with poor prognosis (132). Furthermore, association of CTC with macrophages or 
fibroblasts has been described (174, 175), and recent data showed enhanced metastatic 
potential of clustered CTC (168). 
1.4.4 Colonization of the target organ 
Once metastatic cells arrive in the target organ, they must extravasate and invade the 
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parenchyma or, in case it occluded the capillary vessel, proliferate within its bed (2).  
For extravasation and survival CTCs require CCL-2 to both directly activate vessel 
endothelium and attract inflammatory monocytes (135, 176, 177). Monocytes directly support 
extravasation by local production of VEGF, analogously to the situation in the primary 
tumour (178). A transcriptome analysis of primary ovarian tumours and matched peritoneal 
metastases showed that CCL-2 expression was high at the metastatic sites, whereas in primary 
tumours this pathway was inactivated (179). 
In some circumstances, an important role in colonization might be played also by 
granulocytes. Tumour cells can adhere directly to neutrophils, what connects them to the 
endothelium and results in increased tumour burden (180). Furthermore, upon stimulation 
neutrophils release neutrophil extracellular traps (NETs), which are webs of genomic DNA 
bound with bactericidal proteins, like e.g. neutrophil elastase (181, 182). In case of 
postsurgical infection, this mechanism might enable trapping CTCs and sequester them from 
circulation, thus facilitating establishment of metastatic lesion (183). 
Metastatic cancer cells that escape control of immune system and overcome the growth 
restrictive environment of the target organ can develop clinically detectable lesions. However, 
some of the micrometastases do not progress for prolonged period of time. 
1.4.4 Metastatic dormancy 
Patients with years-long cancer remission remain under elevated risk of relapse and require 
monitoring (184-186). Outgrowth of breast cancer metastases can occur up to 20 year after 
initial diagnosis and removal of primary tumour, suggesting that metastases can be kept in a 
controlled, dormant state for prolonged periods of time (187). Consistently, even with 
frequent micrometastases in the bone marrow, only 50% patients develops any clinically 
detectable metastatic lesions in time frame of 10 years (3). Furthermore, studies on CTCs 
suggest that majority of the disseminated cancer cells cannot establish a lesion and are driven 
into a state of dormancy or undergo apoptosis (2, 3, 132, 188).  
Dormancy might be induced by non-immune mediated mechanisms, like high production of 
TGF-β (189, 190) or anti-angiogenic factors, like angiostatin and prosaposin (191, 192). 
Alternatively, this can be explained by induction of an equilibrium state, in which the tumours 
persist in the organs, but are kept in check by immune cells (41). 
First of all, clinical observations have shown that the rate of MHC class I downregulation is 
higher in metastatic lesions than in primary tumours (29). This goes in line with 
phylogenetically determined pattern of antigen expression in metastatic foci of various organs 
(193) and suggests that dormancy might be controlled by CD8+ T cells. 
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Second, in preclinical studies, maintenance of dormancy of B cell lymphomas in immunized 
mice requires CD8+ T cell-derived IFN-γ (194). In other models, dormancy of bone 
metastases is mediated by type I interferons that are produced by both T and NK cells (187).  
Third, RET-oncogene transgenic mice, which develop uveal melanoma, have a prominent 
spread of occult cells to various organs. Depletion of CD8+ T cells shortens the time between 
the seeding and metastasis outgrowth in lung and reproductive tract, but not skin, showing 
that dormancy induced by CD8+ T cells might depend on the organ context (195). 
Fourth, so-called “latency competent cancer cells”, which were isolated from primary lesions 
of lung and breast cancer patients, can enter state of NK cell-triggered dormancy. These cells 
are expressing WNT inhibitor, which in an auto- and paracrine way induces downregulation 
of ULBP ligands of NKG2D, but also slows down cell cycling. This mechanism shows that 
dormancy might be also regarded as a mechanism to avoid immune surveillance (79).  
It is important to note that cytotoxic immune cells continue their protective role even once the 
control over micrometastases is lost and lesions progress to clinically detectable tumours. 
This is exemplified by the observation that survival of metastatic melanoma patients 
correlates with density and composition of immune infiltrate in the metastatic lesions, 
mirroring observations for primary tumours (196). 
1.5 Cancer immunotherapy 
As described in the previous sections, immune cells play a profound role in control, as well 
support of tumour growth. It is thus an outstanding goal to design therapies that would 
harness patients’ own immune system to fight cancer. This can be achieved by boosting the 
anti-cancer cytotoxic cells or by targeting the protumorigenic immune stroma. Such therapies 
bear the promise of treating both primary lesions as wells as disseminated tumour cells and 
could potentially induce anti-cancer immune memory, thus activating sustained control of 
tumour cells. Recent clinical trials have shown that immunotherapy is an encouraging 
direction in the drug development, but more work is needed to achieve successful responses 
in all the patients. 
Several types of immunotherapies currently being evaluated, including cancer vaccines, 
cytokine therapies, adoptive transfers of cytotoxic lymphocytes, toll-like receptor agonists, 
antibodies and small molecules modifying the immunosuppressive stroma. 
1.5.1 Cancer vaccines 
As opposite to prophylactic vaccination, immunization against cancer necessitates activation 
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of immune system against an existing pathology. This requires proper adjuvants and 
identification of tumour-specific antigens that can be used in such preparation. Furthermore, it 
must overcome immune regulation, which is often associated with chronic conditions. 
Anti-cancer immunization protocols are currently tested in e.g. lung and skin cancers (197). 
Their development is however hindered by the scarcity of tumour antigens shared between 
the patients. Antigens can be also tracked individually for each patient prior to formulation of 
vaccine (197) or, the same can be achieved by adoptive transfer of patients’ own APCs (197, 
198). 
The latter approach has been implemented in the only currently approved by US Food and 
Drug Administration (FDA) cancer vaccine, sipuleucel-T. It is a recombinant fusion protein 
containing prostatic acid phosphatase and GM-CSF. It is used to stimulate patient’s own 
APCs ex vivo, which, upon transfer back into patient, activate lymphocytes to clear prostate 
cancer cells (198). 
1.5.2 Cytokine therapies 
Cytokine therapies are targeting three mechanisms: promote the APC activity, stimulate 
function and improve survival of the cytotoxic lymphocytes. 
One of the best-studied cytokine therapies designed for the APC stimulation is based on 
GM-CSF. It is stimulating APC differentiation and maturation, but its overexpression in the 
tumour microenvironment can also trigger APC dysfunction (96, 199, 200). GM-CSF is 
tested as adjuvant for conventional therapies (201), but as well in anti-cancer immunization, 
similarly to IL-4 (198, 202). It can be delivered locally, by gene therapy or by transfer of 
non-dividing autologous or allogeneic tumour cells that express this cytokine (GVAX), what 
has shown beneficial effects in early clinical trials (201, 203). 
Cytokine therapies acting directly on NK and T cells that reached clinical trials include IL-2, 
IL-7, IL-12, IL-15, IL-21 and type I interferons (75, 202, 204-207). Despite indications for 
clinical efficacy, their use is hindered by significant adverse side effects and short serum 
half-lives (202, 208). This can be addressed by local administration (205) and usage of 
immune complexes consisting of cytokines and anti-cytokine antibodies (204, 207) or 
cytokines and the soluble form of their receptors (209). 
Up to date only two cytokine-based therapies have been approved for the use in clinics: IFN-α 
as adjuvant for advanced stage melanoma and high dose IL-2 for melanoma and renal cell 
carcinoma (202, 210-212). Although IL-2 induces durable responses in patients, the therapy 
with high dose IFN-α shows mixed results and patient benefits are discussable (202, 213). 
Cytokines are currently validated as supplementary treatment to adoptive cell transfer 
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therapies. This includes delivery of IL-2, IL-7, IL-12 and IL-15 directly to patients, or their 
use for ex vivo expansion of lymphocytes (202).  
1.5.3 Adoptive transfer of cytotoxic lymphocytes 
Adoptive transfer of T and NK cells is tested in clinics since early 1990’ and has shown 
promising results in therapy of blood as well as multiple types of solid tumours (196, 214-
217). It was initially performed with autologous T cells purified from the peripheral blood or 
tumour. However, expansion of endogenous T cell pool is not a successful therapeutic 
approach due to the negative selection and dysfunction of tumour-infiltrating lymphocytes  
(196, 214, 216, 217). New technologies have been developed to improve the targeting, 
including transduction with genes coding antigen-specific TCRs, or chimeric antigen 
receptors (CARs) (214, 216). Whereas antigen-specific TCR enable recognition of both 
surface and intracellular antigens, the antigen specificity of CARs is achieved by adaptation 
of antibodies against tumour-specific surface molecules. This is achieved by fusion of 
variable region of an cancer cell-targeted antibody with and intracellular moiety derived from 
TCR and linked with costimulatory molecules, like CD28 or 4-1BB (214). These approaches 
are efficient in clearance of haematological malignancies, whereas treatment of solid cancers 
is more problematic, mainly due to necessity to achieve infiltration to the tumour stroma and 
then to maintain T cell function as well as avoid off-target effects (214, 216, 218).  
The inherent requirement for successful adoptive transfer of T cells is the availability of 
antigen and transfer of NK cells can overcome this barrier. Anti-cancer activity is in this case 
achieved by partial mismatch of KIR repertoire (allogeneic transfer) or in vitro activation of 
autologous NK cells with cytokines, like IL-2, IL-12, IL-15 or IL-18 (215, 219). Furthermore, 
there are studies on possibility to use NK cell lines, what facilitates the transfer preparation 
(219, 220). 
As both T and NK cells become dysfunctional in the tumour environment, it is necessary to 
develop novel therapies combining adoptive transfer with other immunostimulatory 
therapeutics, as for example cytokines (218, 221).  
1.5.4 Blocking of immune checkpoint inhibitor pathways 
One of the most successful classes of immunotherapeutics is the immune checkpoint 
blockade. Immune reaction depends on a balance between the stimulatory and inhibitory 
signalling, and blocking the latter can liberate cancer-targeted immune response (222).  In 
clinics there are currently two types of checkpoint-blocking drugs – targeting cytotoxic 
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T-lymphocyte-associated protein (CTLA)-4 and the PD-1/PD-1L axis. Both of them have 
been approved for the therapy of advanced melanoma and clinical trails in other tumour types 
are ongoing (223-227) 
CTLA-4 is present on both activated CD8+ T cells as well as CD4+ T helper cells and Tregs 
(222). The mechanism by which blocking CTLA-4 elucidates its immunostimulatory function 
is not fully elucidated, but might include both improved costimulatory signalling through 
CD28 and simultaneous depletion of Treg pool (66, 222). Similarly, PD-1 is initially 
upregulated upon TCR ligation, but then its further upregulation marks T cell exhaustion 
(137-139). PD-1 is also present on Tregs and its ligation is sufficient to induce Treg 
proliferation (222).  
Furthermore, both PD-1 and CTLA-4 are present on NK cells and their blockade can increase 
NK cell activity, but our understanding of therapeutic role of NK cells in checkpoint blocking 
therapy is only emerging (208, 228, 229). It has been shown however that anti-PD-1 
combined with anti-CTLA-4 induces NK cell-mediated protection from metastasis in a 
preclinical model (208). 
Beneficial effects are also observed for treatment with anti-PD-L1 antibodies, which prevent 
the induction of lymphocyte anergy by blocking lymphocyte interaction with PD-L1 
expressed by the tumour or stromal cells (230, 231). 
The success of anti-CTLA-4 and anti-PD-1 turned focus into finding new targets for 
checkpoint blocking therapeutics. This includes multiple molecules present on T and NK 
cells, like lymphocyte activation gene-3 (LAG-3) (232), T-cell immunoglobulin mucin-3 
(TIM-3) (233), cytokine-inducible SH2-containing protein (CIS) (208) and CD96 (58). 
Furthermore, there are promising results on the potential of blocking TIGIT (234). Upcoming 
clinical trials will evaluate which of these molecules are the most promising targets in cancer 
therapy. 
Importantly, blocking multiple immune checkpoint molecules enables overcoming 
development of resistance and could potentially increase the response rates (208, 233, 235). 
Combination of anti-PD-1 and anti-CTLA-4 has already proven to be superior over single 
therapy (223, 236) and checkpoint blockade can also benefit from combination with other 
immunostimulatory therapeutics (221). 
1.5.5 Therapy with antibodies stimulating immune response 
In addition to immune checkpoint blocking antibodies, much effort has been invested in 
development of agonistic antibodies against immune activating receptors. 
The first clinically tested antibody in this class was agonistic anti-CD28 antibody, which 
	 22 
activates T cells without the necessity of TCR interaction. However, the first in-human study 
failed due to excessive toxicity and induction of cytokine storm (237). This has hindered the 
development of antibodies against other targets, however recent studies show promising 
results with antibodies stimulating OX-40, CD278 and 4-1BB (237, 238). All of these 
molecules are expressed only by activated lymphocytes, reducing the risk of autoimmune 
reaction (237) 
Another potential target is CD27, a molecule constitutively expressed on T and NK cells. Its 
ligation stimulates lymphocyte activity and it is currently tested in early clinical trials (237, 
239, 240). 
Furthermore, T and NK cells can be stimulated indirectly by targeting APCs. One of the most 
promising approaches is stimulation of the CD40/CD40L pathway, what in normal conditions 
increases antigen presentation and cytokine production, thus could potentially improve the 
outcome of checkpoint inhibition (38). Therapies based on soluble CD40L and agonistic 
anti-CD40 antibodies are under development and have been successfully tested in early 
clinical trials (241, 242). At the same time, further development has been hindered by strong 
adverse reactions related to systemic increase of inflammatory cytokines and liver toxicity 
(243). Triggering excessive systemic inflammation is an intrinsic feature of all the 
immunostimulatory therapies targeting receptors expressed by non-stimulated leukocytes and 
should be taken into consideration in designing future therapies (237). 
1.5.6 Toll-like receptor agonists 
Toll-like receptors (TLRs) sense molecules released by pathogens or own stressed and dying 
cells (244, 245). Because of their potent proinflammatory function, they have been 
investigated as adjuvants for vaccination as well as in cancer monotherapy. 
There are currently three clinically used immunotherapeutics targeting TLRs. These are 
imiquimod, a TLR7 agonist approved as topical treatment of non-melanoma skin cancer (246-
248), monophosphoryl lipid A, a lipopolysaccharide derivative as adjuvant to HPV 
prophylactic vaccines (249) and bacillus Calmettte-Guérin for treatment of non-invasive 
bladder cancer (249, 250). Furthermore, imiquimod was successfully tested in off-label 
therapy of lymphomas (251, 252). Multiple other TLR agonists are currently in clinical trials, 
mainly activating TLR3, TLR7 and TLR9 pathways (253). Resiquimod, a TLR7 and TLR8 
agonist is under evaluation as adjuvants in anti-cancer peptide vaccines (253). 
In most of the cases the direct anti-cancer mechanism of these therapeutics is not clear, but 
includes induction of acute local inflammation. 
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1.5.7 Targeting the tumour-associated myeloid cells 
A quickly developing class of immune therapeutics is focusing on targeting the myeloid cells 
in the tumour stroma. The primal aim here is to reduce numbers of TAMs, what can be 
achieved by blocking migration of monocytes or their differentiation and survival. 
Recent studies using small molecule inhibitors and antibodies blocking CSF1R and antibodies 
blocking this receptor showed promising results in preclinical models (106, 114, 116, 254, 
255). Clinical trials to determine clinical applicability of such and approach are currently 
ongoing, as CSF1R blockade is tested in solid tumours, in a single treatment regimen and in 
combination with checkpoint blocking antibodies (113, 256). The first available results for 
antibody blocking CSF1R showed no dose limiting toxicities, but further studies are 
necessary to determine efficacy of such therapy (256). 
On the other hand, preclinical studies have shown that pharmacological inhibition of 
monocyte migration by blocking CCL-2 can have adverse effects on the metastatic outcome 
(161). Targeting TAMs with the currently available drugs inherently targets all the monocytes 
and it can have profound systemic side effects. 
1.6 Models of metastasis 
Our understanding of the biology and therapy of metastatic disease is hindered by the scarcity 
of biologically relevant models. 
Even though new models are being developed, much of our knowledge is based on  models of 
experimental metastasis. Here tumour cells are injected intravenously into the tail vein, giving 
rise to “metastatic” lesions in the lungs. In addition, intrasplenic injection of tumour cells 
followed by splenectomy results in “metastases” in the liver and intracardiac injection results 
in spread to bones (257, 258). Although these models enable studying metastatic seeding, 
they cannot address other events of the metastatic cascade including the impact of the primary 
tumour. Furthermore, a single injection of a large number of tumour cells (usually in 
hundreds of thousands) does not compare with continuous shedding of low numbers from the 
primary tumour. 
Another approach is to use xenograft models, in some of which animals develop spontaneous 
metastases.  However, these models don’t allow studying the interaction of metastasising 
cancer cells with the adaptive immune system, thus have limited applicability in cancer 
immunology (259, 260). New generations of humanized mice might partially overcome these 
problems. Alternatively, induction of central immune tolerance might be achieved by 
microinjection of tumour cells into the blastocysts of immunocompetent mice (260). 
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The metastatic cascade is best studied in mouse models of breast cancer. For example, the 
autochthonous PyMT carcinoma model, in which carcinogenesis is triggered by expression of 
the polyoma virus middle T protein. These mice develop mammary hyperplasia at four weeks 
of age, which progresses to carcinoma and form variable number of metastatic lesions, mainly 
in the lung (261). This is however a lengthy process and tumour bearing mice have to be kept 
until old age. Other metastasising breast carcinoma model is the injection of the 4T1 cells 
orthotopically in the mammary fat pad, what gives rise to prominent lung metastasis in a 
reproducible way and a relatively short time frame (262). 
Orthotopic models have been developed also for colorectal cancer. Injection of tumour cells 
in the colon and cecum enables establishment of primary lesions that give rise to liver 
metastases (263).  
Other autochthonous models include RET.AAD mice (expression of human oncogene RET 
and chimeric mouse/human MHC antigen AAD), which develop uveal melanoma that in 
older animals metastasises to multiple organs, including lungs, brain and reproductive track 
(195). Also TRAMP (transgenic adenocarcinoma of the mouse prostate) mice progress to 
metastatic disease, albeit mainly to the lymph nodes (264). The drawbacks of most 
spontaneous models are that it takes long until metastases occur, they are not synchronised 
and incidence is often low. 
Resection of subcutaneous tumours in immunocompetent mice is an approach is to study all 
the aspects of metastasis. This is the setup I have used in my experiments.  
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2. Aims 
The aim of my thesis was to contribute to our understanding of how components of the 
immune system impact on metastatic seeding or progression. Therefore, I have established a 
model of spontaneous metastasis from subcutaneously injected Lewis Lung Carcinoma cells 
(LLC, 3LL) that I have tagged with luciferase using lentiviral transduction. In this model 50-
60% of mice develop metastasis mainly to lung, liver and draining lymph nodes, which 
allowed the analysis of interventions that either promote or prevent metastasis. 
I have addressed following questions: 
1. Inhibition of signalling via the CSF1R aims to deplete tumour-promoting 
macrophages and is currently in clinical trials. Preclinical data suggest that CSF1R-
blockade inhibits the growth of primary tumours, however, very little data are 
available on the impact of CSF1R-blockade on metastasis. I have investigated the 
effect of CSF1R-blockade on metastatic seeding and progression. 
2. Recent data have shown that production of the pro-inflammatory mediator PGE2 in 
the tumour promotes tumour growth, mainly by inhibiting immune defence. As the 
role of tumour-derived PGE2 on metastasis is largely unknown, I have compared 
metastasis formation from resected tumours that do or do not produce PGE2. 
3. It is well established that NK cells are important in controlling metastatic seeding of 
tumour cells and recent data suggest that, in analogy to T cells, the function of NK 
cells is under checkpoint control. Therefore, I have investigated whether immune 
stimulation by agonistic and/or checkpoint-blocking antibodies impact on the 
rate of metastasis. 
4. ALCAM is an adhesion molecules expressed by a wide variety of cells and, amongst 
others, plays a role in leukocyte transmigration through blood and lymphatic vessels. 
Because intra- and extravasation are crucial steps in the metastatic cascade, I have 
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Despite recent advances in oncology, metastatic disease remains the major cause of 
cancer-related death. The cascade of events involved in this process includes invasion 
of surrounding tissue, intravasation into the blood or lymph vasculature, survival in 
the circulation and extravasation and colonization of distant tissue. Each of these steps 
involves crosstalk between tumor cells and hematopoietic cells, including 
lymphocytes and different cell types of myeloid origin (1). 
NK cells were primarily recognized to remove circulating tumor cells (2, 3) and 
CD8+ T cells can control transformed cells in the primary tumors as well as in the 
metastatic lesions (4, 5). Whereas CD8+ T cells became an attractive target for 
immune-activating therapies (6, 7) and approaches to boost NK cell responses are 
under development (8, 9), the development of therapeutic strategies based on 
targeting the myeloid cell compartment have proven more complicated due to the dual 
role these cells play in the tumor progression and metastasis. On the one hand, 
myeloid cells can produce proinflammatory cytokines and survival factors for NK and 
T cells such as IL-2, IL-12 and IL-15 (10-14) and comprise antigen-presenting cells 
(APCs) that are crucial to T cell activation (15). On the other hand, they are recruited 
to tumors where they contribute to local immunosuppression, promote tumor growth 
and directly facilitate formation of metastases (16-19). Targeting tumor-associated 
macrophages (TAMs) by inhibition of CSF1R has shown promising results in 
preclinical cancer models (20-23). However, little is known about the impact of such 
treatment on the formation or progression of metastasis. 
Here we aimed to diminish metastatic disease by manipulating the myeloid 
compartment using two interventions that are currently being evaluated in clinical 
trials: Agonistic anti-CD40 antibody (24) and blockade of CSF1R (25), thus 
activating APCs and depleting TAMs, respectively.  
Results 
Anti-CD40 protects against metastatic disease 
We used a model of spontaneous metastasis from resected, primary Lewis lung 
carcinoma tumors expressing luciferase (LLC-LUC) in immunocompetent mice. 
Approximately 50% of mice developed metastases preferentially in the lungs, livers 
and tumor-draining lymph nodes within 3 weeks after surgery. In order to investigate 
whether monotherapy with anti-CD40 prevents seeding of metastatic cells or their 
progression in the metastatic organ, we started treatment before (Fig. 1A, upper panel) 
or after the surgery (Fig. 1A, lower panel), respectively. Administration of anti-CD40 
shortly before resection reduced the rate of metastasis by 50-70%, whereas 
administration immediately after resection had no impact on the metastatic frequency 
or load (Fig. 1B). The metastatic burden of those mice that developed metastases 
despite anti-CD40 treatment before surgery was comparable to that of untreated mice 
(Fig. 1C and 1D). This suggests that the control of metastasis triggered by anti-CD40 
occurs early in the metastatic cascade, e.g. during the seeding phase. We confirmed 
the protective activity of anti-CD40 treatment in a model of spontaneous metastasis 
from breast cancer tumors (4T1) in BALB/c mice (Fig. S1). 
Inflammatory response to anti-CD40 causes a favorable switch in Treg to CD8+ T 





To understand how anti-CD40 protects against metastasis, we first measured the 
amount of proinflammatory cytokines in the serum 24 h after injection of anti-CD40. 
Anti-CD40 triggered the production of interferon g (IFNg), tumor necrosis factor α 
(TNFα), interleukin (IL)-12 and IL-6 (Fig. 2A), pointing towards a type I immune 
response signature (26). In addition, we detected increased amounts of the monocyte 
chemoattractant chemokine (C-C) motif ligand 2 (CCL-2) (27) (Fig. 2A). 
Because anti-CD40 was effective only when given before resection of the primary 
tumor, we analyzed immune populations in the primary tumor immediately after 
resection. Treatment with anti-CD40 did not change the number of neutrophils, 
inflammatory monocytes, macrophages, NK or CD8+ T cells (Fig. S2), but led to a 
IFNg-dependent (28) and data not shown) deletion of tumor-infiltrating CD4+ T cells 
(Fig. 2B). Although this decrease was not specific to T regulatory cells (Tregs) (Fig. 
2C and S2), it resulted in a favorable decrease of the Tregs to CD8+ T cell ratio (Fig. 
2D) (29, 30). 
Based on these results, we reasoned that the beneficial effect of anti-CD40 required 
sufficient tumor antigen, activated APCs and T cells. As the number of CD4+ T cells 
was diminished upon anti-CD40 treatment, we assumed that CD8+ T cells were the 
main effector cells preventing metastasis. We depleted CD8+ T cells 24 h prior to 
anti-CD40 treatment (Fig. 2E), which resulted in sustained depletion until the time 
point of resection (Fig. S3). Absence of CD8+ T cells did not, however, influence the 
size of the primary tumor (Fig. S4) and had no impact on the anti-CD40-mediated 
reduction of the metastatic burden (Fig. 2F). Thus, anti-CD40 protects against 
metastases independently of T cells. 
Anti-CD40 triggers systemic activation of NK cells and NK-mediated clearance of 
metastasizing tumor cells 
We observed increased amounts of IL-12 in the serum after anti-CD40 treatment (Fig. 
2D). Because IL-12 is a potent activator of NK cells (31), we analyzed the phenotype 
and function of NK cells in lungs of tumor-bearing mice, as the lungs are most 
frequently affected by metastasis in this model. Twenty-four hours after anti-CD40 
treatment NK cells produced (2) and upregulated the expression of molecules 
associated with NK cell activation and effector function, including killer cell lectin-
like receptor subfamily G member 1 (KLRG1), NKG2D, Fas ligand (FasL) and 
granzyme B (Fig. 3A), in an IL-12-dependent fashion (Fig. S5) (10, 32, 33). 
Furthermore, anti-CD40 induced systemic changes in the maturation of NK cells, as 
measured by changes in the surface levels of CD11b and CD27 (34), with an 
accumulation of CD11b- CD27+ cells (Fig. 3B). 
To investigate whether NK cells are essential for the anti-metastatic effect of anti-
CD40, we depleted NK cells starting immediately prior to anti-CD40 treatment and 
continuing until tumor resection (Fig. 3C). Depletion of NK cells had no effect on the 
size of primary tumors (Fig. S6), however, it resulted in a dramatically increased rate 
of metastasis (Fig. 3D), suggesting that NK cells do not act on the primary tumor but 
rather control metastasis in the circulation and/or at the metastatic site. Depletion of 
NK cells completely prevented the protective effect of anti-CD40 treatment (Fig. 3D), 
indicating that anti-CD40-mediated protection against metastasis essentially depends 
on NK cells.  
Because the effect of anti-CD40 did not require the activity of T cells, we considered 





Alternatively, the primary tumor may serve as continuous supply of circulating, 
metastasizing tumor cells, which have a short half-life in the circulation (35, 36), and 
anti-CD40 may prevent metastasis at the level of circulating tumor cells. To directly 
address whether NK cells are involved in the elimination of circulating LLC-LUC 
tumor cells, we injected tumor cells intravenously (i.v.) (Fig. 3E). Depletion of NK 
cells prior to i.v. injection resulted in increased tumor burden in the lungs and reduced 
survival of mice (Fig. 3F and data not shown). 
Targeting tumor-associated macrophages abolishes the protective effect of anti-CD40 
and promotes metastatic disease 
Macrophages, defined as CD45.2+ CD11b+ Ly6G- F4/80+ Ly6Cint CSF1R+ cells 
(Fig. S2A, S7), are numerous in LLC-LUC tumors (Fig. S2) and are often described 
to play a tumor-promoting role (37). Therefore, we argued that targeting TAMs may 
potentiate the anti-metastatic effect of anti-CD40. To address the impact of TAMs on 
the development of metastasis, we administered BLZ945, a small-molecule inhibitor 
that blocks CSF1R signaling (CSF1Ri), and thus prevents the development and 
maintenance of various myeloid cell subsets including TAMs (23, 38, 39). We 
administered CSF1Ri starting 3 days before the first dose of anti-CD40 and 
continuing until resection (Fig. 4A). Administration of CSF1Ri strongly reduced the 
numbers of TAMs  (Fig. 4B), but had no impact on the growth of primary tumors 
(Fig. 4C). Instead of the expected synergy between anti-CD40 and CSF1Ri, we 
observed that CSF1Ri abolished the anti-metastatic effect of anti-CD40 (Fig. 4D). We 
next investigated the impact of TAM-reduction by CSF1Ri on the rate of metastasis 
independently of anti-CD40 and treated mice with CSF1Ri from the day of injection 
of tumors until surgery (Fig. 4E). Also in this situation, CSF1Ri resulted in an 
increased rate of metastasis (Fig. 4F) without impact on primary tumor growth (Fig. 
S8). When CSF1Ri was given immediately after the primary tumor was resected, the 
metastatic rate was unchanged (Fig. 4F and 4G). We confirmed these observations 
using antibody-mediated blockade of CSF1R in the 4T1 model of spontaneous 
metastasis from breast cancer in BALB/c mice, thus excluding the possibility that our 
results are a peculiarity of the small molecule inhibitor of CSF1R, surgery, the mouse 
strain or the model used (Fig. 5A, 5B and 5C).  
Systemic inhibition of CSF1R affects NK cell homeostasis 
To understand why CSF1R blockade promoted metastasis and prevented the anti-
metastatic effect of anti-CD40, we determined circulating leukocyte counts in mice 
treated with CSF1Ri. As expected, treatment with CSF1Ri for 3 days reduced 
numbers of Ly6Chi and Ly6Clow monocytes (Fig. 6A), whereas numbers of CD4+, 
CD8+ and B cells as well as neutrophils did not change (data not shown). However, 
treatment with CSF1Ri decreased numbers of NK cells (Fig. 6B), which is explained 
by the fact that NK cell homeostasis depends on IL-15 trans-presented by CSF1R-
dependent monocytes (40). 
Administration of exogenous IL-15 restores NK cell numbers and allows metastasis 
control under CSF1Ri treatment  
To address whether increased metastasis after CSF1Ri was caused by the concomitant 
reduction of myeloid cells or of NK cells, we treated mice with CSF1Ri and 
supplemented one group with IL-15/IL-15Rα complexes (IL-15c) in order to rescue 
NK cell numbers in the face of low numbers of CSF1R-dependent myeloid cells (41, 





counts, whereas CSF1Ri-treated mice receiving exogenous IL-15c showed normal 
NK but still low myeloid cell numbers (Fig. 6D and 6E, and data not shown). 
Decreased numbers of NK cells but not myeloid cells correlated with increased 
metastatic load in the lungs (Fig. 6F and 6G). Together these data demonstrate that 
NK cells are essential for the protection against metastatic seeding to the lungs. 
Although IL-15 is also required for survival of CD8+ memory T cells (43), we do not 
think that the effects described here involve CD8+ T cells, as depletion of this subset 
had no impact on metastasis formation in the model of spontaneous metastasis. 
Discussion 
There is increasing evidence that metastasis is under control of the immune system 
(44-46). Using clinically relevant models of spontaneous metastasis formation, we 
have investigated whether modulating the myeloid compartment impacts on the rate 
of metastasis. Specifically, we used anti-CD40 to activate APCs and CSF1R-blockade 
to target tumor-promoting TAMs in pre- and post-surgical regimens. Both of these 
approaches are currently tested in clinical trials (24, 25). 
We demonstrated that activation of the CD40 pathway before resection of the primary 
tumor protects against metastasis independently of T cells. Our observations that 
those mice developing metastases despite anti-CD40 treatment have a comparable 
metastatic burden to the control cohort and treatment is not successful when primary 
tumor is resected suggest that anti-CD40 interferes with the seeding of metastatic 
cells, rather than with progression of metastatic lesions. We identified NK cells as the 
major protective population against spontaneous metastasis and found that anti-CD40 
activates NK cells at different anatomical sites in an IL-12-dependent fashion. This 
goes in line with a recently published phase I study of a chimeric anti-CD40 agonistic 
antibody, in which both elevated levels of serum IL-12 and peripheral NK cell 
activation was observed (24). Although NK cells are essential to control metastasis, 
we observed little or no influence of these cells on the progression of the primary 
tumor. The fact that primary tumors contain few infiltrating NK cells may explain this 
observation, but the compromised NK cell maturation within tumors may also be 
important (47, 48). In addition, circulating tumor cells may be particularly vulnerable 
to NK cells, as stress conditions such as oxidative or shear stress can upregulate the 
expression of ligands for NKG2D on tumor cells (49, 50). 
Our attempt to further potentiating anti-CD40 treatment by depletion of tumor-
promoting TAMs, however, unexpectedly nullified anti-CD40-mediated protection. 
This stands in apparent contrast to published findings showing that CSF1R-blockade 
retarded the development of primary tumors (20, 23, 51), but goes in line with the 
observation that CSF1R-blockade promotes the development of metastases (52). 
Swierczak et al. showed that CSF1R-blockade increased the amount of G-CSF in the 
serum and therefore speculated (but did not show) that neutrophilia is the main cause 
for increased metastasis. Neutrophilia downstream of CSF1R-blockade, however, 
may be a peculiarity of tumors that produce high amounts of G-CSF such as 4T1 (3, 
53) as we do not observe it in BLZ945-treated mice. Furthermore, it was recently 
shown that anti-macrophage therapy based on blocking C-C chemokine ligand 2 
(CCL-2) increases the risk to develop metastasis upon treatment cessation due to 
enhanced angiogenesis and monocyte counts (54). Thus, targeting myeloid cells in 
cancer may be less straightforward than thought and a better understanding of the role 






We show that depletion of TAMs and other CSF1R-dependent myeloid cells 
concomitantly reduces the number of NK cells, thus providing a mechanistic 
explanation of the apparently controversial action of CSF1R-blockade (20, 23, 51, 
52). Maintenance of peripheral NK cells depends crucially on IL-15, as it controls the 
intracellular levels of anti-apoptotic Bcl-2 (55). NK cells express IL-15Rb/g, which 
binds IL-15 with high affinity only when it is trans-presented on IL-15Ra (56) 
expressed by myeloid cells in steady state conditions (40). We observed that the 
detrimental effect of CSF1R-blockade on metastasis is reversed by exogenous IL-
15/IL15-Ra complexes (41, 42), which restores the number of NK cells in the face of 
low numbers of CSF1R-dependent myeloid cells. Together, these data show that NK 
cells are essential for protection against metastatic seeding and at the same time 
excludes a major role for myeloid cells other that supporting NK cell survival. This 
may seem to contradict the recently published findings by Hanna et al., who showed 
that control of metastasis required the presence of Nr4a1+ patrolling monocytes (45). 
Nr4a1+ patrolling monocytes are Ly6Clow monocytes (57) that are enriched in the 
microvasculature of the lung. Although this study showed that Nr4a1+ patrolling 
monocytes attract NK cells, a functional role of NK cells in protection against 
metastasis was not addressed. As patrolling monocytes express CSF1R (45), they may 
be targeted by CSF1Ri as well. We did not specifically investigate Nr4a1+ monocytes 
here, but the fact that supplementation with IL-15/IL15-Ra complexes rescues NK 
cell counts without restoring the numbers of myeloid cells and prevents CSF1Ri-
promoted metastasis, clearly identifies NK cells as the major cell type protecting 
against metastasis to the lung. NK cells are currently being investigated as potential 
effector cells in multiple cancer therapy approaches, including in vivo cytokine 
therapies (58, 59) and adoptive transfers (8, 9) thus opening additional beneficial 
perspectives in a clinical application of such a treatment. 
In summary, we found that anti-CD40 prevents the development of metastatic disease 
in an NK cell-dependent fashion. Moreover, our results suggest that NK cells control 
the seeding of circulating tumor cells to the metastatic site rather than progression of 
metastasis. The fact that control of metastasis crucially depends on NK cells also 
explains why blockade of CSF1R signaling promoted metastasis: CSF1Ri-mediated 
reduction of myeloid cells concomitantly diminishes the amount of IL-15 that is trans-
presented to NK cells and is essential for their survival. This is of clinical relevance 
because of ongoing clinical studies on CSF1R-targeting therapies. 
Thus, although blockade of CSF1R-signaling depletes TAMs and may impede tumor 
progression, at the same time it may foster metastatic disease, suggesting that this 
intervention should be applied under particular circumstances and with great care. Our 
results suggest that treatment with CSF1Ri or CSF1R-blocking antibodies targeting 
TAMs bears the risk of increasing metastatic disease, which can be efficiently 
counteracted by concomitant administration of an NK cell survival factor such as IL-
15. 
Materials and Methods 
Mice 
C57BL/6JOlaHsd1 mice were obtained from Harlan Laboratories (Envigo), Il12rb2-/- 
mice from Jackson and BALB/cJRj mice from Janvier. Mice were kept under specific 






Female mice of 6-8 weeks were used for all experiments. Experiments were 
performed in accordance with the Swiss federal and cantonal regulations on animal 
protection and were approved by The Cantonal Veterinary Office Zurich. 
Cell lines 
LLC1 cells were obtained form ATCC and lentivirally transduced to express firefly 
luciferase (LUC) generating LLC-LUC cells. Viral particles were a gift from Prof. 
Christian Münz (University of Zurich). Cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% with fetal bovine serum (FBS), 2 
mM L-glutamine, penicillin and streptomycin (all Invitrogen). 4T1 cells were a gift 
from Prof. Michael Detmar (Swiss Federal Institute of Technology in Zurich) and 
were grown in Roswell Park Memorial Institute (RPMI) 1640 Medium supplemented 
with 10% FBS, 2 mM L-glutamine, penicillin and streptomycin (all Invitrogen) 
Models of metastasis 
For spontaneous metastasis from LLC-LUC tumors, C57BL/6 mice were injected 
subcutaneously (s.c.) with 2x105 LLC-LUC cells in 100 µl PBS. Groups were 
randomized before the start of treatment. After 25-28 days mice were anesthetized 
with 2.5% attane (Piramal Healthcare Ltd.) and 0.04 mg/kg fentanyl 
(Kantonsapotheke Zurich) injected intraperitoneally (i.p). Primary tumors were 
subsequently resected and wounds were clipped with Autoclip wound clips (Becton 
Dickinson). Mice with primary tumors below 200 mg were removed from the analysis 
of the metastatic rate. For post-operative analgesia, temgesic (Schering-Plough) was 
given s.c. at 0.1 mg/kg immediately after surgery and in drinking water at 10 µg/ml 
for 48 hours ad libitum. Three weeks after surgery mice were anesthetized with 2.5% 
attane (Piramal Healthcare Ltd.) and injected i.p. with 150 mg/kg D-luciferin (TBD-
Biodiscovery). Photon flux in vivo as well as from dissected organs was measured 
using an IVIS 200 imaging system (Perkin Elmer). To compare data between 
experiments, rates of metastasis of treatment groups were normalized to the rate of the 
control group, which was set at 100%. 
For spontaneous metastasis from orthotopic breast cancer, 1x105 4T1 cells in 50 µl 
PBS were injected into the second mammary fat pad of BALB/c mice and animals 
were sacrificed on day 23 or 25, as indicated. Mice with primary tumors below 1500 
mg were removed from the analysis of metastatic burden. For counting metastases, 
India ink (15% in PBS) was injected intratracheally, lungs were removed, washed 
with PBS and fixed in Fekete’s solution (62% ethanol, 3.3% formaldehyde, 0.25 M 
acetic acid). Metastatic foci were counted blinded using a dissecting microscope. 
For experimental metastasis, C57BL/6 mice were injected intravenously (i.v.) into the 
tail vein with 5x105 LLC-LUC cells in 200 µl PBS. Mice were sacrificed on days 
mentioned in the Fig. legends and bioluminescence was measured as described above. 
Treatment of animals 
Mice were injected with 50 µg anti-CD40 (FGK45) or isotype antibody (2A3) per 
dose. To deplete CD8+ T cells, 500 µg anti-CD8 (YTS169.4) was injected at day -1 
relative to the first dose of anti-CD40. To deplete NK cells, 200 µg anti-NK1.1 
(PK136) was injected at day -2 and day 0 relative to anti-CD40 in the spontaneous 
model or on day -3 and -1 relative to i.v. injection of LLC-LUC tumor cells. Anti-
CD40, anti-NK1.1 and anti-CD8 antibodies were purified from hybridoma culture 
supernatant using protein G sepharose 4 Fast Flow (Sigma-Aldrich). Isotype antibody 





BioXCell and was used at 500 µg per dose. All antibodies were administered i.p. in 
200 µl PBS. 
The small molecule inhibitor of CSF1R (CSF1Ri) BLZ945 was supplied by Novartis 
AG and dissolved at 12.5 mg/ml in 20% Captisol as vehicle (Ligand). CSF1Ri or 
vehicle were administered daily per os (p.o.) at 200 mg/kg. 
IL-15 complexes were prepared by mixing recombinant murine IL-15 (Affymetrix 
eBioscience) and recombinant murine IL-15Ra (R&D Biosystems) in a 1:1 molar 
ratio and subsequent incubation at 37°C for 30 minutes as described (29). IL-15 
complexes were administered i.p. at 4.5 µg/mouse in 200 µl of PBS. 
Measurement of inflammatory cytokines 
Serum was collected using vacutainer rapid serum tubes (BD) and inflammatory 
cytokines were quantified using a CBA Mouse Inflammation Kit (BD). 
Flow cytometry 
Primary tumors were collected in PBS, cut into pieces and digested for 45 minutes at 
37°C in RPMI medium containing 10% FBS, 1 mg/ml collagenase IV and 2.6 µg/ml 
DNase I (both Sigma-Aldrich). Samples were washed with PBS by centrifugation for 
5 minutes at 350 g, the pellet was resuspended in PBS and filtered to remove debris. 
For intracellular IFNγ detection cells were incubated for 4 hours at 37°C in presence 
of 10 µg/ml brefeldin A (Sigma-Aldrich). For surface staining antibodies against the 
following proteins were used: CD3 (17A2), CD4 (RM4-5), CD8a (53-6.7), CD11b 
(M1/70), CD11c (N418), CD27 (LG.3A10), CSF1R (AFS98), CD45.2 (104), CD49b 
(DX5), F4/80 (BM8), FasL (MFL3), Granzyme B (NGZB), KLRG1 (26), Ly6C 
(HK1.4), Ly6G (1A8), MHCII (M5/114), NK1.1 (PK136), NKp46 (29A1.4). For 
viability staining, Zombie Violet Fixable Viability Kit was used. Antibodies and 
viability stain were purchased from Biolegend, except for Granzyme B (Affymetrix 
eBioscience). For surface and viability staining, samples were incubated in PBS for 
25 minutes at 4°C. Subsequently, cells were washed and fixed for 25 minutes with 4% 
paraformaldehyde in PBS. For intracellular staining, samples were washed with 
permeabilization buffer (PBS containing 20 mM EDTA, 2% FBS, 0.03% NaN3, 0.1% 
saponin) and incubated overnight with antibody against IFNγ (XMG1.2) (Biolegend). 
FoxP3 staining was performed according to the manufacturer’s protocol (Affymetrix 
eBioscience). For quantitative analysis, CountBright absolute counting beads were 
used (Thermo Fisher Scientific). Samples were acquired using a CyAn ADP 9 flow 
cytometer (Beckman Coulter) and analyzed using FlowJo v9.8.5 software (Tree Star). 
Histology 
Five µm thick sections of formalin-fixed, paraffin-embedded tissue were stained with 
hematoxylin (Merck Millipore) and eosin (Carl Roth AG) according to a standard 
protocol. Pictures were taken using a Leica DMI 6000 microscope. 
Statistical analysis 
For comparison of two experimental groups, two-tailed Student’s t-test with Welch’s 
correction was performed. More than two groups were compared using non-
parametric Kruskal-Wallis tests with Dunns post-tests. Rates of metastases were 
compared using chi-square test. All tests were performed with GraphPad Prism 5.0 







Fig. S1. Anti-CD40 reduces metastases from orthotopic breast cancer. 
Fig. S2. Immune infiltrate of primary LLC-LUC tumors. 
Fig. S3. Depletion of CD8+ T cells. 
Fig. S4. Depletion of CD8+ T cells has no impact on the size of primary LLC-LUC 
tumors. 
Fig. S5. Anti-CD40 activates NK cells in an IL-12-dependent manner. 
Fig. S6. Depletion of NK cells with anti-NK1.1 antibody cells has no impact on the 
sizes of primary LLC-LUC tumors. 
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Figure 1. Administration of anti-CD40 reduces metastasis from resected tumors. 
(A) Experimental timelines. (B) Rate of metastasis normalized to the control group. 
Mean ± SD. **p<0.005 (Chi-square test). Groups consisted of 5-9 mice. 
Representative data from at least 3 independent experiments are shown. (C) 
Metastatic burden measured as cumulative luminescence signal from lungs, tumor-
draining lymph nodes and livers in mice with metastatic lesions from (B). Points 
above the upper dotted line depict mice that had to be sacrificed before the endpoint 
because of high metastatic burden. Points below the lower dotted line depict mice that 
were metastasis-free. Each symbol represents an individual mouse. (D) 
Representative sections of metastatic lesions in lungs from data shown in (B) stained 
with haematoxylin and eosin. Scale bar 200 µm. 





























































































Figure 2. Anti-CD40 triggers a type I immune response, but controls metastasis 
independently of CD8+ T cells. (A) Amount of inflammatory cytokines in the serum 
24 h after the first dose of anti-CD40. Each symbol represents an individual mouse. 
Mean ± SD. **p<0.005 ***p<0.0005 (two-tailed Student’s t-test with Welch’s 
correction). (B-D) Flow cytometry analysis of the LLC-LUC tumor infiltrate on the 
day of surgery (d 28). Each symbol represents an individual mouse. Mean ± SD. 
**p<0.005 ***p<0.0005 (two-tailed Student’s t-test with Welch’s correction). (E) 
Treatment schedule. (F) Rate of metastasis normalized to the control group. *p<0.05 
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Figure 3. Anti-CD40 activates NK cells that are crucial to control of metastasis. 
(A) Expression of IFNγ, Granzyme B, FasL, NKG2D and KLRG1 by lung NK cells 
in tumor-bearing mice measured by flow cytometry 24 hours after injection of anti-
CD40. Each symbol represents an individual mouse. Mean ± SD. ***p<0.0005 (two-
tailed Student’s t-test with Welch’s correction). Representative data from at least 2 
independent experiments are shown. gMFI -  geometric mean fluorescence intensity. 
(B) NK cell maturation in the spleens of tumor-bearing mice measured by flow 
cytometry 24 hours after injection of anti-CD40. Pooled data from 3 mice. Mean ± 
SD. (C) Experimental timeline. (D) Rate of metastasis normalized to the control 
group. *p<0.05 **p<0.005 (Chi-square test). Groups consisted of 9-10 mice. 
Representative data from 3 independent experiments are shown. (E) Experimental 
timeline. (F) Tumor burden in lungs quantified as luminescence signal of lungs. 
Points above the upper dotted line depict mice that had to be sacrificed before the 
endpoint because of high metastatic burden. Each symbol represents an individual 










































































































































































Figure 4. CSF1R blockade abrogates the anti-metastatic effect of anti-CD40 and 
increases the rate of metastasis. (A) Experimental timeline. (B) Flow cytometry 
analysis of the LLC-LUC tumor infiltrate on the day of surgery (d 27). Each symbol 
represents an individual mouse. Mean ± SD. ***p<0.0005 (non-parametric Kruskal-
Wallis tests with Dunn’s post-tests). Representative data from 2 independent 
experiments are shown. (C) Tumor sizes on the day of surgery. Each symbol 
represents an individual mouse. Mean ± SD. ***p<0.0005 (non-parametric Kruskal-
Wallis tests with Dunn’s post-tests). Representative data from 2 independent 
experiments are shown. (D) Rate of metastasis normalized to the control group. 
*p<0.05 (Chi-square test). Groups consisted of 10 mice. Representative data from 2 
independent experiments are shown. (E) Experimental timeline. (F) Rate of 
metastasis normalized to the control group. *p<0.05 (Chi-square test). Groups 
consisted of 4-7 mice. Representative data from 2 independent experiments are 
















Figure 5. Anti-CSF1R treatment promotes metastasis from orthotopic breast 
cancer. (A) Experimental timeline. (B) Tumor weight on the endpoint. Mean ± SD. 
(C) Number of lung metastases. Mean ± SD. *p<0.05 (two-tailed Student’s t-test with 
Welch’s correction). Each symbol represents an individual mouse. Representative 










































































Figure 6. Increase of metastasis mediated by CSF1R blockade is caused by 
disrupted NK homeostasis and can be restored by supplementation with IL-15. 
(A) Numbers of inflammatory (Ly6Chi) and patrolling (Ly6Clow) monocytes in 
blood measured by flow cytometry 3 days after the start of CSF1Ri treatment. Each 
symbol represents an individual mouse. Mean ± SD. *p<0.05 **p<0.005 
***p<0.0005 (two-tailed Student’s t-test with Welch’s correction). Representative 
data from 2 independent experiments are shown. (B) Numbers of NK cells in blood 
measured by flow cytometry 3 days after the start of CSF1Ri treatment. Each symbol 
represents an individual mouse. Mean ± SD. *p<0.05 **p<0.005 ***p<0.0005 (two-
tailed Student’s t-test with Welch’s correction). Representative data from 2 
independent experiments are shown. (C) Experimental timeline. (D) Numbers of NK 





represents an individual mouse. Mean ± SD. *p<0.05 **p<0.005 (two-tailed Student’s 
t-test with Welch’s correction). Representative data from 2 independent experiments 
are shown. (E) Quantification of tumor burden in the lungs. Points above the upper 
dotted line depict mice that had to be sacrificed before the endpoint because of high 
metastatic burden. Each symbol represents an individual mouse. Mean ± SD. *p<0.05 
**p<0.005 (two-tailed Student’s t-test with Welch’s correction). Representative data 
from 2 independent experiments are shown. (F) Representative bioluminescence 
































Figure S1. Anti-CD40 reduces metastases from orthotopic breast cancer. (A) 
Experimental timelines. (B) Tumor weight at the endpoint. Mean ± SD. (C) Number 
of lung metastases. Mean ± SD. *p<0.05 (two-tailed Student’s t-test with Welch’s 
correction). Each symbol represents an individual mouse. Representative data from 2 





































































Figure S2. Immune infiltrate of primary LLC-LUC tumors. (A) Gating strategy. 
(B) Flow cytometry analysis on the day of surgery (d 28). Mean ± SD. Each symbol 























































































































































































































Figure S3. Depletion of CD8+ T cells. Flow cytometry analysis on the day of surgery 
(d 31). Mean ± SD. *p<0.05 **p<0.005 (non-parametric Kruskal-Wallis tests with 
Dunn’s post-tests). Mice were treated as described in Figure 2E. Each symbol 












































Figure S4. Depletion of CD8+ T cells has no impact on the size of primary LLC-
LUC tumors. Measurement taken on the day of surgery (d 31). Mean ± SD. Mice 
were treated as described in Figure 3C. Each symbol represents an individual mouse. 
anti-CD40
anti-CD8
























Figure S5. Anti-CD40 activates NK cells in an IL-12-dependent manner. 
Expression of IFNγ, FasL, NKG2D, KLRG1 by lung NK cells measured by flow 
cytometry 24 hours after injection of anti-CD40 in wild-type (control) and Il12rb2 
deficient mice (IL-12Rb2-/-). Each symbol represents an individual mouse. Mean ± 
SD. *p<0.05 ***p<0.0005 (two-tailed Student’s t-test with Welch’s correction). ns – 
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Figure S6. Depletion of NK cells with anti-NK1.1 antibody cells has no impact on 
the sizes of primary LLC-LUC tumors. Measurement taken on the day of surgery. 
Mean ± SD. Mice were treated as described in Figure 3C. Each symbol represents an 

































Figure S7. Targeting CSF1R-expressing TAMs has no impact on the size of 
primary LLC-LUC tumors. (A) Flow cytometry analysis. A representative example 
of 5 mice is shown. (B) Size of primary tumor measured on the day of surgery (d 21). 
Mean ± SD. Mice were treated as described in Figure 4A. Each symbol represents an 
individual mouse. Representative data from 2 independent experiments are shown. 
 































3.2 The role of tumour-derived prostaglandin E2 in the development of 
metastatic disease 
Michal Beffinger1, Yannick Montagnolo1, Maries van den Broek1 
1 Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland 
3.2.1 Introduction 
Prostaglandin E2 (PGE2) is an important mediator of inflammation. It is produced by myeloid 
cells, like macrophages and neutrophils (100, 265) and triggers vascular permeability and 
fever, thus playing a significant role in the early steps of inflammatory response (266). 
However, recent studies have shown that tumours hijack this mechanism to induce 
tumour-promoting chronic inflammation (267) and render T and NK cell dysfunctional (60, 
267, 268). PGE2 can also induce production of IL-23 by dendritic cells (DCs), which drives 
differentiation of CD4+ T cells into tumour-beneficial IL-17-producing cells (269). 
Furthermore, PGE2 can stimulate macrophage polarization towards a tumour-promoting 
phenotype, which induces neovasculogenesis through vascular endothelial growth factor 
(VEGF) production. Besides this, PGE2 induces as well VEGF-independent angiogenesis 
(161, 268). 
PGE2 synthesis is a three-step process, which starts with the release of arachidonic acid from 
the cell membrane and processing into PGG2 and PGH2 by cyclooxygenase (COX)-1 and 
COX-2. PGH2 is further metabolised into various prostaglandins by respective enzymes. 
PGE2 production depends on three independent synthases, namely membrane-bound PGE 
synthase (mPGES)-1, mPGES-2 and cytosolic PGES (cPGES). These enzymes have different 
subcellular localization (mPGES-1 in the perinuclear membrane, mPGES-2 in both Golgi and 
cytosol whereas cPGES in the cytosol only) but also a different preference for the upstream 
COX enzymes: mPGES-1 processes PGH2 from COX-2, mPGES-2 from COX-1 and COX-2, 
whereas cPGES mainly from COX-1 (270). 
COX-2 has been associated with intestinal tumorigenesis (271) and its overexpression has 
been observed in tumour-associated macrophages (TAMs) (272). COX-2 inhibitors potentiate 
anti-angiogenic therapy in preclinical studies (268) and are tested for colorectal cancer 
treatment (273), exemplifying the importance of prostaglandin-mediated inflammatory 
mechanisms in the cancer development or progression 
We aimed to investigate whether PGE2 has an impact on the metastatic cascade. We used a 
model of spontaneous metastasis from resected Lewis Lung Carcinoma (LLC) tumours, 
which produce high amounts of PGE2 (109, 274, 275). This has been correlated with tumour 
cell motility (275), ability to establish tumours after subcutaneous injection into syngeneic 
	 55 
mice (274), but also induction of immunosuppressive function in tumour-associated as well as 
alveolar macrophages (109, 276). It remains however unclear if PGE2 is directly involved in 
the process of metastasis. 
Here we show that disruption of PGE2 production in cancer cells is sufficient to reduce their 
ability to metastasise, which is correlated with increased infiltration of the primary tumours 
with CD4+ T and NK cells, but decreased numbers of neutrophils. 
3.2.2 Materials and methods 
Mice 
C57BL/6JOlaHsd1 mice were obtained from Harlan Laboratories (Envigo). Mice were kept 
under specific pathogen-free conditions at the Laboratory Animal Services Center at the 
University of Zurich. 
Female mice of 6-8 weeks were used for all experiments. Experiments were performed in 
accordance with the Swiss federal and cantonal regulations on animal protection and were 
approved by The Cantonal Veterinary Office Zurich. 
Model of spontaneous metastasis 
Mice were injected subcutaneously (s.c.) with 2 × 105 LLC-LUC or LLC-LUC-mP1/mP2/cP-/- 
cells in 100 µl PBS. Groups were randomized before the start of treatment. After 25-28 days 
mice were anesthetized with 2.5% attane (Piramal Healthcare Ltd.) and 0.04 mg/kg fentanyl 
(Kantonsapotheke Zurich) injected intraperitoneally (i.p). Primary tumours were subsequently 
resected and wounds were clipped with Autoclip wound clips (Becton Dickinson). Mice with 
primary tumours below 200 mg were removed from the analysis of the metastatic rate. For 
post-operative analgesia, temgesic (Schering-Plough) was given s.c. at 0.1 mg/kg 
immediately after surgery and in drinking water at 10 µg/ml for 48 hours ad libitum. Three 
weeks after surgery mice were anesthetized with 2.5% attane (Piramal Healthcare Ltd.) and 
injected i.p. with 150 mg/kg D-luciferin (TBD-Biodiscovery). Photon flux in vivo as well as 
from dissected organs was measured using an IVIS 200 imaging system (Perkin Elmer). To 
compare data between experiments, rates of metastasis of treatment groups were normalized 
to the rate of the control group, which was set at 100%. 
Cell lines 
Parental LLC-LUC tumour cells are described in chapter 3.1. To generate PGE2-deficient 
LLC-LUC cells, we used the microbial clustered regularly interspaced short palindromic 
repeats (CRISPR)/Cas9 nuclease system to mutate three downstream PGE synthases: 
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mPGES-1, mPGES-2 and cPGES (270, 277). To maximise chances of disrupting their 
enzymatic function, we aimed to introduce double strand breaks in the vicinity of the active 
centres of the enzymes, which were arginine100 in mPGES-1 (278), cysteine110 (279) and 
tyrosine9 in cPGES (280). Single-guide RNA (sgRNA) were designed using an online tool 
(281) and cloned into a plasmid coding CRISPR backbone as well as Cas9 tagged through a 
self-cleaving AA peptide with enhanced green fluorescent protein (eGFP). Cells were grown 
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% with fetal bovine 
serum (FBS), 2 mM L-glutamine, penicillin and streptomycin (all Invitrogen).  
Transfected cells were sorted based on their GFP expression using FACS Aria III 5L (Becton 
Dickinson). After the last sorting round, we have derived monoclonal cell lines. 
Plasmid purification and cloning 
The backbone plasmid pSpCas9(BB)-2A-GFP (Addgene) was purified from Escherichia coli 
culture using QIAGEN Plasmid Kits (Qiagen), digested using BbsI restriction enzyme 
(Thermo Fisher Scientific) and purified by gel electrophoresis using QIAquick Gel Extraction 
Kit (Qiagen). Ligation of sgRNA into the backbone was achieved using T4 DNA Ligase 
(NEB). 
sgRNA design, synthesis and DNA sequencing 
sgRNA were designed using CHOPCHOP tool (281). Synthesis of sgRNA and sequencing of 
DNA was performed by Microsynth AG. 
Transfection 
LLC-LUC cells were transfected using branched Mw=25000 polythylenimine (PEI) (Sigma 
Aldrich). Briefly, 106 LLC-LUC cells were seeded on a single well of 6 well plate. 2 µg of 
plasmid was mixed with 15 µg of PEI in FBS-free medium and incubated for 8 minutes in 
room temperature. Cells were washed with PBS. Plasmid-PEI solution was mixed with 
complete medium and added to the cells for 2 h. After that time, cells were washed and 
medium was changed to standard. Transfection efficacy was checked by flow cytometry 24 h 
after washing. 
Cell sorting 
Transfected cells were sorted based on their GFP expression using FACS Aria III 5L (Becton 
Dickinson). 
Flow cytometry 
Primary tumours were collected in PBS, cut into pieces and digested for 45 minutes at 37°C 
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in RPMI medium containing 10% FBS, 1 mg/ml collagenase IV and 2.6 µg/ml DNase I (both 
Sigma-Aldrich). Samples were washed with PBS by centrifugation for 5 minutes at 350 g, the 
pellet was resuspended in PBS and filtered to remove debris. For surface staining antibodies 
against the following proteins were used: CD3 (17A2), CD4 (RM4-5), CD11b (M1/70), 
CD19 (6D5), CD45.2 (104), F4/80 (BM8), Ly6C (HK1.4), Ly6G (1A8), NK1.1 (PK136). For 
viability staining, Zombie Violet Fixable Viability Kit was used. Antibodies and viability 
stain were purchased from Biolegend. For surface and viability staining, samples were 
incubated in PBS for 25 minutes at 4°C. For quantitative analysis, CountBright absolute 
counting beads were used (Thermo Fisher Scientific). Samples were acquired using a CyAn 
ADP 9 flow cytometer (Beckman Coulter) and analyzed using FlowJo v9.8.5 software (Tree 
Star). 
Quantitative Real Time PCR 
RNA was purified using TRI Reagent following producer’s protocol (Ambion). Remaining 
DNA was digested using 1 unit DNase I (NEB) for 10 µg of RNA. Retrotranscription was 
performed using MultiScribe Reverse Transcriptase following producer’s protocol (Thermo 
Fisher Scientific). Real Time PCR was performed using EvaGreen mastermix (Biotum) and 
LightCycler 480 thermocycler (Roche Life Science). Transcript levels were normalised to 
Gapdh as an internal control. Following primers were used: 
- Gapdh 











mPGES-1, mPGES-2 and cPGES primers were designed using Universal ProbeLibrary Assay 
Design Center tool (Roche Life Science). 
PGE2 detection 
Cells were seeded at 100 000 cells / well on a 96-well plate. After 24 h supernatants were 
collected and PGE2 was quantified using PGE2 ELISA kit (Enzo Life Sciences). 
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Statistical analysis 
For comparison of two experimental groups, two-tailed Student’s t-test with Welch’s 
correction was performed. Rates of metastases were compared using chi-square test. All tests 
were performed with GraphPad Prism 5.0 and GraphPad QuickCalcs (GraphPad Software). 
*p<0.05, **p<0.005, ***p<0.0005. 
3.2.3 Results 
Generation of PGE2-deficient cell lines 
Transfection of LLC-LUC using polythylenimine resulted in a low albeit reproducible 
transfection rate (<5%) and cells retained their GFP expression for up to 4 days (data not 
shown). First we have performed transfection with a plasmid encoding sgRNA for mPGES-1 
and sorted GFP+ cells. Second, we have repeated the procedure with a plasmid encoding the 
mPGES-2 sgRNA and finally with cPGES sgRNA. After the last sorting round, we have 
derived monoclonal cell lines. Further selection has been done based on the amount of 
transcripts of the three synthases (Fig. 1 A) and production of PGE2 (Fig. 1 B) resulting in 

















LLC-LUC-mP1/mP2/cP-/-:  ———GT——TACGCGG 
Predicted cutting site:  
 
       ^  
 
Figure 1. Generation of LLC-LUC derivative deficient in PGE2 production (A) Amounts 
of mPGES-1, mPGES-2 and cPGES transcripts measured by quantitative real time PCR. (B) 
PGE2 measured by ELISA. (C) Double strand break induced in the mPGES-1 gene introduced 
a two-nucleotide deletion. Sequencing of the genomic DNA of parental and 
LLC-LUC-mP1/mP2/cP-/-. 
 
There is no quantitative difference in mPGES-1 transcripts between the parental LLC-LUC 
and LLC-LUC-mP1/mP2/cP-/-, but targeted sequencing of mPGES-1 around the predicted 
cutting site revealed introduction of mutations  (Fig. 1 C). 
These data confirm that we have successfully generated a cell line deficient in synthesis of 
PGE2. 
Reduction of tumour-derived PGE2 does not influence the growth of primary tumours, but 
induces changes in their immune infiltrate 
To validate whether tumour-derived PGE2 is important in the metastatic cascade, we have 
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Figure 2. Absent PGE2 production does not interfere with the growth of primary 
tumour, but changes in the immune infiltrate (A) Growth of primary tumours. (B) Immune 
infiltrate of primary tumours on the day of surgery (day 26). CD4+ T cells (live CD45.2+ 
CD3+ CD4+), NK cells (live CD45.2+ CD3- NK1.1+) and neutrophils (live CD45.2+ CD11b+ 
Ly6G+). Dead cells were excluded from the analysis. Mean ± SD, *p<0.05 **p<0.005 (two-




There was no difference in the growth of primary tumours between the groups (Fig. 2 A). 
Tumours were resected on day 26 followed by analysis of immune infiltrate by flow 
cytometry. LLC-LUC-mP1/mP2/cP-/- tumours contain more NK cells and CD4+ T cells, 
whereas numbers of neutrophils are reduced. No difference was observed in numbers of 
monocytes, macrophages and B cells between the two cohorts (Fig. 2 B). 
Mice bearing tumours deficient in PGE2 production are less prone to develop metastatic 
disease 
Three weeks after resection of the primary tumours we have screened mice for the presence 
of metastatic lesions. Whereas 78% of control animals (7/9) developed metastases, only 27% 
in the LLC-LUC-mP1/mP2/cP-/- group (3/11) had metastases (Fig. 3). This points to an 





Figure 3. Production of PGE2 is crucial for establishment of metastasis. Rate of 
metastasis normalized to the control group. ***p<0.0005 (Chi-square test).  
 
3.2.4 Discussion 
We show that PGE2 derived from the tumour cells is sufficient for development of metastatic 
disease. As also macrophages and other myeloid cells can produce prostaglandins, it is likely 
that also this contributes to metastasis, but we did not formally address this here.  
PGE2 is a potent inducer of polarization of TAMs into protumorigenic M2 cells (109). As the 
majority of the leukocytes in the tumours are macrophages, it will be interesting to investigate 
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whether TAMs in the LLC-LUC-mP1/mP2/cP-/- tumours exhibit maturation differences as 
compared to those in the parental tumours. These could be measured by expression levels of 
arginase I or mannose receptor (CD206). Furthermore, protumorigenic macrophages produce 
high amounts of VEGFs (161). It is thus possible that LLC-LUC-mP1/mP2/cP-/- tumours 
contain higher amounts of VEGF and as a consequence have changes in lymph or blood 
vasculature, what could explain the decreased metastatic rate in these animals. 
PGE2 can also inhibit the function of CD8+ T and NK cells (60, 68). The data described in 
chapter 3.1 show that NK cells are crucial to metastatic seeding. It is important to characterise 
both tumour and blood NK cells with respect to their maturation and expression of activating 
receptors. Furthermore, although there are no differences in numbers of CD8+ T cells, we did 
not yet investigate their effector function. 
Tumours can induce changes in distant organs, for example the accumulation of immature 
myeloid cells (134, 136), often referred to as the pre-metastatic niche. It is interesting to 
investigate whether tumour-derived PGE2 impacts on the pre-metastatic niche during cancer 
progression. As we have observed decreased infiltration of neutrophils into the primary 
tumours, it is possible that mice have lower numbers of neutrophils in the circulation or 
potentially directly in the metastasis target organs, like lungs or livers. Neutrophils were 
previously shown to dampen CD8+ T cell responses and inhibit NK cells from lysing 
circulating tumour cells (124, 125). Reduced neutrophil counts could also underline potential 
differences in activity of tumour-infiltrating lymphocytes. 
It can be speculated that decrease in the metastatic burden is a result of insufficient autocrine 
signalling of prostaglandin, which could lead to increased apoptosis of metastasising tumour 
cells (85). This is however unlikely, as LLC-LUC-mP1/mP2/cP-/- tumours have similar 
growth kinetics in vivo to the parental cells. 
Furthermore, when injected subcutaneously, tumours deficient in PGE2 production grow 
equally fast as the parental LLC-LUC. This stands in contrast to the reported data showing 
that genetic deletion of COX-1 and COX-2 in melanoma cells induces immune-mediated 
rejection of tumours through both innate and adaptive immunity (267). This discrepancy may 
be explained by differences in immunogenicity or in tumour-associated immune infiltrate 
between melanoma cells and the LLC cells we used. It would be interesting to see if 
increasing the antigenicity of tumour cells, e.g. by inducing expression of an additional 
antigen would reveal an impact of PGE2 on tumour-specific T cells or on growth of the 
primary tumour. Alternatively, COX-1 and COX-2 are not specific for PGE2 and can process 
PGH2 into other prostanoids, like PGD2, PGI2, PGF2α, and thromboxane A2 (TXA2), which 
might partially explain the differences between studies (268). 
It is also possible that primary LLC-LUC-mP1/mP2/cP-/- tumours grow equally well as the 
parental ones the loss of immunomodulatory function of PGE2 is compensated by other 
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mechanisms. CD4+ T cells better infiltrate lLC-LUC-mP1/mP2/cP-/- tumours and at this stage 
it cannot be excluded that these CD4+ T cell are FoxP3+ T regulatory cells. 
The next step would be to define if LLC-LUC-mP1/mP2/cP-/- tumour cells can extravasate in 
the target organs as efficiently as the parental cell line. This can be addressed by intravenous 
injection of tumour cells. Depletion of NK cells in this context would also allow determining 
if LLC-LUC-mP1/mP2/cP-/- cells were susceptible to NK cell-mediated control. 
Further experiments are required to delineate the mechanism by which tumour-derived PGE2 
promotes metastasis. Such data may ultimately open new perspectives for using 
anti-inflammatory drugs in prevention of metastatic disease. 
  
	 64 
3.3 The efficacy of agonistic anti-CD27 antibody, agonistic anti-CD40 and 
checkpoint blockade in protection against spontaneous metastases. 
Michal Beffinger1, Yannick Montagnolo1, Aron Gagliardi1, Nikola Misljencevic1, Hideo 
Yagita2, Maries van den Broek1 
1 Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland. 
2 Department of Immunology, Juntendo University School of Medicine, Tokyo, 113-8421, 
Japan. 
3.3.1 Introduction 
CD27 is a member of the TNF receptor superfamily expressed on T as well as NK cells (282). 
Its ligation stimulates CD8+ T cell activation, survival and acquisition of memory phenotype, 
as well as IFN-γ production by CD4+ T cells (283). On the NK cells, CD27, in combination 
with CD11b, defines four stages of maturation, where immature NK cells are CD27- CD11b-. 
Along maturation process, NK cells upregulate CD27 (CD27+ CD11b+), what is followed by 
increased CD11b expression (CD27+ CD11b+) and downregulation of CD27 in the final stage 
(CD27- CD11b+) (284). Agonistic anti-CD27 antibodies have been tested in preclinical 
models of lymphoma and melanoma where they stimulate T as well as NK cell-mediated 
responses (282, 283, 285). 
Also CD40 is also a member of the TNF receptor superfamily. It is expressed on APC, like B 
cells, DCs and monocytes (38). Ligation of CD40 by CD40L-expressing CD4+ T helper cell 
drives APC maturation and licenses them for priming of CD8+ T cells (243). This is achieved 
by increasing antigen presentation (signal 1), co-stimulation (signal 2) and secretion of 
cytokines, like type I interferons and IL-12 (signal 3) (286). Using a model of spontaneous 
metastasis we have shown that anti-CD40-mediated protection from metastases is driven 
mainly by NK cells (chapter 3.1). 
Although anti-CD40 protects the majority of mice, about 10 - 20% still develop metastasis, 
suggesting that the anti-metastatic efficacy of anti-CD40 can be improved. We therefore 
supplemented anti-CD40 therapy with immune checkpoint blocking antibodies (anti-CTLA-4 
+ anti-PD-1). In addition, we investigated the protective potential of agonistic anti-CD27 
antibody as a monotherapy. 
3.3.2 Materials and methods 
Mice 
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C57BL/6JOlaHsd1 mice were obtained from Harlan Laboratories (Envigo). Mice were kept 
under specific pathogen-free conditions at the Laboratory Animal Services Center at the 
University of Zurich. 
Female mice of 6-8 weeks were used for all experiments. Experiments were performed in 
accordance with the Swiss federal and cantonal regulations on animal protection and were 
approved by The Cantonal Veterinary Office Zurich. 
Model of spontaneous metastasis 
Mice were injected subcutaneously (s.c.) with 2 × 105 LLC-LUC cells in 100 µl PBS. To 
exclude the possibility that tumour size impacts on the rate of metastasis, we have excluded 
mice with tumours < 200 mg. Resection of primary tumours as well as detection of metastatic 
lesions was performed as described under 3.2.2. 
Treatment of animals 
Mice were injected with 100 µg anti-CD27 (clone RM27-3E5), 50 µg anti-CD40 (FGK45), 
200 µg anti-CTLA-4 (9H10), 200 µg anti-PD-1 (RMP1-14) or 50 µg isotype antibody (2A3) 
per dose. Anti-CD40 and anti-CTLA-4 antibodies were purified from hybridoma culture 
supernatant using protein G sepharose 4 Fast Flow (Sigma-Aldrich). Anti-CD27 and 
anti-PD-1 were provided by Prof. Dr. Hideo Yagita. Isotype antibody was obtained from 
BioXCell. All antibodies were administered i.p. in 200 µl PBS. 
Flow cytometry 
Primary tumours were collected in PBS, cut into pieces and digested for 45 minutes at 37°C 
in RPMI medium containing 10% FBS, 1 mg/ml collagenase IV and 2.6 µg/ml DNase I (both 
Sigma-Aldrich). Samples were washed with PBS by centrifugation for 5 minutes at 350 g, the 
pellet was resuspended in PBS and filtered to remove debris. Blood samples were collected in 
PBS supplemented with 2% FCS (Invitrogen), 20 mM EDTA (Sigma Aldrich) and 0.03% 
NaN3 (Sigma Aldrich). For surface staining antibodies against the following proteins were 
used: CD3 (17A2), CD4 (RM4-5), CD8α (53-6.7), CD11b (M1/70), CD19 (6D5), CD27 
(LG.3A10), CD45.2 (104), F4/80 (BM8), KLRG1 (26), Ly6C (HK1.4), Ly6G (1A8), NK1.1 
(PK136). For viability staining, Zombie Violet Fixable Viability Kit was used. Antibodies 
and viability stain were purchased from Biolegend. For surface and viability staining, samples 
were incubated in PBS for 25 minutes at 4°C. Subsequently, cells were washed and fixed for 
25 minutes with 4% paraformaldehyde in PBS. FoxP3 staining was performed according to 
the manufacturer’s protocol (Affymetrix eBioscience). For quantitative analysis, CountBright 
absolute counting beads were used (Thermo Fisher Scientific). Samples were acquired using a 
CyAn ADP 9 flow cytometer (Beckman Coulter) and analyzed using FlowJo v9.8.5 software 
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(Tree Star). 
Measurement of inflammatory cytokines 
Serum was collected using vacutainer rapid serum tubes (BD) and inflammatory cytokines 
were quantified using a CBA Mouse Inflammation Kit (BD). 
Statistical analysis 
For comparison of two experimental groups, two-tailed Student’s t-test with Welch’s 
correction was performed. Rates of metastases were compared using chi-square test. All tests 
were performed with GraphPad Prism 5.0 and GraphPad QuickCalcs (GraphPad Software). 
*p<0.05, **p<0.005, ***p<0.0005. 
3.3.3 Results 
Anti-CD27 drives accumulation of maturate NK cells 
Mice were injected s.c. with LLC-LUC tumours and treated with the first dose of anti-CD27 
antibody when tumours were established (average 90 mm2) (Fig. 1 A). In order to determine 
if anti-CD27 induced changes in peripheral blood leukocyte composition we took blood 
samples 24 hours after the first dose of anti-CD27. There were no differences in percentage of 
CD8+, CD4+ T nor NK cells (Fig. 1 B). However, NK cells in anti-CD27-treated group were 
more mature, as depicted by CD11b expression (Fig. 1 C). Based on these results, we 
measured the expression of killer cell lectin-like receptor subfamily G member 1 (KLRG1), a 
maturation and effector function marker, as well as stress receptor natural-killer group 2, 
member D (NKG2D). On the day of surgery, peripheral blood NK cells express higher levels 
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Figure 1. Administration of anti-CD27 does not change blood leukocyte composition, 
but drives maturation of NK cells. (A) Experimental timeline for anti-CD27 administration 
before the surgery. Primary tumours were resected on day 23 from the injection of tumour 
cells. (B) Percentage of CD4+ (CD45.2+ CD3+ CD4+), CD8+ T (CD45.2+ CD3+ CD8+), cells 
and NK (CD45.2+ CD3- NK1.1+), cells in total peripheral blood leukocytes on day -4. (C) 
Maturation of peripheral blood NK cells measured by CD11b expression on the day of 
surgery. (D) KLRG1 and NKG2D expression by peripheral blood NK cells. Blood samples 
taken on the day of surgery. Mean ± SD, *p<0.05 **p<0.005 (two-tailed Student’s t-test with 
Welch’s correction) 
 
Furthermore, we have analysed the immune infiltrate of primary tumours. There were no 
differences in numbers of B, T and NK cells nor myeloid cells, including Ly6C+ monocytes, 
macrophages and neutrophils (Fig. 2 A). As in the peripheral blood, tumour-infiltrating NK 
cells exhibited more mature, KLRG1+ phenotype (Fig. 2 B). Agonistic anti-CD27 antibody 
had no impact on the size of primary tumour (Fig. 2 C). 
A   
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We therefore conclude that a single dose of anti-CD27 in tumour-bearing animals does not 
stimulate significant proliferation of NK or T cells, although it drives accumulation of mature 
NK cells. 
Anti-CD27 does not stimulate systemic inflammation 
In order to define if anti-CD27 induces a systemic inflammatory response, we have measured 














Figure 2. Changes induced by anti-CD27 in primary tumours resemble those from 
periphery. (A) Numbers of B (live CD45.2+ CD19+), CD4+ (live CD45.2+ CD3+ CD4+), and 
CD8+ T cells (live CD45.2+ CD3+ CD8+), NK cells (live CD45.2+ CD3- NK1.1+), neutrophils 
(live CD45.2+ CD11b+ Ly6G+), inflammatory monocytes (live CD45.2+ CD11b+ Ly6C+), and 
macrophages (live CD45.2+ CD11b+ F4/80+ Ly6Cint), in the tumour on the day of surgery. (B) 
Expression of KLRG1 by tumour-infiltrating NK cells. (C) Weight of primary tumours.  
Mean ± SD, *p<0.05 (two-tailed Student’s t-test with Welch’s correction) 
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serum levels of IL-6, IL-12, TNF, CCL-2 and IFN-γ as well as anti-inflammatory cytokine 
IL-10 24 h after the first dose of anti-CD27. We observed no induction of IL-6, TNF or 
CCL-2 (Fig. 3), whereas the amount of IL-10, IL-12 and IFN-γ were below the detection limit 
(data not shown). 
 
 
Stimulation of immune system with anti-CD27 is not sufficient to treat metastatic disease 
To determine if anti-CD27 impacts on the development of progression of metastatis, we have 
compared therapy started before the resection of primary tumour (Fig. 1 A) and after the 
surgery (Fig. 4 A). None of the regimens changed the rate of metastasis (Fig. 4 B). 
Based on these results we conclude that agonistic anti-CD27 antibody as a monotherapy is not 









Figure 3. Single dose of anti-CD27 does not induce systemic inflammation. Amount of 
inflammatory cytokines in the serum 24 hours after the first injection of anti-CD27 (day -4).  






Blockade of CTLA-4 and PD does not improve the anti-metastatic effect of agonistic 
anti-CD40 antibody 
Because anti-CD40 has a significant anti-metastatic effect but did not prevent metastasis in all 
the mice (chapter 3.1), we have investigated whether additional stimulation of immunity with 
checkpoint blocking antibodies improves the anti-metastatic efficacy of anti-CD40 treatment. 
Anti-CD40 prevents development of metastatic disease only if given before the surgery. 
However, to sustain the elicited immune response we have continued checkpoint blockade 
treatment until the endpoint, according to the treatment scheme (Fig. 5 A). Tumours were 
resected on day 28 from tumour cell injection and we have analysed their immune infiltrate. 	  
 
 
Figure 4. Anti-CD27 has no anti-metastatic effect when given neither before nor after 
the surgery. (A) Experimental timeline for anti-CD27 administration after the surgery.  
Primary tumours were resected on day 23 from the injection of tumour cells. (B) Rate of 
metastasis normalized to the control group. 
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Compared to the animals treated with anti-CD40 alone, we observed a reduced percentage of 
Tregs within CD4+ T cell pool (Fig. 5 B). This is mediated by anti-CTLA-4 (Fig. 5 C) and is 
consistent with the observation that those anti-CTLA4 clones, which bind Fcγ-receptors, elicit 
antibody-dependent cell-mediated cytotoxicity (ADCC) resulting in depletion of CTLA-4high 
Tregs (66). The anti-CTLA-4 clone 9H10 clone we have used binds FcγRIV (66), which is 
expressed on ADCC-competent macrophages in the infiltrate of LLC-LUC tumours (Fig. 5 
D). 
We have compared the anti-metastatic activity of combination of antibodies to anti-CD40 
alone in the two regimens: starting before (Fig. 5 A, Fig. 6 A) and after the surgery (Fig. 6 B, 
C). In both regimens, combination of antibodies was not more beneficial than the anti-CD40 
alone (Fig. 6 D, E). We conclude that in our model the anti-metastatic effect of anti-CD40 














Figure 5. Combination of anti-CD40, anti-CTLA-4 and anti-PD-1 reduces percentage of 
Tregs in CD4+ T cell pool. (A) Experimental time line of combination treatment starting 
before the surgery.  Primary tumours were resected on day 28 from the injection of tumour 
cells. (B) Percentage of Tregs in total CD4+ T cell infiltrate of primary tumour on the day of 
surgery.  Mean ± SD, ***p<0.0005 (non-parametric Kruskal-Wallis tests with Dunn’s post-
tests). (C) Percentage of Tregs in total CD4+ T cell (live CD45.2+ CD3+ CD4+ FoxP3+) 
infiltrate of primary tumour on the day of surgery. Mice were treated with anti-CTLA-4 on 
day -5 and -2.  Mean ± SD, *p<0.05 (two-tailed Student’s t-test with Welch’s correction). (D) 
Expression of FcγRIV on MHCII+ population of tumour-associated macrophages (live 






It was shown previously that agonistic anti-CD27 antibody reduced the number of metastasis 












Figure 6. Supplementation of anti-CD40 therapy with anti-CTLA-4 and anti-PD-1 does 
not improve the anti-metastatic effect. (A) Experimental time line of combination treatment 
starting after the surgery.  Primary tumours were resected on day 23 from the injection of 
tumour cells. (B) Experimental time line of anti-CD40 treatment starting before the surgery.  
Primary tumours were resected on day 23 from the injection of tumour cells. (C) 
Experimental time line of anti-CD40 treatment starting after the surgery.  Primary tumours 
were resected on day 23 from the injection of tumour cells. (D, E) Rate of metastasis 
normalized to the control group. *p<0.05, ***p<0.0005 (Chi-square test) 
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not observe an impact of anti-CD27 treatment on the growth of primary tumours or 
metastasis. As anti-CD27 promotes development of effector T cells, this discrepancy might be 
explained by the fact that B16-OVA cells are more immunogenic than the LLC-LUC cells we 
used. It is interesting to test this hypothesis by using LLC-LUC-OVA cells. However, another 
study that used a different clone of anti-CD27 also reported control of parental B16 
melanoma cells (283). In both cases, mice were treated with seven injections of anti-CD27, 
whereas we have used only two. A two-dose regimen was used in another study to induce 
rejection of lymphomas, what was mediated by CD8+ T cells with minor contribution of NK 
cells (285). In this reported experiment treatment was initiated on day six, when tumour were 
below 20 mm2 (285), whereas we have started injecting anti-CD27 on day 18, when tumours 
reached size of approximately 60 mm2. This means longer exposition of lymphocytes to 
immune-subversive tumour environment. It is possible that continued anti-CD27 treatment is 
necessary to sustain anti-tumour response to established tumour lesions and it could explain 
why we have not seen any impact on the size of primary tumours. It cannot however explain 
equal rates of metastasis between the treatment groups. 
Besides stimulating T cell responses, agonistic anti-CD27 induces NK cell activation (282, 
285). We have observed increased percentage of mature CD11b+ and KLRG1+ NK cells, but 
no differences in total NK cell numbers, arguing against major expansion of NK cells. The 
impact of anti-CD27 on NK cell cytotoxicity against LLC-LUC tumours needs to be further 
elucidated. Furthermore, we have shown previously that the anti-metastatic effect of anti-
CD40 is dependent on NK cells without contribution of CD8+ T cells (chapter 3.1). 
Analogously, it cannot be excluded that the anti-CD27 does not provide sufficient activation 
of NK cells, whereas in our model CD8+ T cells are not able to control metastatic tumours. 
In order to improve the anti-metastatic effect of anti-CD40 we have combined it with 
blocking anti-CTLA-4 and anti-PD-1 antibodies. Such therapy has the potential to mount an 
efficient T cell-mediated anti-tumour response (223-226) and, as NK cells also express PD-1 
and CTLA-4, can improve the NK cell-mediated control of disseminated tumour cells (208, 
228, 229). We have not observed therapeutic benefit of combination therapy compared to 
anti-CD40 alone, suggesting that in this experimental setup further activation of NK cells is 
not possible using checkpoint blocking antibodies. In addition, such therapy is insufficient to 
trigger T cell-mediated anti-metastatic response or shows that T cells play a minor role in 
controlling metastatic seeding. The latter is in agreement with our observation that 
CD8-depletion does not increase the metastatic load in our model (chapter 3.1). 
The most prominent change triggered by the combination treatment in the immune infiltrate 
of primary tumours was reduced percentage of Tregs in the CD4+ T cell pool. This is 
consistent with previous report (66) and can have potential effect on NK and CD8+ T cell 
activity. On the other hand its impact may be overridden by deletion of total CD4+ T cells that 
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is triggered by anti-CD40 alone (chapter 3.1). Consistently, we have not detected changes in 
the primary tumour size induced by the combination therapy, although it cannot be excluded 
that this could occur if treatment was initiated earlier, e.g. during the first week from injection 
of tumour cells.   
Finally, none of the tested therapies were successful when treatment was started after the 
surgery, showing that although immune system can control the metastatic cascade on multiple 
steps, further work is required to establish a therapy that prevents both the establishment and 
outgrowth of the metastatic lesions. 	  
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3.4 Role of the activated leukocyte cell adhesion molecule (ALCAM) in the 
metastatic cascade 
Michal Beffinger1, Ann-Helen Willrodt2, Yannick Montagnolo1, Cornelia Halin Winter2, 
Maries van den Broek1 
1 Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland. 
2 Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland. 
* These results will be part of a manuscript by Willrodt, et al. (in preparation). 
3.4.1 Introduction 
Activated leukocyte cell adhesion molecule (ALCAM, CD166) is a member of the 
immunoglobulin superfamily and is expressed during steady state by a wide array of cells, 
including leukocytes, fibroblasts, epithelial cells, hepatocytes, neurons and mesenchymal as 
well as hematopoietic stem cells (287, 288). In addition, ALCAM expression is induced on 
lymphatic endothelium in the context of inflammation (289). ALCAM enables adhesion 
through binding with CD6, L1CAM, galectin-8 or homophilic interaction with other ALCAM 
molecules (287, 289). 
ALCAM participates in leukocyte transmigration through endothelial walls, but is also 
involved in angiogenesis and in interaction between DCs and lymphocytes (287, 288). 
Furthermore, blockade of ALCAM reduces DC adhesion to lymphatic endothelial cells (289). 
Cancer cells can express ALCAM, presumably as a result of inflammatory signalling and 
NFκB activation (290). More than 70% of melanomas are ALCAM-positive and it is 
suggested that it contributes to metastasis by enabling adhesion of circulating tumour cells to 
the endothelium (290). Furthermore, ALCAM is a marker of colorectal cancer stem cells 
(288). Overexpression of soluble ALCAM by cancer cells, which blocks ALCAM 
interactions, reduces the amount of lung metastases in nude mice (290). Alternatively, 
ALCAM may induce a change in the cellular pathways linking proliferation and invasiveness, 
as was shown for other adhesion molecules like E-cadherin and L1CAM (287).  
Here we show that Alcam-deficient mice develop significantly less metastasis from resected 
LLC-LUC tumours compared to wild type mice.  
3.4.2 Materials and methods 
Mice 
C57BL/6J mice were obtained from Jackson Laboratory. B6.129(FVB)-Alcamtm1Jawe/J 
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(Alcam-/-) mice were originally obtained from Jackson Laboratory and bred under specific 
pathogen-free conditions at the Rodent Center HCI ETH Zurich. 
During experiments mice were kept under specific pathogen-free conditions at the Laboratory 
Animal Services Center at the University of Zurich. Female mice of 6-8 weeks were used for 
all experiments. Experiments were performed in accordance with the Swiss federal and 
cantonal regulations on animal protection and were approved by The Cantonal Veterinary 
Office Zurich. 
Model of spontaneous metastasis 
Mice were injected subcutaneously (s.c.) with 2 × 105 LLC-LUC cells in 100 µl PBS. To 
exclude the possibility that tumour size impacts on the rate of metastasis, we have excluded 
mice with tumours below 200 mg and over 1000 mg. Resection of primary tumours as well as 
detection of metastatic lesions was performed as described under 3.2.2.  
Flow cytometry 
Blood samples were collected in PBS supplemented with 2% FCS (Invitrogen), 20 mM 
EDTA (Sigma Aldrich), 0.03% NaN3 (Sigma Aldrich). Primary tumours were collected in 
PBS, cut into pieces and digested for 45 minutes at 37°C in RPMI medium containing 10% 
FBS, 1 mg/ml collagenase IV and 2.6 µg/ml DNase I (both Sigma-Aldrich). Samples were 
washed with PBS by centrifugation for 5 minutes at 350 g, the pellet was resuspended in PBS 
and filtered to remove debris. For surface staining antibodies against the following proteins 
were used: CD3 (17A2), CD4 (RM4-5), CD11b (M1/70), CD19 (6D5), CD45.2 (104), F4/80 
(BM8), Ly6C (HK1.4), Ly6G (1A8), NK1.1 (PK136). For viability staining, Zombie Violet 
Fixable Viability Kit was used. Antibodies and viability stain were purchased from 
Biolegend. For surface and viability staining, samples were incubated in PBS for 25 minutes 
at 4°C. For quantitative analysis, CountBright absolute counting beads were used (Thermo 
Fisher Scientific). Samples were acquired using a CyAn ADP 9 flow cytometer (Beckman 
Coulter) and analyzed using FlowJo v9.8.5 software (Tree Star). 
Statistical analysis 
For comparison of two experimental groups, two-tailed Student’s t-test with Welch’s 
correction was performed. Rates of metastases were compared using chi-square test. All tests 
were performed with GraphPad Prism 5.0 and GraphPad QuickCalcs (GraphPad Software). 
*p<0.05, **p<0.005, ***p<0.0005. 
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3.4.3 Results 
Naïve and tumour-bearing Alcam-deficient mice show changes in circulating leukocyte 
During the metastatic cascade immune cells can interact with tumour cells in three 
environments: in the primary tumour, circulation and the target organ. We have thus analysed 
leukocyte populations in these three compartments. 
In tumour-naïve Alcam-/- mice we observed elevated leukocytes counts in the peripheral blood 
(Fig.1 A). This can be partially explained by increased numbers of granulocytes and 
monocytes (Fig. 1 B, C). Among the total monocyte population in the blood of Alcam-/- mice 
there is lower percentage of inflammatory, Ly6C+ monocytes (Fig. 1 G) Numbers of NK cells 
(Fig. 1 D) were not changed although NK cells express a lower amount of the maturation 
marker CD11b (Fig. 1H). The numbers of circulating CD4+ and CD8+ T cells were reduced 
(Fig. 1 E, F). Leukocyte numbers in lungs and liver were similar to those in wild type mice 




















Figure 1.  Naïve Alcam-/- mice exhibit changes in the peripheral blood leukocytes as 
compared to the control mice. (A) Total leukocyte counts in peripheral blood of Alcam-/- 
mice. Blood counts of granulocytes (CD45.2+ CD11b+ SShigh) (B), monocytes (CD45.2+ 
CD11b+ CSF1R+) (C), NK cells  (CD45.2+ CD3- NK1.1+)  (D), CD4+ (CD45.2+ CD3+ CD4+)  
(E) and CD8+ T cells (CD45.2+ CD3+ CD8+) (F). (G) Percentage of inflammatory, Ly6Chi 
monocytes in the total monocyte pool. (H) Percentage of CD11b+ NK cells in the total NK 
cell pool. Mean ± SD, *p<0.05 **p<0.005 ***p<0.0005 (two-tailed Student’s t-test with 




To determine if the changes in blood leukocyte counts are sustained in the context of tumour 
development, we have injected mice with LLC-LUC tumour cells and analysed blood on day 
14, what corresponds to tumour size of approximately 60 mm2. As in tumour-naïve mice, 
total leukocyte counts were elevated (Fig. 2 B), as were granulocytes (Fig. 2 C) and 
monocytes (Fig. 2 D). NK cells were constantly expressing lower levels of CD11b, 
suggesting tumour-independent changes in NK cell maturation (Fig. 2 H). There was however 
no difference in numbers of T cells (Fig. 2 E, F) nor in the percentage of inflammatory 



















Figure 2.  Changes in blood leukocyte counts Alcam-/- are partially sustained in tumour-
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Because circulating immune cells in Alcam-/- differ from those in wild type mice with respect 
to number and subset distribution, we analysed the leukocyte infiltrate in established LLC-
LUC tumours (d 24). We observed no differences between control and Alcam-/- mice in any of 
the leukocyte populations analysed (Fig. 3 
bearing animals. (A) Total leukocyte counts in peripheral blood of ALCAM-/- mice. Blood 
counts of granulocytes (CD45.2+ CD11b+ SShigh) (B), monocytes (CD45.2+ CD11b+ CSF1R+) 
(C), NK cells  (CD45.2+ CD3- NK1.1+)  (D), CD4+ (CD45.2+ CD3+ CD4+)  (E) and CD8+ T 
cells (CD45.2+ CD3+ CD8+) (F). (G) Percentage of inflammatory, Ly6Chi monocytes in the 
total monocyte pool. (H) Percentage of CD11b+ NK cells in the total NK cell pool. Mean ± 

























Alcam-/- mice are protected against spontaneous metastasis 
Three weeks after resection of primary tumours, mice were sacrificed and analysed for the 
presence of metastatic lesions. 
Out of nine mice in the control cohort, five developed metastasis (56%), whereas in the 
Alcam-/- group only two out nine (22%) (Fig. 4). We conclude that absence of ALCAM in the 
















Figure 3. Alcam-/- and control mice have similar composition of the immune infiltrate of 
the primary tumour (A) Leukocyte counts in primary tumours of Alcam-/- mice. Numbers of 
B cells in the primary tumour infiltrate (live CD45.2+ CD19+) (B), CD4+ (live CD45.2+ CD3+ 
CD4+)  (C) and CD8+ T cells (live CD45.2+ CD3+ CD8+) (D), NK cells (live CD45.2+ CD3- 
NK1.1+)  (E), neutrophils (live CD45.2+ CD11b+ Ly6G+) (F), eosinophils (live CD45.2+ 
CD11b+ Siglec F+) (G), Ly6Chi monocytes (live CD45.2+ CD11b+ Ly6Chi) (H) and 
macrophages (live CD45.2+ CD11b+ Ly6Cint) (I). Mean ± SD. 
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We have observed that deletion of the Alcam gene in host reduces the metastatic potential of 
tumour cells. In order to establish a metastatic lesion, tumour cells have to intravasate into 
vessels of the primary tumour, survive in the circulation, extravasate through the endothelium 
and overcome potentially hostile environment of the target organ (2). Adhesion molecules, 
like ALCAM, influence this process in multiple stages. 
First of all, it is possible that ALCAM interactions are important for tumour cell migration 
through endothelial barriers, as it is for leukocytes (287, 288). This is achieved by 
ALCAM-mediated adhesion to the vasculature and by affecting this step, tumour cells would 
not be able to form metastases because of inefficient seeding from the primary tumours. The 
same disrupted ALCAM-dependent adhesion to endothelium could block tumour cell 
extravasation in the target organ, thus protect from forming micrometastases in an immune 
system-independent manner. 
Alternatively, the effect on metastasis might be caused by disrupted adhesion of leukocytes. 
The intra- and extravasation of tumour cells is facilitated by interaction with macrophages in 
the primary tumours as well as inflammatory monocytes in the metastatic organ. These cells 
induce vascular permeability by local production of VEGF, TGF-β and MMP-1 (157, 158, 
178).  In a similar manner, neutrophils activate endothelial cells through IL-1β and secrete 
matrix-modifying enzymes (124). They can also locally inhibit NK and CD8+ T cells, thus 
protecting tumour cells during extravasation and establishment of micrometastases (124, 
125). In the absence of interaction with myeloid cells, tumour cells might not be able to 
intravasate in the primary tumours nor extravasate and survive in the parenchyma of the target 
organ. Disturbed adhesion to endothelium could also explain elevated blood counts of 
monocytes and granulocytes in both naïve and tumour bearing mice. 
Alternatively, the reduced metastatic rates could be explained by the beneficial effect of 
increased numbers of Ly6Clow monocytes. This population of cells is responsible for 
patrolling of the blood endothelium, can sense invading tumour cells and attract cytotoxic 
cells, like NK cells (149). This would lead to increased lysis of metastatic tumour cells before 
they establish micrometastases. 
Furthermore, disrupted migration of leukocytes could potentially affect the ability of immune 
cells to control extravasated tumour cells in the target organs. 
Finally, it cannot be excluded that the difference we observe is directly linked with changes 
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NK cell activity. NK cells were shown to play a crucial role in control of metastatic tumour 
cells (170). Alcam-/- mice have elevated numbers of immature CD11b- NK cells and this is 
independent of the presence of primary tumours. It is unclear weather murine NK cells 
cytotoxicity changes with maturation. It was reported however that compared to splenic cells, 
lung NK cells have lower cytotoxic activity, what was directly correlated with bigger fraction 
of fully mature, CD11b+ CD27- NK cells in this organ (291). The same has been reported for 
the two populations of liver NK cells that differ regarding their CD11b expression (147). This 
opens the possibility that NK cells in Alcam-/- mice may be more proficient in lysis of 
metastatic tumour cells. Characterisation of NK cells in the ALCAM-/- animals would give 
evidence for this hypothesis. 
LLC-LUC used in our model cells express ALCAM (data not shown). It remains to be seen if 
similar reduction in metastatic potential could be achieved by tumour-specific ablation of this 
adhesion molecule. This would point towards the homotypic ALCAM- ALCAM interactions 
as one of the crucial mechanisms underlying the metastatic cascade and explain the increased 
ALCAM expression on the metastatic cancer cells  (290). However, at this stage, it cannot be 
excluded that the observed effect is due to tumour-intrinsic production of other ALCAM 
ligands, like CD6, galectin-8 or L1CAM (287, 289). 
Our data show that expression of ALCAM on host cells is important for the development of 
metastatic disease. Further experiments are necessary to delineate the precise mechanism and 
define if this phenomenon depends on tumour cell interaction with immune cells or 




Recent years have seen major progress in the development of immunotherapies. Antibodies, 
adoptive transfer of tumour-specific T cells, cytokines, TLR agonists and anti-cancer vaccines 
are becoming standard treatment for cancer patients. This is only possible because of the 
progress made in our understanding of the interaction between cancer and the immune 
system. 
It is known since a long time that tumours are infiltrated by leukocytes (292), but only 
recently we have started understanding the complexity of the immune response in the tumour 
context. Different innate and adaptive immune cells are involved in each step of tumour 
progression and tumours actively sculpt their phenotype. Much of our understanding of these 
processes comes from studies focused on T lymphocytes and initially, therapies aimed to 
directly activate cytotoxic T cells. More recent data suggest that also innate immune cells 
including NK cells and ILCs are promising therapeutic targets.  
The mutual interaction between cancer and the immune system has been integrated in the 
concept of immunoediting, in which tumours adapt to immunological pressure and as a result 
escape from immune control. Immunoediting assumes three phases of interaction between the 
immune system and cancer cells (41): 
- Elimination, when tumours are killed by the immune system 
- Equilibrium, in which tumour are kept in check by leukocytes, but are not eradicated 
- Escape, when tumours progress due to acquisition of features that enable avoidance 
of immune surveillance. 
This scheme is observed in both primary tumours as well as in metastatic lesions, suggesting 
that immunotherapy can treat metastases, even once the control of primary tumour has been 
lost. 
Because insufficient activation of APCs is one of the major stumble stones for the induction 
of cancer-specific immune defence, we investigated whether APC activation by agonistic 
anti-CD40 antibody protects against metastasis. Anti-CD40 has been used to stimulate T 
cell-mediated immunity (293-295), but was shown also to activate NK cells (296), 
macrophages (297) and other cell types, including B cells (298). However, in majority of the 
studies the therapy was started when the tumour burden was low and none of them focused on 
the formation of metastasis. On the contrary, we have used anti-CD40 in advanced tumours 
and monitored reaction to both primary and metastatic lesions. 
We observed that anti-CD40 prevents metastatic disease in an NK cell-dependent fashion. 
The anti-metastatic effect was only seen when anti-CD40 was administered before resection 
of the primary tumour. We interpret this finding such that anti-CD40 activates NK cells to 
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eliminate circulating tumour cells, of which the primary tumour is a continuous source.  
In an attempt to potentiate anti-CD40 treatment, we used a small molecule inhibitor of 
CSF1R to deplete tumour-infiltrating macrophages. Unexpectedly, we observed that this 
nullifies the protective effect of anti-CD40. Systemic targeting of CSF1R-positive cells 
deregulates NK cell homeostasis, which has negative effect on the control of metastasising 
tumour cells. We have not observed beneficial effects of CSF1R inhibition on the primary 
tumour or on the outgrowth of metastatic lesions, although such observations were reported in 
other models (106, 114-116, 254, 255). However, none of these studies monitored 
development of metastatic disease. 
Both anti-CD40 and CSF1R-targeting are currently tested in clinical trials (38, 242, 256, 
299). Our results support the notion that NK cell activation can be used in therapy of 
metastatic tumours. This can be achieved by adoptive transfer approach, application of 
cytokines or, as we have shown here, activating leukocytes that orchestrate the immune 
response. Furthermore, our data suggest that loss of NK cells as a result of CSF1R inhibition 
can be prevented by supplementation of survival factors for NK cells, as shown here for 
IL-15.  
We have tried to improve anti-CD40 therapy by combining it with two clinically relevant 
drugs – anti-CTLA-4 and anti-PD-1 antibodies. We have not observed improved control of 
metastasis compared to anti-CD40 alone, suggesting that checkpoint blockade does not have 
an additive or synergistic effect when given together with anti-CD40. Furthermore, the use of 
agonistic anti-CD27 antibody as monotherapy had not impact on development or progression 
of metastasis. These data suggest that therapies, which mainly impact on T cells, have limited 
capacity to prevent metastatic seeding or short-term outgrowth in the model we used here. 
This may be explained by our observation that T cells seem to play a minor role in these 
processes. T cells relatively poorly infiltrate LLC-LUC tumours and the control of metastasis 
seems to largely depend on NK cells. It remains to be clarified to what degree NK cells 
contribute to the therapeutic effect of checkpoint blockade and anti-CD27 therapy. In case of 
more immunogenic tumours, however, checkpoint blockade or anti-CD27 may have an 
anti-metastatic effect.  
The importance of tumour-promoting inflammation is underlined by our findings regarding 
the prometastatic role of prostaglandins. Genetic engineering of LLC tumour cells to prevent 
the production of PGE2 significantly reduced the capacity to metastasise, although it did not 
influence the kinetics of primary tumour growth. Our study shows that cancer-derived PGE2 
is sufficient to drive metastatic cascade, although the detailed mechanism needs to be further 
clarified. Most probable explanations include direct effect of PGE2 on macrophage and 
neutrophil polarization, which contributes to the immunosuppressive tumour 
microenvironment (60, 267-269). Furthermore, PGE2 alone is an angiogenesis-stimulating 
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factor (161, 268) and stimulates aggregation of platelets. The latter could prevent NK 
cell-mediated clearance of CTCs (3, 172, 173, 300). 
In clinics, prostaglandin synthesis is targeted by blockade of cyclooxygenases with 
non-steroidal anti-inflammatory drugs (268). These can be used as adjuvants to conventional 
therapy (273, 301) and aspirin, a non-specific inhibitor of COX-1/COX-2 and platelet 
aggregation, has been linked to prevention of colon adenomas (302). This might open 
possibility to use anti-inflammatory therapeutics to block tumour-intrinsic chronic 
inflammation. Because acute inflammation is an essential stimulus for the initiation of 
immune responses, anti-inflammatory drugs should be applied with great care. Therefore, 
further understanding of cancer-associated inflammation is needed to block chronic 
inflammation and allowing protective immunity response at the same time. 
Our observation that deletion of the adhesion molecule ALCAM in the host is sufficient to 
prevent metastasis but not the growth of primary tumours is interesting. At this point, 
however, we do not sufficiently understand which steps of the metastatic cascade are affected 
in Alcam-/- mice. The fact that many different cell types including leukocytes, cells of 
mesenchymal origin, endothelial and epithelial cells express ALCAM, makes it hard to 
predict which interactions are essential for metastasis. Using mice in which ALCAM is absent 
in distinct cell types may help to elucidate the role of ALCAM in metastasis.  
In conclusion, successful cancer immunotherapy should trigger pathways of both innate and 
adaptive immunity and target primary lesions as well as disseminated tumour cells. This will 
be most probably achieved by combination of various classes of therapeutics. However, until 
we fully understand the mechanisms ruling immunity and its crosstalk with cancer cells, we 
have to be careful when designing novel drugs in order to avoid triggering detrimental side 
effects. Improving our understanding of tumour immunology paves the way for new therapies 
in the benefit of cancer patients.  
	 87 
5. References 
1. B. W. Stewart and C. P. Wild, World Cancer Report 2014.  (2014). 
2. C. L. Chaffer and R. A. Weinberg, A perspective on cancer cell metastasis. Science 
331, 1559-1564 (2011). 
3. S. Valastyan and R. A. Weinberg, Tumor metastasis: molecular insights and evolving 
paradigms. Cell 147, 275-292 (2011). 
4. H. Choi, J. Sheng, D. Gao, F. Li, A. Durrans, S. Ryu, S. B. Lee, N. Narula, S. Rafii, 
O. Elemento, N. K. Altorki, S. T. Wong and V. Mittal, Transcriptome analysis of individual 
stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model. Cell 
Rep 10, 1187-1201 (2015). 
5. S. Meng, D. Tripathy, E. P. Frenkel, S. Shete, E. Z. Naftalis, J. F. Huth, P. D. Beitsch, 
M. Leitch, S. Hoover, D. Euhus, B. Haley, L. Morrison, T. P. Fleming, D. Herlyn, L. W. 
Terstappen, T. Fehm, T. F. Tucker, N. Lane, J. Wang and J. W. Uhr, Circulating tumor cells 
in patients with breast cancer dormancy. Clin Cancer Res 10, 8152-8162 (2004). 
6. C. M. Ghajar, H. Peinado, H. Mori, I. R. Matei, K. J. Evason, H. Brazier, D. Almeida, 
A. Koller, K. A. Hajjar, D. Y. R. Stainier, E. I. Chen, D. Lyden and M. J. Bissell, The 
perivascular niche regulates breast tumour dormancy. Nature Cell Biology 15, 807-817 
(2013). 
7. D. Hanahan and R. A. Weinberg, The hallmarks of cancer. Cell 100, 57-70 (2000). 
8. C. A. Klein, Parallel progression of primary tumours and metastases. Nature Reviews 
Cancer 9, 302-312 (2009). 
9. H. Imanishi, K. Hattori, R. Wada, K. Ishikawa, S. Fukuda, K. Takenaga, K. Nakada 
and J. Hayashi, Mitochondrial DNA mutations regulate metastasis of human breast cancer 
cells. PLoS One 6, e23401 (2011). 
10. D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation. Cell 144, 
646-674 (2011). 
11. W. Wei, Y. S. Shin, M. Xue, T. Matsutani, K. Masui, H. Yang, S. Ikegami, Y. Gu, K. 
Herrmann, D. Johnson, X. Ding, K. Hwang, J. Kim, J. Zhou, Y. Su, X. Li, B. Bonetti, R. 
Chopra, C. D. James, W. K. Cavenee, T. F. Cloughesy, P. S. Mischel, J. R. Heath and B. 
Gini, Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs 
Targeted Combination Therapy in Glioblastoma. Cancer Cell 29, 563-573 (2016). 
12. F. Dietlein, L. Thelen and H. C. Reinhardt, Cancer-specific defects in DNA repair 
pathways as targets for personalized therapeutic approaches. Trends Genet 30, 326-339 
(2014). 
	 88 
13. S. B. Baylin, DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 
Suppl 1, S4-11 (2005). 
14. J. F. Goodwin, V. Kothari, J. M. Drake, S. Zhao, E. Dylgjeri, J. L. Dean, M. J. 
Schiewer, C. McNair, J. K. Jones, A. Aytes, M. S. Magee, A. E. Snook, Z. Zhu, R. B. Den, R. 
C. Birbe, L. G. Gomella, N. A. Graham, A. A. Vashisht, J. A. Wohlschlegel, T. G. Graeber, 
R. J. Karnes, M. Takhar, E. Davicioni, S. A. Tomlins, C. Abate-Shen, N. Sharifi, O. N. Witte, 
F. Y. Feng and K. E. Knudsen, DNA-PKcs-Mediated Transcriptional Regulation Drives 
Prostate Cancer Progression and Metastasis. Cancer Cell 28, 97-113 (2015). 
15. A. Marino-Enriquez and C. D. Fletcher, Shouldn't we care about the biology of 
benign tumours? Nat Rev Cancer 14, 701-702 (2014). 
16. M. J. Bissell and D. Radisky, Putting tumours in context. Nat Rev Cancer 1, 46-54 
(2001). 
17. D. F. Quail and J. A. Joyce, Microenvironmental regulation of tumor progression and 
metastasis. Nature Medicine 19, 1423-1437 (2013). 
18. G. Dranoff, Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4, 
11-22 (2004). 
19. M. F. Flajnik and M. Kasahara, Origin and evolution of the adaptive immune system: 
genetic events and selective pressures. Nat Rev Genet 11, 47-59 (2010). 
20. T. Boehm, Evolution of vertebrate immunity. Curr Biol 22, R722-732 (2012). 
21. K. Movahedi, D. Laoui, C. Gysemans, M. Baeten, G. Stange, J. Van den Bossche, M. 
Mack, D. Pipeleers, P. In't Veld, P. De Baetselier and J. A. Van Ginderachter, Different tumor 
microenvironments contain functionally distinct subsets of macrophages derived from 
Ly6C(high) monocytes. Cancer Res 70, 5728-5739 (2010). 
22. Y. Nakasone, M. Fujimoto, T. Matsushita, Y. Hamaguchi, D. L. Huu, M. Yanaba, S. 
Sato, K. Takehara and M. Hasegawa, Host-derived MCP-1 and MIP-1alpha regulate 
protective anti-tumor immunity to localized and metastatic B16 melanoma. Am J Pathol 180, 
365-374 (2012). 
23. M. F. Flajnik and L. Du Pasquier, Evolution of innate and adaptive immunity: can we 
draw a line? Trends Immunol 25, 640-644 (2004). 
24. C. Hagerling, A. J. Casbon and Z. Werb, Balancing the innate immune system in 
tumor development. Trends Cell Biol,  (2014). 
25. A. B. Molofsky, F. Van Gool, H. E. Liang, S. J. Van Dyken, J. C. Nussbaum, J. Lee, 
J. A. Bluestone and R. M. Locksley, Interleukin-33 and Interferon-gamma Counter-Regulate 
Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity,  (2015). 
	 89 
26. S. H. B. I. P. K. F. L. H. A. A. N. Stanislav Pantelyushin and B. Burkhard, 
Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque 
formation in mice. Journal of Clinical Investigation 122, 2252-2257 (2012). 
27. J. Strid, O. Sobolev, B. Zafirova, B. Polic and A. Hayday, The intraepithelial T cell 
response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science 334, 1293-
1297 (2011). 
28. L. Van Kaer, V. V. Parekh and L. Wu, Invariant natural killer T cells: bridging innate 
and adaptive immunity. Cell Tissue Res 343, 43-55 (2011). 
29. D. J. Hicklin, F. M. Marincola and S. Ferrone, HLA class I antigen downregulation in 
human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5, 178-186 
(1999). 
30. K. Hildner, B. T. Edelson, W. E. Purtha, M. Diamond, H. Matsushita, M. Kohyama, 
B. Calderon, B. U. Schraml, E. R. Unanue, M. S. Diamond, R. D. Schreiber, T. L. Murphy 
and K. M. Murphy, Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in 
cytotoxic T cell immunity. Science 322, 1097-1100 (2008). 
31. R. Kim, M. Emi and K. Tanabe, Cancer immunoediting from immune surveillance to 
immune escape. Immunology 121, 1-14 (2007). 
32. M. J. Smyth, K. Y. Thia, S. E. Street, D. MacGregor, D. I. Godfrey and J. A. Trapani, 
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp 
Med 192, 755-760 (2000). 
33. S. L. Swain, K. K. McKinstry and T. M. Strutt, Expanding roles for CD4(+) T cells in 
immunity to viruses. Nat Rev Immunol 12, 136-148 (2012). 
34. E. D. Foucher, S. Blanchard, L. Preisser, P. Descamps, N. Ifrah, Y. Delneste and P. 
Jeannin, IL-34- and M-CSF-induced macrophages switch memory T cells into Th17 cells via 
membrane IL-1alpha. Eur J Immunol,  (2014). 
35. D. O. Adeegbe and H. Nishikawa, Natural and induced T regulatory cells in cancer. 
Front Immunol 4, 190 (2013). 
36. O. Preynat-Seauve, E. Contassot, P. Schuler, V. Piguet, L. E. French and B. Huard, 
Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance 
process. Cancer Research 67, 5009-5016 (2007). 
37. F. Sallusto, J. Geginat and A. Lanzavecchia, Central memory and effector memory T 
cell subsets: function, generation, and maintenance. Annual Reviews Immunology 22, 745–
763 (2004). 
38. R. H. Vonderheide and M. J. Glennie, Agonistic CD40 antibodies and cancer therapy. 
Clin Cancer Res 19, 1035-1043 (2013). 
	 90 
39. F. D. Batista and N. E. Harwood, The who, how and where of antigen presentation to 
B cells. Nat Rev Immunol 9, 15-27 (2009). 
40. P. B. Olkhanud, B. Damdinsuren, M. Bodogai, R. E. Gress, R. Sen, K. Wejksza, E. 
Malchinkhuu, R. P. Wersto and A. Biragyn, Tumor-evoked regulatory B cells promote breast 
cancer metastasis by converting resting CD4+ T Cells to T-regulatory cells. Cancer Research 
71, 3505-3515 (2011). 
41. R. D. Schreiber, L. J. Old and M. J. Smyth, Cancer immunoediting: integrating 
immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011). 
42. R. E. Wilson, E. B. Hager, C. L. Hampers, J. M. Corson, J. P. Merrill and J. E. 
Murray, Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J 
Med 278, 479-483 (1968). 
43. C. M. Vajdic and M. T. van Leeuwen, Cancer incidence and risk factors after solid 
organ transplantation. Int J Cancer 125, 1747-1754 (2009). 
44. M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz and N. Hacohen, Molecular and 
genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 
(2015). 
45. M. T, H. F and Z. J, Consequences of the crosstalk between monocytes/macrophages 
and natural killer cells. Front Immunol 3, 403 (2012). 
46. G. Abboud, V. Tahiliani, P. Desai, K. Varkoly, J. Driver, T. E. Hutchinson and S. 
Salek-Ardakani, Natural Killer Cells and Innate Interferon Gamma Participate in the Host 
Defense against Respiratory Vaccinia Virus Infection. J Virol 90, 129-141 (2015). 
47. A. Cerwenka and L. L. Lanier, Natural killer cell memory in infection, inflammation 
and cancer. Nat Rev Immunol 16, 112-123 (2016). 
48. M. G. Morvan and L. L. Lanier, NK cells and cancer: you can teach innate cells new 
tricks. Nat Rev Cancer 16, 7-19 (2015). 
49. Z. Zhou, C. Zhang, J. Zhang and Z. Tian, Macrophages help NK cells to attack tumor 
cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory 
ligand Qa-1. PLoS One 7, e36928 (2012). 
50. L. F. de Andrade, M. J. Smyth and L. Martinet, DNAM-1 control of natural killer 
cells functions through nectin and nectin-like proteins. Immunol Cell Biol 92, 237-244 (2014). 
51. J. Wang, F. Li, M. Zheng, R. Sun, H. Wei and Z. Tian, Lung natural killer cells in 
mice: phenotype and response to respiratory infection. Immunology 137, 37-47 (2012). 
52. N. Nausch and A. Cerwenka, NKG2D ligands in tumor immunity. Oncogene 27, 
5944-5958 (2008). 
	 91 
53. K. Yamamoto, Y. Fujiyama, A. Andoh, T. Bamba and H. Okabe, Oxidative stress 
increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-
2). Biochim Biophys Acta 1526, 10-12 (2001). 
54. S. Gasser, S. Orsulic, E. J. Brown and D. H. Raulet, The DNA damage pathway 
regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190 
(2005). 
55. Y. T. Bryceson, M. E. March, H. G. Ljunggren and E. O. Long, Synergy among 
receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. 
Blood 107, 159-166 (2006). 
56. P. Carrega, B. Morandi, R. Costa, G. Frumento, G. Forte, G. Altavilla, G. B. Ratto, 
M. C. Mingari, L. Moretta and G. Ferlazzo, Natural killer cells infiltrating human nonsmall-
cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability 
to kill tumor cells. Cancer 112, 863-875 (2008). 
57. L. Martinet, L. Ferrari De Andrade, C. Guillerey, J. S. Lee, J. Liu, F. Souza-Fonseca-
Guimaraes, D. S. Hutchinson, T. B. Kolesnik, S. E. Nicholson, N. D. Huntington and M. J. 
Smyth, DNAM-1 expression marks an alternative program of NK cell maturation. Cell Rep 
11, 85-97 (2015). 
58. S. J. Blake, K. Stannard, J. Liu, S. Allen, M. C. Yong, D. Mittal, A. R. Aguilera, J. J. 
Miles, V. P. Lutzky, L. F. de Andrade, L. Martinet, M. Colonna, K. Takeda, F. Kuhnel, E. 
Gurlevik, G. Bernhardt, M. W. Teng and M. J. Smyth, Suppression of Metastases Using a 
New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Cancer Discov 6, 446-459 
(2016). 
59. C. J. Chan, L. Martinet, S. Gilfillan, F. Souza-Fonseca-Guimaraes, M. T. Chow, L. 
Town, D. S. Ritchie, M. Colonna, D. M. Andrews and M. J. Smyth, The receptors CD96 and 
CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 15, 
431-438 (2014). 
60. E. Mamessier, A. Sylvain, M. L. Thibult, G. Houvenaeghel, J. Jacquemier, R. 
Castellano, A. Goncalves, P. Andre, F. Romagne, G. Thibault, P. Viens, D. Birnbaum, F. 
Bertucci, A. Moretta and D. Olive, Human breast cancer cells enhance self tolerance by 
promoting evasion from NK cell antitumor immunity. J Clin Invest 121, 3609-3622 (2011). 
61. T. P. Rygiel, E. H. Stolte, T. de Ruiter, M. L. van de Weijer and L. Meyaard, Tumor-
expressed collagens can modulate immune cell function through the inhibitory collagen 
receptor LAIR-1. Mol Immunol 49, 402-406 (2011). 
62. T. S. K. Eisinger-Mathason, M. S. Zhang, Q. Qiu, N. Skuli, M. S. Nakazawa, T. 
Karakasheva, V. Mucaj, J. E. S. Shay, L. Stangenberg, N. Sadri, E. Pure, S. S. Yoon, D. G. 
Kirsch and M. C. Simon, Hypoxia-dependent modification of collagen networks promotes 
sarcoma metastasis. Cancer Discovery 3, 1190-1205 (2013). 
63. B. C. Ozdemir, T. Pentcheva-Hoang, J. L. Carstens, X. Zheng, C. C. Wu, T. R. 
Simpson, H. Laklai, H. Sugimoto, C. Kahlert, S. V. Novitskiy, A. De Jesus-Acosta, P. 
Sharma, P. Heidari, U. Mahmood, L. Chin, H. L. Moses, V. M. Weaver, A. Maitra, J. P. 
	 92 
Allison, V. S. LeBleu and R. Kalluri, Depletion of carcinoma-associated fibroblasts and 
fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. 
Cancer Cell 25, 719-734 (2014). 
64. M. Challa-Malladi, Y. K. Lieu, O. Califano, A. B. Holmes, G. Bhagat, V. V. Murty, 
D. Dominguez-Sola, L. Pasqualucci and R. Dalla-Favera, Combined genetic inactivation of 
beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse 
large B cell lymphoma. Cancer Cell 20, 728-740 (2011). 
65. S. Kim, K. Iizuka, H. S. Kang, A. Dokun, A. R. French, S. Greco and W. M. 
Yokoyama, In vivo developmental stages in murine natural killer cell maturation. Nat 
Immunol 3, 523-528 (2002). 
66. T. R. Simpson, F. B. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. 
Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, K. S. Peggs, J. V. Ravetch, J. P. 
Allison and S. A. Quezada, Fc-dependent depletion of tumor-infiltrating regulatory T cells 
co-defines the efficacy of anti–CTLA-4 therapy against melanoma. Journal of Experimental 
Medicine 210, 1695-1710 (2013). 
67. T. Krneta, A. Gillgrass, M. Chew and A. A. Ashkar, The breast tumor 
microenvironment alters the phenotype and function of natural killer cells. Cell Mol Immunol,  
(2015). 
68. M. Benish and S. Ben-Eliyahu, Surgery as a double-edged sword: a clinically feasible 
approach to overcome the metastasis-promoting effects of surgery by blunting stress and 
prostaglandin responses. Cancers (Basel) 2, 1929-1951 (2010). 
69. M. Bodogai, K. Moritoh, C. Lee-Chang, C. M. Hollander, C. A. Sherman-Baust, R. 
P. Wersto, Y. Araki, I. Miyoshi, L. Yang, G. Trinchieri and A. Biragyn, Immune suppressive 
and pro-metastatic functions of myeloid-derived suppressive cells rely upon education from 
tumor-associated B cells. Cancer Res,  (2015). 
70. N. D. Huntington, The unconventional expression of IL-15 and its role in NK cell 
homeostasis. Immunol Cell Biol 92, 210-213 (2014). 
71. N. Sato, H. J. Patel, T. A. Waldmann and Y. Tagaya, The IL-15/IL-15Ralpha on cell 
surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory 
T cells. Proc Natl Acad Sci U S A 104, 588-593 (2007). 
72. T. Ranson, C. A. Vosshenrich, E. Corcuff, O. Richard, W. Muller and J. P. Di Santo, 
IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 101, 4887-4893 
(2003). 
73. K. Soderquest, N. Powell, C. Luci, N. van Rooijen, A. Hidalgo, F. Geissmann, T. 
Walzer, G. M. Lord and A. Martin-Fontecha, Monocytes control natural killer cell 
differentiation to effector phenotypes. Blood 117, 4511-4518 (2011). 
74. P. Allavena, G. Giardina, G. Bianchi and A. Mantovani, IL-15 is chemotactic for 
natural killer cells and stimulates their adhesion to vascular endothelium. J Leukoc Biol 61, 
729-735 (1997). 
	 93 
75. A. E. Gillgrass, M. V. Chew, T. Krneta and A. A. Ashkar, Overexpression of IL-15 
promotes tumor destruction via NK1.1+ cells in a spontaneous breast cancer model. BMC 
Cancer 15, 293 (2015). 
76. T. N. Schumacher and R. D. Schreiber, Neoantigens in cancer immunotherapy. 
Science 348, 69-74 (2015). 
77. E. Stronen, M. Toebes, S. Kelderman, M. M. van Buuren, W. Yang, N. van Rooij, M. 
Donia, M. L. Boschen, F. Lund-Johansen, J. Olweus and T. N. Schumacher, Targeting of 
cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337-1341 
(2016). 
78. M. F. Gjerstorff, M. H. Andersen and H. J. Ditzel, Oncogenic cancer/testis antigens: 
prime candidates for immunotherapy. Oncotarget 6, 15772-15787 (2015). 
79. S. Malladi, D. G. Macalinao, X. Jin, L. He, H. Basnet, Y. Zou, E. de Stanchina and J. 
Massague, Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. 
Cell 165, 45-60 (2016). 
80. S. Hadrup, M. Donia and P. Thor Straten, Effector CD4 and CD8 T cells and their 
role in the tumor microenvironment. Cancer Microenviron 6, 123-133 (2013). 
81. A. J. Cochran, R. R. Huang, J. Lee, E. Itakura, S. P. Leong and R. Essner, Tumour-
induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6, 659-670 (2006). 
82. T. Saito, H. Nishikawa, H. Wada, Y. Nagano, D. Sugiyama, K. Atarashi, Y. Maeda, 
M. Hamaguchi, N. Ohkura, E. Sato, H. Nagase, J. Nishimura, H. Yamamoto, S. Takiguchi, T. 
Tanoue, W. Suda, H. Morita, M. Hattori, K. Honda, M. Mori, Y. Doki and S. Sakaguchi, Two 
FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. 
Nat Med 22, 679-684 (2016). 
83. G. Betts, E. Jones, S. Junaid, T. El-Shanawany, M. Scurr, P. Mizen, M. Kumar, S. 
Jones, B. Rees, G. Williams, A. Gallimore and A. Godkin, Suppression of tumour-specific 
CD4(+) T cells by regulatory T cells is associated with progression of human colorectal 
cancer. Gut 61, 1163-1171 (2012). 
84. R. Carretero, I. M. Sektioglu, N. Garbi, O. C. Salgado, P. Beckhove and G. J. 
Hammerling, Eosinophils orchestrate cancer rejection by normalizing tumor vessels and 
enhancing infiltration of CD8(+) T cells. Nat Immunol 16, 609-617 (2015). 
85. K. Yaacoub, R. Pedeux, K. Tarte and T. Guillaudeux, Role of the tumor 
microenvironment in regulating apoptosis and cancer progression. Cancer Lett,  (2016). 
86. N. Gagliani, C. F. Magnani, S. Huber, M. E. Gianolini, M. Pala, P. Licona-Limon, B. 
G. G. Guo, D. R. Herbert, A. Bulfone, F. Trentini, C. Di Serio, R. Bacchetta, M. Andreani, L. 
Brockmann, S. Gregori, R. A. Flavell and M. G. Roncarolo, Coexpression of CD49b and 
LAG-3 identifies human and mouse T regulatory type 1 cells. Nature Medicine 19, 739-746 
(2013). 
	 94 
87. S. J. Oosterling, G. J. van der Bij, G. A. Meijer, C. W. Tuk, E. van Garderen, N. van 
Rooijen, S. Meijer, J. R. van der Sijp, R. H. Beelen and M. van Egmond, Macrophages direct 
tumour histology and clinical outcome in a colon cancer model. J Pathol 207, 147-155 
(2005). 
88. R. A. Franklin, W. Liao, A. Sarkar, M. V. Kim, M. R. Bivona, K. Liu, E. G. Pamer 
and M. O. Li, The cellular and molecular origin of tumor-associated macrophages. Science 
344, 921-925 (2014). 
89. E. Y. Lin, J. F. Li, L. Gnatovskiy, Y. Deng, L. Zhu, D. A. Grzesik, H. Qian, X. N. 
Xue and J. W. Pollard, Macrophages regulate the angiogenic switch in a mouse model of 
breast cancer. Cancer Res 66, 11238-11246 (2006). 
90. T. A. Wynn, A. Chawla and J. W. Pollard, Macrophage biology in development, 
homeostasis and disease. Nature 496, 445-455 (2013). 
91. T. Lucas, A. Waisman, R. Ranjan, J. Roes, T. Krieg, W. Muller, A. Roers and S. A. 
Eming, Differential roles of macrophages in diverse phases of skin repair. J Immunol 184, 
3964-3977 (2010). 
92. H. F. Dvorak, Tumors: wounds that do not heal-redux. Cancer Immunol Res 3, 1-11 
(2015). 
93. L. Strauss, S. Sangaletti, F. M. Consonni, G. Szebeni, S. Morlacchi, M. G. Totaro, C. 
Porta, A. Anselmo, S. Tartari, A. Doni, F. Zitelli, C. Tripodo, M. P. Colombo and A. Sica, 
RORC1 Regulates Tumor-Promoting “Emergency” Granulo-Monocytopoiesis. Cancer Cell 
28, 253-269 (2015). 
94. F. Ginhoux and S. Jung, Monocytes and macrophages: developmental pathways and 
tissue homeostasis. Nat Rev Immunol 14, 392-404 (2014). 
95. S. K. Biswas, L. Gangi, S. Paul, T. Schioppa, A. Saccani, M. Sironi, B. Bottazzi, A. 
Doni, B. Vincenzo, F. Pasqualini, L. Vago, M. Nebuloni, A. Mantovani and A. Sica, A 
distinct and unique transcriptional program expressed by tumor-associated macrophages 
(defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107, 2112-2122 (2006). 
96. E. Van Overmeire, B. Stijlemans, F. Heymann, J. Keirsse, Y. Morias, Y. Elkrim, L. 
Brys, C. Abels, Q. Lahmar, C. Ergen, L. Vereecke, F. Tacke, P. De Baetselier, J. A. Van 
Ginderachter and D. Laoui, M-CSF and GM-CSF Receptor Signaling Differentially Regulate 
Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment. Cancer 
Res 76, 35-42 (2016). 
97. N. Umemura, M. Saio, T. Suwa, Y. Kitoh, J. Bai, K. Nonaka, G. F. Ouyang, M. 
Okada, M. Balazs, R. Adany, T. Shibata and T. Takami, Tumor-infiltrating myeloid-derived 
suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type 
characteristics. J Leukoc Biol 83, 1136-1144 (2008). 
98. Y. Sawanobori, S. Ueha, M. Kurachi, T. Shimaoka, J. E. Talmadge, J. Abe, Y. 
Shono, M. Kitabatake, K. Kakimi, N. Mukaida and K. Matsushima, Chemokine-mediated 
	 95 
rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111, 5457-
5466 (2008). 
99. P. J. Murray, J. E. Allen, S. K. Biswas, E. A. Fisher, D. W. Gilroy, S. Goerdt, S. 
Gordon, J. A. Hamilton, L. B. Ivashkiv, T. Lawrence, M. Locati, A. Mantovani, F. O. 
Martinez, J. L. Mege, D. M. Mosser, G. Natoli, J. P. Saeij, J. L. Schultze, K. A. Shirey, A. 
Sica, J. Suttles, I. Udalova, J. A. van Ginderachter, S. N. Vogel and T. A. Wynn, Macrophage 
activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14-20 
(2014). 
100. F. O. Martinez, S. Gordon, M. Locati and A. Mantovani, Transcriptional profiling of 
the human monocyte-to-macrophage differentiation and polarization: new molecules and 
patterns of gene expression. J Immunol 177, 7303-7311 (2006). 
101. M. L. Broz, M. Binnewies, B. Boldajipour, A. E. Nelson, J. L. Pollack, D. J. Erle, A. 
Barczak, M. D. Rosenblum, A. Daud, D. L. Barber, S. Amigorena, L. J. Van't Veer, A. I. 
Sperling, D. M. Wolf and M. F. Krummel, Dissecting the Tumor Myeloid Compartment 
Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. Cancer Cell 
26, 638-652 (2014). 
102. S. J. Priceman, J. L. Sung, Z. Shaposhnik, J. B. Burton, A. X. Torres-Collado, D. L. 
Moughon, M. Johnson, A. J. Lusis, D. A. Cohen, M. L. Iruela-Arispe and L. Wu, Targeting 
distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor 
evasion of antiangiogenic therapy. Blood 115, 1461-1471 (2010). 
103. E. Dondossola, R. Rangel, L. Guzman-Rojas, E. M. Barbu, H. Hosoya, L. S. St John, 
J. J. Molldrem, A. Corti, R. L. Sidman, W. Arap and R. Pasqualini, CD13-positive bone 
marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc 
Natl Acad Sci U S A 110, 20717-20722 (2013). 
104. O. R. Colegio, N. Q. Chu, A. L. Szabo, T. Chu, A. M. Rhebergen, V. Jairam, N. 
Cyrus, C. E. Brokowski, S. C. Eisenbarth, G. M. Phillips, G. W. Cline, A. J. Phillips and R. 
Medzhitov, Functional polarization of tumour-associated macrophages by tumour-derived 
lactic acid. Nature 513, 559-563 (2014). 
105. S. J. Mandriota, L. Jussila, M. Jeltsch, A. Compagni, D. Baetens, R. Prevo, S. 
Banerji, J. Huarte, R. Montesano, D. G. Jackson, L. Orci, K. Alitalo, G. Christofori and M. S. 
Pepper, Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour 
metastasis. EMBO J 20, 672-682 (2001). 
106. J. Escamilla, S. Schokrpur, C. Liu, S. J. Priceman, D. Moughon, Z. Jiang, F. Pouliot, 
C. Magyar, J. L. Sung, J. Xu, G. Deng, B. L. West, G. Bollag, Y. Fradet, L. Lacombe, M. E. 
Jung, J. Huang and L. Wu, CSF1 receptor targeting in prostate cancer reverses macrophage-
mediated resistance to androgen blockade therapy. Cancer Res 75, 950-962 (2015). 
107. T. Y. Lu, R. Ramakrishnan, S. Altiok, J. I. Youn, P. Y. Chong, E. Celis, V. Pisarev, 
S. Sherman, M. B. Sporn and D. Gabrilovich, Tumor-infiltrating myeloid cells induce tumor 
cell resistance to cytotoxic T cells in mice. Journal of Clinical Investigation 121, 4015-4029 
(2011). 
	 96 
108. P. C. Rodriguez, D. G. Quiceno and A. C. Ochoa, L-arginine availability regulates T-
lymphocyte cell-cycle progression. Blood 109, 1568-1573 (2007). 
109. P. C. Rodriguez, C. P. Hernandez, D. Quiceno, S. M. Dubinett, J. Zabaleta, J. B. 
Ochoa, J. Gilbert and A. C. Ochoa, Arginase I in myeloid suppressor cells is induced by 
COX-2 in lung carcinoma. J Exp Med 202, 931-939 (2005). 
110. A. Zippelius, J. Schreiner, P. Herzig and P. Muller, Induced PD-L1 Expression 
Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment. Cancer Immunol Res 3, 
236-244 (2015). 
111. G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner, A. C. Obenauf, H. 
Angell, T. Fredriksen, L. Lafontaine, A. Berger, P. Bruneval, W. H. Fridman, C. Becker, F. 
Pages, M. R. Speicher, Z. Trajanoski and J. Galon, Spatiotemporal dynamics of intratumoral 
immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013). 
112. M. Bruchard, G. Mignot, V. Derangere, F. Chalmin, A. Chevriaux, F. Vegran, W. 
Boireau, B. Simon, B. Ryffel, J. L. Connat, J. Kanellopoulos, F. Martin, C. Rebe, L. Apetoh 
and F. Ghiringhelli, Chemotherapy-triggered cathepsin B release in myeloid-derived 
suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19, 
57-64 (2013). 
113. Y. Mao, N. Eissler, K. Le Blanc, J. I. Johnsen, P. Kogner and R. Kiessling, Targeting 
suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous 
neuroblastoma. Clin Cancer Res,  (2016). 
114. Y. Zhu, B. L. Knolhoff, M. A. Meyer, T. M. Nywening, B. L. West, J. Luo, A. Wang-
Gillam, S. P. Goedegebuure, D. C. Linehan and D. G. DeNardo, CSF1/CSF1R Blockade 
Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint 
Immunotherapy in Pancreatic Cancer Models. Cancer Res 74, 5057-5069 (2014). 
115. D. C. Strachan, B. Ruffell, Y. Oei, M. J. Bissell, L. M. Coussens, N. Pryer and D. 
Daniel, CSF1R inhibition delays cervical and mammary tumor growth in murine models by 
attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 
T cells. Oncoimmunology 2, e26968 (2013). 
116. J. Xu, J. Escamilla, S. Mok, J. David, S. Priceman, B. West, G. Bollag, W. McBride 
and L. Wu, CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves 
the efficacy of radiotherapy in prostate cancer. Cancer Res 73, 2782-2794 (2013). 
117. J. M. Weiss, L. A. Ridnour, T. Back, S. P. Hussain, P. He, A. E. Maciag, L. K. 
Keefer, W. J. Murphy, C. C. Harris, D. A. Wink and R. H. Wiltrout, Macrophage-dependent 
nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 
immunotherapy. J Exp Med 207, 2455-2467 (2010). 
118. K. Tsung, J. P. Dolan, Y. L. Tsung and J. A. Norton, Macrophages as effector cells in 
interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 62, 5069-5075 (2002). 
119. B. Z. Qian and J. W. Pollard, Macrophage diversity enhances tumor progression and 
metastasis. Cell 141, 39-51 (2010). 
	 97 
120. U. Grohmann, M. L. Belladonna, C. Vacca, R. Bianchi, F. Fallarino, C. Orabona, M. 
C. Fioretti and P. Puccetti, Positive regulatory role of IL-12 in macrophages and modulation 
by IFN-gamma. J Immunol 167, 221-227 (2001). 
121. A. Satomi, S. Murakami, K. Ishida, M. Mastuki, T. Hashimoto and M. Sonoda, 
Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol 
34, 69-73 (1995). 
122. I. Mishalian, R. Bayuh, L. Levy, L. Zolotarov, J. Michaeli and Z. G. Fridlender, 
Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor 
progression. Cancer Immunol Immunother 62, 1745-1756 (2013). 
123. Z. Granot, E. Henke, E. A. Comen, T. A. King, L. Norton and R. Benezra, Tumor 
entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20, 300-314 
(2011). 
124. A. Spiegel, M. W. Brooks, S. Houshyar, F. Reinhardt, M. Ardolino, E. Fessler, M. B. 
Chen, J. A. Krall, J. DeCock, I. K. Zervantonakis, A. Iannello, Y. Iwamoto, V. Cortez-
Retamozo, R. D. Kamm, M. J. Pittet, D. H. Raulet and R. A. Weinberg, Neutrophils suppress 
intraluminal NK-mediated tumor cell clearance and enhance extravasation of disseminated 
carcinoma cells. Cancer Discov 6, 630-649 (2016). 
125. S. B. Coffelt, K. Kersten, C. W. Doornebal, J. Weiden, K. Vrijland, C. S. Hau, N. J. 
Verstegen, M. Ciampricotti, L. J. Hawinkels, J. Jonkers and K. E. de Visser, IL-17-producing 
gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature,  
(2015). 
126. M. Albanesi, D. A. Mancardi, F. Jonsson, B. Iannascoli, L. Fiette, J. P. Di Santo, C. 
A. Lowell and P. Bruhns, Neutrophils mediate antibody-induced antitumor effects in mice. 
Blood 122, 3160-3164 (2013). 
127. Y. Ma, S. Adjemian, S. R. Mattarollo, T. Yamazaki, L. Aymeric, H. Yang, J. P. P. 
Catani, D. Hannani, H. Duret, K. Steegh, I. Martins, F. Schlemmer, M. Michaud, O. Kepp, A. 
Q. Sukkurwala, L. Menger, E. Vacchelli, N. Droin, L. Galluzzi, R. Krzysiek, S. Gordon, P. R. 
Taylor, P. Van Endert, E. Solary, M. J. Smyth, L. Zitvogel and G. Kroemer, Anticancer 
chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting 
cells. Immunity 38, 729-741 (2013). 
128. E. Elinav, R. Nowarski, C. A. Thaiss, B. Hu, C. Jin and R. A. Flavell, Inflammation-
induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev 
Cancer 13, 759-771 (2013). 
129. B. Mlecnik, G. Bindea, A. Kirilovsky, H. K. Angell, A. C. Obenauf, M. Tosolini, S. 
E. Church, P. Maby, A. Vasaturo, M. Angelova, T. Fredriksen, S. Mauger, M. Waldner, A. 
Berger, M. R. Speicher, F. Pages, V. Valge-Archer and J. Galon, The tumor 
microenvironment and Immunoscore are critical determinants of dissemination to distant 
metastasis. Sci Transl Med 8, 327ra326 (2016). 
130. Z. K. Ballas, C. M. Buchta, T. R. Rosean, J. W. Heusel and M. R. Shey, Role of NK 
cell subsets in organ-specific murine melanoma metastasis. PLoS ONE 8, e65599 (2013). 
	 98 
131. G. Gundem, P. Van Loo, B. Kremeyer, L. B. Alexandrov, J. M. Tubio, E. 
Papaemmanuil, D. S. Brewer, H. M. Kallio, G. Hognas, M. Annala, K. Kivinummi, V. 
Goody, C. Latimer, S. O'Meara, K. J. Dawson, W. Isaacs, M. R. Emmert-Buck, M. Nykter, C. 
Foster, Z. Kote-Jarai, D. Easton, H. C. Whitaker, I. P. U. Group, D. E. Neal, C. S. Cooper, R. 
A. Eeles, T. Visakorpi, P. J. Campbell, U. McDermott, D. C. Wedge and G. S. Bova, The 
evolutionary history of lethal metastatic prostate cancer. Nature,  (2015). 
132. S. S. McAllister and R. A. Weinberg, The tumour-induced systemic environment as a 
critical regulator of cancer progression and metastasis. Nat Cell Biol 16, 717-727 (2014). 
133. S. Hiratsuka, K. Nakamura, S. Iwai, M. Murakami, T. Itoh, H. Kijima, J. M. Shipley, 
R. M. Senior and M. Shibuya, MMP9 induction by vascular endothelial growth factor 
receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289-300 (2002). 
134. C. F. Wu, L. Andzinski, N. Kasnitz, A. Kroger, F. Klawonn, S. Lienenklaus, S. Weiss 
and J. Jablonska, The lack of type I interferon induces neutrophil-mediated pre-metastatic 
niche formation in the mouse lung. Int J Cancer,  (2015). 
135. S. Hiratsuka, S. Ishibashi, T. Tomita, A. Watanabe, S. Akashi-Takamura, M. 
Murakami, H. Kijima, K. Miyake, H. Aburatani and Y. Maru, Primary tumours modulate 
innate immune signalling to create pre-metastatic vascular hyperpermeability foci. Nat 
Commun 4, 1853 (2013). 
136. J. Sceneay, M. T. Chow, A. Chen, H. M. Halse, C. S. Wong, D. M. Andrews, E. K. 
Sloan, B. S. Parker, D. D. Bowtell, M. J. Smyth and A. Moller, Primary tumor hypoxia 
recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell 
cytotoxicity in the premetastatic niche. Cancer Res 72, 3906-3911 (2012). 
137. T. Bald, T. Quast, J. Landsberg, M. Rogava, N. Glodde, D. Lopez-Ramos, J. 
Kohlmeyer, S. Riesenberg, D. van den Boorn-Konijnenberg, C. Homig-Holzel, R. Reuten, B. 
Schadow, H. Weighardt, D. Wenzel, I. Helfrich, D. Schadendorf, W. Bloch, M. E. Bianchi, C. 
Lugassy, R. L. Barnhill, M. Koch, B. K. Fleischmann, I. Forster, W. Kastenmuller, W. 
Kolanus, M. Holzel, E. Gaffal and T. Tuting, Ultraviolet-radiation-induced inflammation 
promotes angiotropism and metastasis in melanoma. Nature 507, 109-113 (2014). 
138. R. N. Kaplan, R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent, C. Costa, D. D. 
MacDonald, D. K. Jin, K. Shido, S. A. Kerns, Z. Zhu, D. Hicklin, Y. Wu, J. L. Port, N. 
Altorki, E. R. Port, D. Ruggero, S. V. Shmelkov, K. K. Jensen, S. Rafii and D. Lyden, 
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. 
Nature 438, 820-827 (2005). 
139. A. Riedel, D. Shorthouse, L. Haas, B. A. Hall and J. Shields, Tumor-induced stromal 
reprogramming drives lymph node transformation. Nat Immunol,  (2016). 
140. W. Zhang, C. Zhang, W. Li, J. Deng, A. Herrmann, S. J. Priceman, W. Liang, S. 
Shen, S. K. Pal, D. S. Hoon and H. Yu, CD8 T-cell immunosurveillance constrains lymphoid 
premetastatic myeloid cell accumulation. Eur J Immunol,  (2014). 
141. W. Zhang, S. K. Pal, X. L. Liu, C. M. Yang, S. Allahabadi, S. Bhanji, R. A. Figlin, H. 
Yu and K. L. Reckamp, Myeloid Clusters Are Associated with a Pro-Metastatic Environment 
	 99 
and Poor Prognosis in Smoking-Related Early Stage Non-Small Cell Lung Cancer. PLoS 
ONE 8, e65121 (2013). 
142. M. Skobe, T. Hawighorst, D. G. Jackson, R. Prevo, L. Janes, P. Velasco, L. Riccardi, 
K. Alitalo, K. Claffey and M. Detmar, Induction of tumor lymphangiogenesis by VEGF-C 
promotes breast cancer metastasis. Nature Medicine 7, 192-198 (2001). 
143. S. Matsukuma, T. Kono, H. Takeo, Y. Hamakawa and K. Sato, Tumor-to-tumor 
metastasis from lung cancer: a clinicopathological postmortem study. Virchows Archiv 463, 
525-534 (2013). 
144. M. Y. Kim, T. Oskarsson, S. Acharyya, D. X. Nguyen, X. H. Zhang, L. Norton and J. 
Massague, Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009). 
145. D. Vermijlen, D. Luo, C. J. Froelich, J. P. Medema, J. A. Kummer, E. Willems, F. 
Braet and E. Wisse, Hepatic natural killer cells exclusively kill splenic/blood natural killer-
resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol 72, 668-676 (2002). 
146. H. Peng, X. Jiang, Y. Chen, D. K. Sojka, H. Wei, X. Gao, R. Sun, W. M. Yokoyama 
and Z. Tian, Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. 
J Clin Invest 123, 1444-1456 (2013). 
147. D. K. Sojka, B. Plougastel-Douglas, L. Yang, M. A. Pak-Wittel, M. N. Artyomov, Y. 
Ivanova, C. Zhong, J. M. Chase, P. B. Rothman, J. Yu, J. K. Riley, J. Zhu, Z. Tian and W. M. 
Yokoyama, Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and 
conventional splenic NK cells. Elife 3, e01659 (2014). 
148. K. Takeda, E. Cretney, Y. Hayakawa, T. Ota, H. Akiba, K. Ogasawara, H. Yagita, K. 
Kinoshita, K. Okumura and M. J. Smyth, TRAIL identifies immature natural killer cells in 
newborn mice and adult mouse liver. Blood 105, 2082-2089 (2005). 
149. R. N. Hanna, C. Cekic, D. Sag, R. Tacke, G. D. Thomas, H. Nowyhed, E. Herrley, N. 
Rasquinha, S. McArdle, R. Wu, E. Peluso, D. Metzger, H. Ichinose, I. Shaked, G. Chodaczek, 
S. K. Biswas and C. C. Hedrick, Patrolling monocytes control tumor metastasis to the lung. 
Science 350, 985-990 (2015). 
150. S. Hiratsuka, S. Goel, W. S. Kamoun, Y. Maru, D. Fukumura, D. G. Duda and R. K. 
Jain, Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the 
lungs via E-selectin up-regulation. PNAS 108, 3725-3730 (2011). 
151. S. Paget, The distribution of secondary growths in cancer of the breast. The Lancet 
133, 571-573 (1889). 
152. A. D. Rhim, P. E. Oberstein, D. H. Thomas, E. T. Mirek, C. F. Palermo, S. A. Sastra, 
E. N. Dekleva, T. Saunders, C. P. Becerra, I. W. Tattersall, C. B. Westphalen, J. Kitajewski, 
M. G. Fernandez-Barrena, M. E. Fernandez-Zapico, C. Iacobuzio-Donahue, K. P. Olive and 
B. Z. Stanger, Stromal elements act to restrain, rather than support, pancreatic ductal 
adenocarcinoma. Cancer Cell 25, 735-747 (2014). 
	 100 
153. L. L. Wan, K. Pantel and Y. B. Kang, Tumor metastasis: moving new biological 
insights into the clinic. Nature Medicine 19, 1450-1464 (2013). 
154. P. F. Vazquez, M. J. Carlini, M. C. Daroqui, L. Colombo, M. L. Dalurzo, D. E. 
Smith, J. Grasselli, M. G. Pallotta, M. Ehrlich, E. D. Bal de Kier Joffe and L. Puricelli, TGF-
beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: 
implications for human non-small cell lung cancer. Clinical & Experimental Metastsis 30, 
993-1007 (2013). 
155. K. R. Fischer, A. Durrans, S. Lee, J. Sheng, F. Li, S. T. Wong, H. Choi, T. El Rayes, 
S. Ryu, J. Troeger, R. F. Schwabe, L. T. Vahdat, N. K. Altorki, V. Mittal and D. Gao, 
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to 
chemoresistance. Nature 527, 472-476 (2015). 
156. J. B. Wyckoff, J. G. Jones, J. S. Condeelis and J. E. Segall, A critical step in 
metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Research 60, 2504-
2511 (2000). 
157. J. B. Wyckoff, Y. Wang, E. Y. Lin, J. F. Li, S. Goswami, E. R. Stanley, J. E. Segall, 
J. W. Pollard and J. Condeelis, Direct visualization of macrophage-assisted tumor cell 
intravasation in mammary tumors. Cancer Research 67, 2649-2656 (2007). 
158. A. S. Harney, E. N. Arwert, D. Entenberg, Y. Wang, P. Guo, B. Z. Qian, M. H. 
Oktay, J. W. Pollard, J. G. Jones and J. S. Condeelis, Real-Time Imaging Reveals Local, 
Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi 
Macrophage-Derived VEGFA. Cancer Discov 5, 932-943 (2015). 
159. B. Qian, Y. Deng, J. H. Im, R. J. Muschel, Y. Zou, J. Li, R. A. Lang and J. W. 
Pollard, A distinct macrophage population mediates metastatic breast cancer cell 
extravasation, establishment and growth. PLoS One 4, e6562 (2009). 
160. A. Swierczak, A. D. Cook, J. C. Lenzo, C. M. Restall, J. P. Doherty, R. L. Anderson 
and J. A. Hamilton, The promotion of breast cancer metastasis caused by inhibition of CSF-
1R/CSF-1 signaling is blocked by targeting the G-CSF receptor. Cancer Immunol Res 2, 765-
776 (2014). 
161. L. Bonapace, M. M. Coissieux, J. Wyckoff, K. D. Mertz, Z. Varga, T. Junt and M. 
Bentires-Alj, Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting 
angiogenesis. Nature,  (2014). 
162. L. H. Tai, C. T. de Souza, S. Belanger, L. Ly, A. A. Alkayyal, J. Zhang, J. L. Rintoul, 
A. A. Ananth, T. Lam, C. J. Breitbach, T. J. Falls, D. H. Kirn, J. C. Bell, A. P. Makrigiannis 
and R. A. Auer, Preventing postoperative metastatic disease by inhibiting surgery-induced 
dysfunction in Natural Killer cells. Cancer Research 73, 97-107 (2013). 
163. O. A. Martin, R. L. Anderson, P. A. Russell, R. A. Cox, A. Ivashkevich, A. 
Swierczak, J. P. Doherty, D. H. Jacobs, J. Smith, S. Siva, P. E. Daly, D. L. Ball, R. F. Martin 
and M. P. MacManus, Mobilization of viable tumor cells into the circulation during radiation 
therapy. Int J Radiat Oncol Biol Phys 88, 395-403 (2014). 
	 101 
164. G. Bouchard, G. Bouvette, H. Therriault, R. Bujold, C. Saucier and B. Paquette, Pre-
irradiation of mouse mammary gland stimulates cancer cell migration and development of 
lung metastases. Br J Cancer 109, 1829-1838 (2013). 
165. I. Sofia Vala, L. R. Martins, N. Imaizumi, R. J. Nunes, J. Rino, F. Kuonen, L. M. 
Carvalho, C. Ruegg, I. M. Grillo, J. T. Barata, M. Mareel and S. C. Santos, Low doses of 
ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS 
One 5, e11222 (2010). 
166. J. Hobson, P. Gummadidala, B. Silverstrim, D. Grier, J. Bunn, T. James and M. 
Rincon, Acute inflammation induced by the biopsy of mouse mammary tumors promotes the 
development of metastasis. Breast Cancer Research and Treatment 139, 391-401 (2013). 
167. A. M. Barradas and L. W. Terstappen, Towards the biological understanding of CTC: 
capture technologies, definitions and potential to create metastasis. Cancers (Basel) 5, 1919-
1642 (2013). 
168. N. Aceto, A. Bardia, D. T. Miyamoto, M. C. Donaldson, B. S. Wittner, J. A. Spencer, 
M. Yu, A. Pely, A. Engstrom, H. Zhu, B. W. Brannigan, R. Kapur, S. L. Stott, T. Shioda, S. 
Ramaswamy, D. T. Ting, C. P. Lin, M. Toner, D. A. Haber and S. Maheswaran, Circulating 
tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110-1122 
(2014). 
169. S. L. Stott, R. J. Lee, S. Nagrath, M. Yu, D. T. Miyamoto, L. Ulkus, E. J. Inserra, M. 
Ulman, S. Springer, Z. Nakamura, A. L. Moore, D. I. Tsukrov, M. E. Kempner, D. M. Dahl, 
C. L. Wu, A. J. Iafrate, M. R. Smith, R. G. Tompkins, L. V. Sequist, M. Toner, D. A. Haber 
and S. Maheswaran, Isolation and characterization of circulating tumor cells from patients 
with localized and metastatic prostate cancer. Sci Transl Med 2, 25ra23 (2010). 
170. N. Hanna and I. J. Fidler, Role of natural killer cells in the destruction of circulating 
tumor emboli. J Natl Cancer Inst 65, 801-809 (1980). 
171. M. Paolino, A. Choidas, S. Wallner, B. Pranjic, I. Uribesalgo, S. Loeser, A. M. 
Jamieson, W. Y. Langdon, F. Ikeda, J. P. Fededa, S. J. Cronin, R. Nitsch, C. Schultz-
Fademrecht, J. Eickhoff, S. Menninger, A. Unger, R. Torka, T. Gruber, R. Hinterleitner, G. 
Baier, D. Wolf, A. Ullrich, B. M. Klebl and J. M. Penninger, The E3 ligase Cbl-b and TAM 
receptors regulate cancer metastasis via natural killer cells. Nature,  (2014). 
172. B. Nieswandt, M. Hafner, B. Echtenacher and D. N. Mannel, Lysis of tumor cells by 
natural killer cells in mice is impeded by platelets. Cancer Research 59, 1295-1300 (1999). 
173. J. S. Palumbo, K. E. Talmage, J. V. Massari, C. M. La Jeunesse, M. J. Flick, K. W. 
Kombrinck, M. Jirouskova and J. L. Degen, Platelets and fibrin(ogen) increase metastatic 
potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105, 178-
185 (2005). 
174. D. L. Adams, S. S. Martin, R. K. Alpaugh, M. Charpentier, S. Tsai, R. C. Bergan, I. 
M. Ogden, W. Catalona, S. Chumsri, C. M. Tang and M. Cristofanilli, Circulating giant 
macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A,  (2014). 
	 102 
175. D. G. Duda, A. M. Duyverman, M. Kohno, M. Snuderl, E. J. Steller, D. Fukumura 
and R. K. Jain, Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl 
Acad Sci U S A 107, 21677-21682 (2010). 
176. M. Roblek, M. Calin, M. Schlesinger, D. Stan, R. Zeisig, M. Simionescu, G. Bendas 
and L. Borsig, Targeted delivery of CCR2 antagonist to activated pulmonary endothelium 
prevents metastasis. J Control Release 220, 341-347 (2015). 
177. T. Kitamura, B. Z. Qian, D. Soong, L. Cassetta, R. Noy, G. Sugano, Y. Kato, J. Li 
and J. W. Pollard, CCL2-induced chemokine cascade promotes breast cancer metastasis by 
enhancing retention of metastasis-associated macrophages. J Exp Med 212, 1043-1059 
(2015). 
178. B. Z. Qian, J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. 
A. Snyder and J. W. Pollard, CCL2 recruits inflammatory monocytes to facilitate breast-
tumour metastasis. Nature 475, 222-225 (2011). 
179. J. A. Malek, A. Martinez, E. Mery, G. Ferron, R. Huang, C. Raynaud, E. Jouve, J. P. 
Thiery, D. Querleu and A. Rafii, Gene expression analysis of matched ovarian primary 
tumors and peritoneal metastasis. J Transl Med 10, 121 (2012). 
180. J. D. Spicer, B. McDonald, J. J. Cools-Lartigue, S. C. Chow, B. Giannias, P. Kubes 
and L. E. Ferri, Neutrophils promote liver metastasis via Mac-1-mediated interactions with 
circulating tumor cells. Cancer Research 72, 3919-3927 (2012). 
181. A. K. Gupta, S. Giaglis, P. Hasler and S. Hahn, Efficient neutrophil extracellular trap 
induction requires mobilization of both intracellular and extracellular calcium pools and is 
modulated by cyclosporine A. PLoS One 9, e97088 (2012). 
182. E. Kolaczkowska and P. Kubes, Neutrophil recruitment and function in health and 
inflammation. Nature Reviews 13, 159-175 (2013). 
183. J. Cools-Lartigue, J. Spicer, B. McDonald, S. Gowing, S. Chow, B. Giannias, F. 
Bourdeau, P. Kubes and L. Ferri, Neutrophil extracellular traps sequester circulating tumor 
cells and promote metastasis. Journal of Clinical Investigation 123, 3446-3458 (2013). 
184. M. W. Teng, J. B. Swann, C. M. Koebel, R. D. Schreiber and M. J. Smyth, Immune-
mediated dormancy: an equilibrium with cancer. J Leukoc Biol 84, 988-993 (2008). 
185. J. L. Phillips and D. C. Currow, Cancer as a chronic disease. Collegian 17, 47-50 
(2010). 
186. X. H. Zhang, M. Giuliano, M. V. Trivedi, R. Schiff and C. K. Osborne, Metastasis 
dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res 19, 6389-6397 (2013). 
187. C. Y. Slaney, J. Rautela and B. S. Parker, The emerging role of immunosurveillance 
in dictating metastatic spread in breast cancer. Cancer Research 73, 5852-5857 (2013). 
	 103 
188. K. J. Luzzi, I. C. MacDonald, E. E. Schmidt, N. Kerkvliet, V. L. Morris, A. F. 
Chambers and A. C. Groom, Multistep nature of metastatic inefficiency: dormancy of solitary 
cells after successful extravasation and limited survival of early micrometastases. Am J 
Pathol 153, 865-873 (1998). 
189. P. Bragado, Y. Estrada, F. Parikh, S. Krause, C. Capobianco, H. G. Farina, D. M. 
Schewe and J. A. Aguirre-Ghiso, TGF-beta2 dictates disseminated tumour cell fate in target 
organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol 15, 1351-1361 
(2013). 
190. H. Gao, G. Chakraborty, A. P. Lee-Lim, Q. Mo, M. Decker, A. Vonica, R. Shen, E. 
Brogi, A. H. Brivanlou and F. G. Giancotti, The BMP inhibitor Coco reactivates breast cancer 
cells at lung metastatic sites. Cell 150, 764-779 (2012). 
191. M. S. O'Reilly, L. Holmgren, Y. Shing, C. Chen, R. A. Rosenthal, M. Moses, W. S. 
Lane, Y. Cao, E. H. Sage and J. Folkman, Angiostatin: a novel angiogenesis inhibitor that 
mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328 (1994). 
192. Y. Kienast, L. von Baumgarten, M. Fuhrmann, W. E. Klinkert, R. Goldbrunner, J. 
Herms and F. Winkler, Real-time imaging reveals the single steps of brain metastasis 
formation. Nat Med 16, 116-122 (2010). 
193. E. K. Bartlett, P. Fetsch, A. C. Filie, A. Abati, S. M. Steinberg, J. R. Wunderlich, D. 
E. White, D. J. Stephens, F. M. Marincola, S. A. Rosenberg and U. S. Kammula, Human 
Melanoma Metastases Demonstrate Non-Stochastic Site-Specific Antigen Heterogeneity that 
Correlates with T Cell Infiltration. Clin Cancer Res,  (2014). 
194. J. D. Farrar, K. H. Katz, J. Windsor, G. Thrush, R. H. Scheuermann, J. W. Uhr and N. 
E. Street, Cancer Dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in 
establishing and maintaining the tumor-dormant state. Journal of Immunology 162, 2842-
2849 (1999). 
195. J. Eyles, A. L. Puaux, X. J. Wang, B. Toh, C. Prakash, M. Hong, T. G. Tan, L. 
Zheng, L. C. Ong, Y. Jin, M. Kato, A. Prevost-Blondel, P. Chow, H. Yang and J. P. 
Abastado, Tumor cells disseminate early, but immunosurveillance limits metastatic 
outgrowth, in a mouse model of melanoma. Journal of Clinical Investigation 120, 2030–2039 
(2010). 
196. G. Erdag, J. T. Schaefer, M. E. Smolkin, D. H. Deacon, S. M. Shea, L. T. Dengel, J. 
W. Patterson and C. L. Slingluff, Immunotype and immunohistologic characteristics of 
tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. 
Cancer Research 72, 1070-1080 (2012). 
197. E. Giarelli, Cancer vaccines: a new frontier in prevention and treatment. Oncology 
(Williston Park) 21, 11-17; discussion 18 (2007). 
198. E. Anassi and U. A. Ndefo, Sipuleucel-T (provenge) injection: the first 
immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T 36, 197-202 
(2011). 
	 104 
199. L. Bonifaz, D. Bonnyay, K. Mahnke, M. Rivera, M. C. Nussenzweig and R. M. 
Steinman, Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the 
steady state leads to antigen presentation on major histocompatibility complex class I 
products and peripheral CD8+ T cell tolerance. Journal of Experimental Medicine 196, 1627-
1638 (2002). 
200. V. Bronte, D. B. Chappell, E. Apolloni, A. Cabrelle, M. Wang, P. Hwu and N. P. 
Restifo, Unopposed production of granulocyte-macrophage colony-stimulating factor by 
tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J 
Immunol 162, 5728-5737 (1999). 
201. C. Hoeller, O. Michielin, P. A. Ascierto, Z. Szabo and C. U. Blank, Systematic 
review of the use of granulocyte-macrophage colony-stimulating factor in patients with 
advanced melanoma. Cancer Immunol Immunother,  (2016). 
202. S. Lee and K. Margolin, Cytokines in cancer immunotherapy. Cancers (Basel) 3, 
3856-3893 (2011). 
203. K. M. Hege, K. Jooss and D. Pardoll, GM-CSF gene-modifed cancer cell 
immunotherapies: of mice and men. Int Rev Immunol 25, 321-352 (2006). 
204. M. Ardolino, C. S. Azimi, A. Iannello, T. N. Trevino, L. Horan, L. Zhang, W. Deng, 
A. M. Ring, S. Fischer, K. C. Garcia and D. H. Raulet, Cytokine therapy reverses NK cell 
anergy in MHC-deficient tumors. J Clin Invest 124, 4781-4794 (2014). 
205. J. Vom Berg, M. Vrohlings, S. Haller, A. Haimovici, P. Kulig, A. Sledzinska, M. 
Weller and B. Becher, Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-
mediated glioma rejection. J Exp Med 210, 2803-2811 (2013). 
206. A. M. Levin, D. L. Bates, A. M. Ring, C. Krieg, J. T. Lin, L. Su, I. Moraga, M. E. 
Raeber, G. R. Bowman, P. Novick, V. S. Pande, C. G. Fathman, O. Boyman and K. C. 
Garcia, Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. 
Nature 484, 529-533 (2012). 
207. S. Letourneau, E. M. van Leeuwen, C. Krieg, C. Martin, G. Pantaleo, J. Sprent, C. D. 
Surh and O. Boyman, IL-2/anti-IL-2 antibody complexes show strong biological activity by 
avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci U S A 107, 
2171-2176 (2010). 
208. R. B. Delconte, T. B. Kolesnik, L. F. Dagley, J. Rautela, W. Shi, E. M. Putz, K. 
Stannard, J. G. Zhang, C. Teh, M. Firth, T. Ushiki, C. E. Andoniou, M. A. Degli-Esposti, P. 
P. Sharp, C. E. Sanvitale, G. Infusini, N. P. Liau, E. M. Linossi, C. J. Burns, S. Carotta, D. H. 
Gray, C. Seillet, D. S. Hutchinson, G. T. Belz, A. I. Webb, W. S. Alexander, S. S. Li, A. N. 
Bullock, J. J. Babon, M. J. Smyth, S. E. Nicholson and N. D. Huntington, CIS is a potent 
checkpoint in NK cell-mediated tumor immunity. Nat Immunol 17, 816-824 (2016). 
209. T. A. Stoklasek, K. S. Schluns and L. Lefrancois, Combined IL-15/IL-15Ralpha 
immunotherapy maximizes IL-15 activity in vivo. J Immunol 177, 6072-6080 (2006). 
	 105 
210. R. F. Kefford, Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann 
Oncol 14, 358-365 (2003). 
211. J. M. Kirkwood, A. A. Tarhini, S. J. Moschos and M. C. Panelli, Adjuvant therapy 
with high-dose interferon alpha2b in patients with high-risk stage IIB/III melanoma. Nat Clin 
Pract Oncol 5, 2-3 (2008). 
212. J. M. Kirkwood, J. G. Ibrahim, J. A. Sosman, V. K. Sondak, S. S. Agarwala, M. S. 
Ernstoff and U. Rao, High-dose interferon alfa-2b significantly prolongs relapse-free and 
overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage 
IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. Journal of Clinical 
Oncology 19, 2370-2380 (2001). 
213. J. M. Kirkwood, J. Ibrahim, D. H. Lawson, M. B. Atkins, S. S. Agarwala, K. Collins, 
R. Mascari, D. M. Morrissey and P. B. Chapman, High-Dose interferon alfa-2b does not 
diminish antibody response to GM2 vaccination in patients with resected melanoma: results 
of the Multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol 
19, 1430-1436 (2001). 
214. S. K. Tey, Adoptive T-cell therapy: adverse events and safety switches. Clin Transl 
Immunology 3, e17 (2014). 
215. M. R. Parkhurst, J. P. Riley, M. E. Dudley and S. A. Rosenberg, Adoptive transfer of 
autologous natural killer cells leads to high levels of circulating natural killer cells but does 
not mediate tumor regression. Clin Cancer Res 17, 6287-6297 (2011). 
216. C. H. June, Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117, 1466-
1476 (2007). 
217. J. N. Brudno, R. P. Somerville, V. Shi, J. J. Rose, D. C. Halverson, D. H. Fowler, J. 
C. Gea-Banacloche, S. Z. Pavletic, D. D. Hickstein, T. L. Lu, S. A. Feldman, A. T. Iwamoto, 
R. Kurlander, I. Maric, A. Goy, B. G. Hansen, J. S. Wilder, B. Blacklock-Schuver, F. T. 
Hakim, S. A. Rosenberg, R. E. Gress and J. N. Kochenderfer, Allogeneic T Cells That 
Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell 
Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation 
Without Causing Graft-Versus-Host Disease. J Clin Oncol 34, 1112-1121 (2016). 
218. M. Kalos and C. H. June, Adoptive T cell transfer for cancer immunotherapy in the 
era of synthetic biology. Immunity 39, 49-60 (2013). 
219. Z. B. Davis, M. Felices, M. R. Verneris and J. S. Miller, Natural Killer Cell Adoptive 
Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J 21, 486-491 
(2015). 
220. M. Cheng, Y. Chen, W. Xiao, R. Sun and Z. Tian, NK cell-based immunotherapy for 
malignant diseases. Cell Mol Immunol 10, 230-252 (2013). 
221. A. Bransi, O. C. Salgado, M. Beffinger, K. Milo, K. Silina, H. Yagita, B. Becher, A. 
Knuth and M. van den Broek, Rational combination of immunotherapies with clinical 
efficacy in mice with advanced cancer. Cancer Immunol Res 3, 1279-1288 (2015). 
	 106 
222. D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat 
Rev Cancer 12, 252-264 (2012). 
223. M. A. Postow, M. K. Callahan and J. D. Wolchok, Immune Checkpoint Blockade in 
Cancer Therapy. J Clin Oncol 33, 1974-1982 (2015). 
224. S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. 
McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. 
Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. 
Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. 
McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton and M. Sznol, Safety, activity, and 
immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 366, 2443-2454 (2012). 
225. O. Hamid, C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, J. D. Wolchok, P. 
Hersey, R. W. Joseph, J. S. Weber, R. Dronca, T. C. Gangadhar, A. Patnaik, H. Zarour, A. M. 
Joshua, K. Gergich, J. Elassaiss-Schaap, A. Algazi, C. Mateus, P. Boasberg, P. C. Tumeh, B. 
Chmielowski, S. W. Ebbinghaus, X. N. Li, S. P. Kang and A. Ribas, Safety and tumor 
responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369, 134-144 (2013). 
226. J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. 
Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. 
A. Kronenberg, B. U. Agunwamba, X. L. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. 
Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta and M. Sznol, Nivolumab plus 
Ipilimumab in Advanced Melanoma. New England Journal of Medicine 369, 122-133 (2013). 
227. A. J. Korman, K. S. Peggs and J. P. Allison, Checkpoint blockade in cancer 
immunotherapy. Adv Immunol 90, 297-339 (2006). 
228. D. M. Benson, Jr., C. E. Bakan, A. Mishra, C. C. Hofmeister, Y. Efebera, B. 
Becknell, R. A. Baiocchi, J. Zhang, J. Yu, M. K. Smith, C. N. Greenfield, P. Porcu, S. M. 
Devine, R. Rotem-Yehudar, G. Lozanski, J. C. Byrd and M. A. Caligiuri, The PD-1/PD-L1 
axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for 
CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286-2294 (2010). 
229. A. Stojanovic, N. Fiegler, M. Brunner-Weinzierl and A. Cerwenka, CTLA-4 is 
expressed by activated mouse NK cells and inhibits NK Cell IFN-gamma production in 
response to mature dendritic cells. J Immunol 192, 4184-4191 (2014). 
230. L. M. Francisco, P. T. Sage and A. H. Sharpe, The PD-1 pathway in tolerance and 
autoimmunity. Immunol Rev 236, 219-242 (2010). 
231. P. Sharma and J. P. Allison, Immune checkpoint targeting in cancer therapy: toward 
combination strategies with curative potential. Cell 161, 205-214 (2015). 
232. J. F. Grosso, C. C. Kelleher, T. J. Harris, C. H. Maris, E. L. Hipkiss, A. De Marzo, R. 
Anders, G. Netto, D. Getnet, T. C. Bruno, M. V. Goldberg, D. M. Pardoll and C. G. Drake, 
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-
tolerance systems. J Clin Invest 117, 3383-3392 (2007). 
	 107 
233. S. Koyama, E. A. Akbay, Y. Y. Li, G. S. Herter-Sprie, K. A. Buczkowski, W. G. 
Richards, L. Gandhi, A. J. Redig, S. J. Rodig, H. Asahina, R. E. Jones, M. M. Kulkarni, M. 
Kuraguchi, S. Palakurthi, P. E. Fecci, B. E. Johnson, P. A. Janne, J. A. Engelman, S. P. 
Gangadharan, D. B. Costa, G. J. Freeman, R. Bueno, F. S. Hodi, G. Dranoff, K. K. Wong and 
P. S. Hammerman, Adaptive resistance to therapeutic PD-1 blockade is associated with 
upregulation of alternative immune checkpoints. Nat Commun 7, 10501 (2016). 
234. R. J. Johnston, X. Yu and J. L. Grogan, The checkpoint inhibitor TIGIT limits 
antitumor and antiviral CD8+ T cell responses. Oncoimmunology 4, e1036214 (2015). 
235. S. Spranger, R. M. Spaapen, Y. Zha, J. Williams, Y. Meng, T. T. Ha and T. F. 
Gajewski, Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor 
microenvironment is driven by CD8(+) T cells. Sci Transl Med 5, 200ra116 (2013). 
236. M. K. Callahan, M. A. Postow and J. D. Wolchok, CTLA-4 and PD-1 Pathway 
Blockade: Combinations in the Clinic. Front Oncol 4, 385 (2014). 
237. M. F. Sanmamed, F. Pastor, A. Rodriguez, J. L. Perez-Gracia, M. E. Rodriguez-Ruiz, 
M. Jure-Kunkel and I. Melero, Agonists of Co-stimulation in Cancer Immunotherapy 
Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 42, 640-655 
(2015). 
238. S. N. Linch, M. J. McNamara and W. L. Redmond, OX40 Agonists and Combination 
Immunotherapy: Putting the Pedal to the Metal. Front Oncol 5, 34 (2015). 
239. C. Riether, C. Schurch and A. F. Ochsenbein, Modulating CD27 signaling to treat 
cancer. Oncoimmunology 1, 1604-1606 (2012). 
240. L. J. Thomas, L. Z. He, H. Marsh and T. Keler, Targeting human CD27 with an 
agonist antibody stimulates T-cell activation and antitumor immunity. Oncoimmunology 3, 
e27255 (2014). 
241. R. H. Vonderheide, Overview of anti-CD40 biology and initial clinical trials. CITN 
Investigator Meeting,  (2011). 
242. P. Johnson, R. Challis, F. Chowdhury, Y. Gao, M. Harvey, T. Geldart, P. Kerr, C. 
Chan, A. Smith, N. Steven, C. Edwards, M. Ashton-Key, E. Hodges, A. Tutt, C. Ottensmeier, 
M. Glennie and A. Williams, Clinical and biological effects of an agonist anti-CD40 
antibody: a Cancer Research UK phase I study. Clin Cancer Res 21, 1321-1328 (2015). 
243. K. L. Brunekreeft, C. Strohm, M. J. Gooden, A. A. Rybczynska, H. W. Nijman, G. U. 
Grigoleit, W. Helfrich, E. Bremer, D. Siegmund, H. Wajant and M. de Bruyn, Targeted 
delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of 
cancer cell death. Mol Cancer 13, 85 (2014). 
244. S. Kaczanowska, A. M. Joseph and E. Davila, TLR agonists: our best frenemy in 
cancer immunotherapy. J Leukoc Biol 93, 847-863 (2013). 
245. K. Takeda and S. Akira, TLR signaling pathways. Seminars in Immunology 16, 3-9 
(2004). 
	 108 
246. K. Gogoll, P. Stein, H. Wei, H. Schild, M. Radsak and P. Langguth, Comparative 
transcutaneous immunization with imiquimod-containing ointments and potential of in vitro 
methods to predict effects. Biopharm Drug Dispos 33, 218-228 (2012). 
247. R. Q. Sven and P. G. Harald, Imiquimod 3.75% cream (Zyclara) for the treatment of 
actinic keratoses. Expert Opin Pharmacother 12, 451-461 (2011). 
248. R. L. Miller, J. F. Gerster, M. L. Owens, H. B. Slade and M. A. Tomai, Imiquimod 
applied topically: a novel immune response modifer and new class of drug. Int J 
Immunopharmacol 21, 1-14 (1999). 
249. E. Vacchelli, L. Galluzzi, A. Eggermont, W. H. Fridman, J. Galon, C. Sautes-
Fridman, E. Tartour, L. Zitvogel and G. Kroemer, Trial watch: FDA-approved Toll-like 
receptor agonists for cancer therapy. Oncoimmunology 1, 894-907 (2012). 
250. H. A. Smith and Y. Kang, Acute infection induces a metastatic niche: a double 
menace for cancer patients. Clin Cancer Res 19, 4547-4549 (2013). 
251. B. Didona, R. Benucci, P. Amerio, F. Canzona, O. Rienzo and R. Cavalieri, Primary 
cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). British 
Journal of Dermatology 150, 1198-1201 (2004). 
252. E. A. Coors, G. Schuler and P. Von den Driesch, Topical imiquimod as treatment for 
different kinds of cutaneous lymphoma. European Journal of Dermatology 16, 391-393 
(2006). 
253. T. Junt and W. Barchet, Translating nucleic acid-sensing pathways into therapies. Nat 
Rev Immunol 15, 529-544 (2015). 
254. D. L. Moughon, H. He, S. Schokrpur, Z. K. Jiang, M. Yaqoob, J. David, C. Lin, M. 
L. Iruela-Arispe, O. Dorigo and L. Wu, Macrophage Blockade Using CSF1R Inhibitors 
Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial 
Ovarian Cancer. Cancer Res 75, 4742-4752 (2015). 
255. S. M. Pyonteck, L. Akkari, A. J. Schuhmacher, R. L. Bowman, L. Sevenich, D. F. 
Quail, O. C. Olson, M. L. Quick, J. T. Huse, V. Teijeiro, M. Setty, C. S. Leslie, Y. Oei, A. 
Pedraza, J. A. Zhang, C. W. Brennan, J. C. Sutton, E. C. Holland, D. Daniel and J. A. Joyce, 
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature 
Medicine 19, 1264-1272 (2013). 
256. P. A. Cassier, A. Italiano, C. A. Gomez-Roca, C. Le Tourneau, M. Toulmonde, M. A. 
Cannarile, C. Ries, A. Brillouet, C. Muller, A. M. Jegg, A. M. Broske, M. Dembowski, K. 
Bray-French, C. Freilinger, G. Meneses-Lorente, M. Baehner, R. Harding, J. Ratnayake, K. 
Abiraj, N. Gass, K. Noh, R. D. Christen, L. Ukarma, E. Bompas, J. P. Delord, J. Y. Blay and 
D. Ruttinger, CSF1R inhibition with emactuzumab in locally advanced diffuse-type 
tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 
1 study. Lancet Oncol 16, 949-956 (2015). 
	 109 
257. J. Y. Hung, D. Horn, K. Woodruff, T. Prihoda, C. LeSaux, J. Peters, F. Tio and S. L. 
Abboud-Werner, Colony-stimulating factor 1 potentiates lung cancer bone metastasis. 
Laboratory Investigation 94, 371-381 (2014). 
258. I. Helfrich, N. Ullrich, P. Zigrino and D. Schadendorf, Primary tumor versus 
metastasis: new experimental models for studies on cancer cell homing and metastasis in 
melanoma. Pigment Cell Melanoma Res 27, 309-316 (2014). 
259. J. K. Park, S. J. Jang, S. W. Kang, S. Park, S. G. Hwang, W. J. Kim, J. H. Kang and 
H. D. Um, Establishment of animal model for the analysis of cancer cell metastasis during 
radiotherapy. Radiat Oncol 7, 153 (2012). 
260. H. J. Chen, J. Sun, Z. Huang, H. Hou, Jr., M. Arcilla, N. Rakhilin, D. J. Joe, J. Choi, 
P. Gadamsetty, J. Milsom, G. Nandakumar, R. Longman, X. K. Zhou, R. Edwards, J. Chen, 
K. Y. Chen, P. Bu, L. Wang, Y. Xu, R. Munroe, C. Abratte, A. D. Miller, Z. H. Gumus, M. 
Shuler, N. Nishimura, W. Edelmann, X. Shen and S. M. Lipkin, Comprehensive models of 
human primary and metastatic colorectal tumors in immunodeficient and immunocompetent 
mice by chemokine targeting. Nat Biotechnol 33, 656-660 (2015). 
261. E. Y. Lin, J. G. Jones, P. Li, U. Y. Zhu, K. D. Whitney, W. J. Muller and J. W. 
Pollard, Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer 
model provides a reliable model for human diseases. American Journal of Pathology 163, 
2113-2126 (2003). 
262. A. Ghochikyan, A. Davtyan, A. Hovakimyan, H. Davtyan, A. Poghosyan, A. Bagaev, 
R. I. Ataullakhanov, E. L. Nelson and M. G. Agadjanyan, Primary 4T1 tumor resection 
provides critical ‘‘window of opportunity’’ for immunotherapy. Clin Exp Metastasis 31, 185-
198 (2014). 
263. W. Tseng, X. Leong and E. Engleman, Orthotopic mouse model of colorectal cancer. 
J Vis Exp, 484 (2007). 
264. A. A. Hurwitz, B. A. Foster, J. P. Allison, N. M. Greenberg and E. D. Kwon, The 
TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol Chapter 20, Unit 20 25 
(2001). 
265. M. F. Denny, S. Yalavarthi, W. Zhao, S. G. Thacker, M. Anderson, A. R. Sandy, W. 
J. McCune and M. J. Kaplan, A distinct subset of proinflammatory neutrophils isolated from 
patients with systemic lupus erythematosus induces vascular damage and synthesizes type I 
IFNs. Journal of Immunology 185, 3779-3779 (2010). 
266. C. Chizzolini and N. C. Brembilla, Prostaglandin E2: igniting the fire. Immunol Cell 
Biol 87, 510-511 (2009). 
267. S. Zelenay, A. G. van der Veen, J. P. Bottcher, K. J. Snelgrove, N. Rogers, S. E. 
Acton, P. Chakravarty, M. R. Girotti, R. Marais, S. A. Quezada, E. Sahai and E. S. C. Reis, 
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 162, 1257-
1270 (2015). 
	 110 
268. L. Xu, J. Stevens, M. B. Hilton, S. Seaman, T. P. Conrads, T. D. Veenstra, D. 
Logsdon, H. Morris, D. A. Swing, N. L. Patel, J. Kalen, D. C. Haines, E. Zudaire and B. St 
Croix, COX-2 Inhibition Potentiates Antiangiogenic Cancer Therapy and Prevents Metastasis 
in Preclinical Models. Sci Transl Med 6, 242ra284 (2014). 
269. C. Yao, D. Sakata, Y. Esaki, Y. Li, T. Matsuoka, K. Kuroiwa, Y. Sugimoto and S. 
Narumiya, Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell 
differentiation and Th17 cell expansion. Nat Med 15, 633-640 (2009). 
270. I. Kudo and M. Murakami, Prostaglandin E synthase, a terminal enzyme for 
prostaglandin E2 biosynthesis. J Biochem Mol Biol 38, 633-638 (2005). 
271. S. Rakoff-Nahoum and R. Medzhitov, Regulation of spontaneous intestinal 
tumorigenesis through the adaptor protein MyD88. Science 317, 124-127 (2007). 
272. C. E. Lewis and J. W. Pollard, Distinct role of macrophages in different tumor 
microenvironments. Cancer Res 66, 605-612 (2006). 
273. W. K. Chia, R. Ali and H. C. Toh, Aspirin as adjuvant therapy for colorectal cancer—
reinterpreting paradigms. Nature Reviews 9, 561-570 (2012). 
274. M. R. Young and S. Knies, Prostaglandin E production by Lewis lung carcinoma: 
mechanism for tumor establishment in vivo. J Natl Cancer Inst 72, 919-922 (1984). 
275. M. R. Young, M. E. Young and H. T. Wepsic, Effect of prostaglandin E2-producing 
nonmetastatic Lewis lung carcinoma cells on the migration of prostaglandin E2-responsive 
metastatic Lewis lung carcinoma cells. Cancer Res 47, 3679-3683 (1987). 
276. M. R. Young, R. A. Endicott, G. P. Duffie and H. T. Wepsic, Suppressor alveolar 
macrophages in mice bearing metastatic Lewis lung carcinoma tumors. J Leukoc Biol 42, 
682-688 (1987). 
277. F. A. Ran, P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott and F. Zhang, Genome 
engineering using the CRISPR-Cas9 system. Nat Protoc 8, 2281-2308 (2013). 
278. M. Murakami, H. Naraba, T. Tanioka, N. Semmyo, Y. Nakatani, F. Kojima, T. Ikeda, 
M. Fueki, A. Ueno, S. Oh and I. Kudo, Regulation of prostaglandin E2 biosynthesis by 
inducible membrane-associated prostaglandin E2 synthase that acts in concert with 
cyclooxygenase-2. J Biol Chem 275, 32783-32792 (2000). 
279. K. Watanabe, H. Ohkubo, H. Niwa, N. Tanikawa, N. Koda, S. Ito and Y. Ohmiya, 
Essential 110Cys in active site of membrane-associated prostaglandin E synthase-2. Biochem 
Biophys Res Commun 306, 577-581 (2003). 
280. S. Hara, D. Kamei, Y. Sasaki, A. Tanemoto, Y. Nakatani and M. Murakami, 
Prostaglandin E synthases: Understanding their pathophysiological roles through mouse 
genetic models. Biochimie 92, 651-659 (2010). 
	 111 
281. T. G. Montague, J. M. Cruz, J. A. Gagnon, G. M. Church and E. Valen, 
CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res 
42, W401-407 (2014). 
282. K. Takeda, H. Oshima, Y. Hayakawa, H. Akiba, M. Atsuta, T. Kobata, K. Kobayashi, 
M. Ito, H. Yagita and K. Okumura, CD27-mediated activation of murine NK cells. J Immunol 
164, 1741-1745 (2000). 
283. D. J. Roberts, N. A. Franklin, L. M. Kingeter, H. Yagita, A. L. Tutt, M. J. Glennie 
and T. N. Bullock, Control of established melanoma by CD27 stimulation is associated with 
enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating 
CD8(+) T cells. J Immunother 33, 769-779 (2010). 
284. L. Chiossone, J. Chaix, N. Fuseri, C. Roth, E. Vivier and T. Walzer, Maturation of 
mouse NK cells is a 4-stage developmental program. Blood 113, 5488-5496 (2009). 
285. T. Sakanishi and H. Yagita, Anti-tumor effects of depleting and non-depleting anti-
CD27 monoclonal antibodies in immune-competent mice. Biochem Biophys Res Commun 
393, 829-835 (2010). 
286. J. E. Smith-Garvin, G. A. Koretzky and M. S. Jordan, T cell activation. Annu Rev 
Immunol 27, 591-619 (2009). 
287. G. W. Swart, Activated leukocyte cell adhesion molecule (CD166/ALCAM): 
developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 
81, 313-321 (2002). 
288. T. G. Levin, A. E. Powell, P. S. Davies, A. D. Silk, A. D. Dismuke, E. C. Anderson, 
J. R. Swain and M. H. Wong, Characterization of the intestinal cancer stem cell marker 
CD166 in the human and mouse gastrointestinal tract. Gastroenterology 139, 2072-2082 
e2075 (2010). 
289. M. Iolyeva, S. Karaman, A. H. Willrodt, S. Weingartner, B. Vigl and C. Halin, Novel 
role for ALCAM in lymphatic network formation and function. FASEB J 27, 978-990 (2013). 
290. R. R. Braeuer, I. R. Watson, C. J. Wu, A. K. Mobley, T. Kamiya, E. Shoshan and M. 
Bar-Eli, Why is melanoma so metastatic? Pigment Cell Melanoma Res 27, 19-36 (2014). 
291. T. Michel, A. Poli, O. Domingues, M. Mauffray, M. Theresine, N. H. Brons, F. 
Hentges and J. Zimmer, Mouse lung and spleen natural killer cells have phenotypic and 
functional differences, in part influenced by macrophages. PLoS One 7, e51230 (2012). 
292. R. Virchow, An Address on the Value of Pathological Experiments. Br Med J 2, 198-
203 (1881). 
293. W. J. Murphy, L. Welniak, T. Back, J. Hixon, J. Subleski, N. Seki, J. M. Wigginton, 
S. E. Wilson, B. R. Blazar, A. M. Malyguine, T. J. Sayers and R. H. Wiltrout, Synergistic 
anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: 
coordination of dendritic and CD8+ cell responses. J Immunol 170, 2727-2733 (2003). 
	 112 
294. J. Honeychurch, M. J. Glennie, P. W. Johnson and T. M. Illidge, Anti-CD40 
monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-
dependent immunity to B-cell lymphoma. Blood 102, 1449-1457 (2003). 
295. A. L. Tutt, L. O'Brien, A. Hussain, G. R. Crowther, R. R. French and M. J. Glennie, 
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J 
Immunol 168, 2720-2728 (2002). 
296. J. G. Turner, A. L. Rakhmilevich, L. Burdelya, Z. Neal, M. Imboden, P. M. Sondel 
and H. Yu, Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK 
cells. J Immunol 166, 89-94 (2001). 
297. H. D. Lum, I. N. Buhtoiarov, B. E. Schmidt, G. Berke, D. M. Paulnock, P. M. Sondel 
and A. L. Rakhmilevich, In vivo CD40 ligation can induce T-cell-independent antitumor 
effects that involve macrophages. J Leukoc Biol 79, 1181-1192 (2006). 
298. A. L. Rakhmilevich, K. L. Alderson and P. M. Sondel, T-cell-independent antitumor 
effects of CD40 ligation. Int Rev Immunol 31, 267-278 (2012). 
299. D. L. Bajor, X. Xu, D. A. Torigian, R. Mick, L. R. Garcia, L. P. Richman, C. 
Desmarais, K. L. Nathanson, L. M. Schuchter, M. Kalos and R. H. Vonderheide, Immune 
activation and a 9-year ongoing complete remission following CD40 antibody therapy and 
metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res 2, 1051-1058 
(2014). 
300. R. Vezza, R. Roberti, G. G. Nenci and P. Gresele, Prostaglandin E2 potentiates 
platelet aggregation by priming protein kinase C. Blood 82, 2704-2713 (1993). 
301. L. M. Carlson, A. Rasmuson, H. Idborg, L. Segerstrom, P. J. Jakobsson, B. 
Sveinbjornsson and P. Kogner, Low-dose aspirin delays an inflammatory tumor progression 
in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis 34, 1081-1088 (2013). 
302. J. A. Baron, B. F. Cole, R. S. Sandler, R. W. Haile, D. Ahnen, R. Bresalier, G. 
McKeown-Eyssen, R. W. Summers, R. Rothstein, C. A. Burke, D. C. Snover, T. R. Church, J. 
I. Allen, M. Beach, G. J. Beck, J. H. Bond, T. Byers, E. R. Greenberg, J. S. Mandel, N. 
Marcon, L. A. Mott, L. Pearson, F. Saibil and R. U. van Stolk, A randomized trial of aspirin 




6.1 Rational combination of immunotherapies with clinical efficacy in mice with 
advanced cancer 
Ali Bransi1, Oscar Camilo Salgado1, Michal Beffinger1, Karim Milo1, Karina Silina1, Hideo 
Yagita2, Burkhard Becher1, Alexander Knuth3, and Maries van den Broek1 
Affiliations: 
1 Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland 
2 Novartis Institutes for Biomedical Research, CA 94608 Emeryville, California, USA 






















7. Curriculum vitae 
Michal Beffinger 
Date and Place of Birth: 12.12.1987, Gdansk, Poland 
Nationality: Polish 
Education 
11.2011 - 10.2016 Studies in the Cancer Biology Ph.D. Program 
Group of Prof. Dr. Maries van den Broek 
Institute of Experimental Immunology, University of Zurich, 
Switzerland 
Thesis: Immunotherapy of metastatic disease 
08.2011 - 09.2011 Science V course  
EU-funded training in knowledge transfer and scientific project 
management 
Innopomerania, PPNT Gdynia, Poland 
02.2010 - 08.2010 Erasmus exchange program studies 
Instituto Superior Técnico, Lisbon, Portugal 
Specialisation: Biological Engineering 
09.2006 - 06.2011 Master of Science and Engineering Studies 
Group of Dr. Eng. Anna Skwarska 
Department of Pharmaceutical Technology and Biochemistry, 
Gdansk University of Technology, Poland 
Specialization: Biotechnology of Medicines 
Thesis: Preclinical studies on the effect of imidazoacridinone 
C-1311 on the receptor tyrosine kinase FLT3 activity in human 
leukemia cells 
09.2003 - 06.2006 High School 
Fifth High School in Gdansk, Poland 
Grants 
06.2016 Swiss Life Jubiläumstiftung 
 
Publications 
Beffinger M., Montagnolo Y., Ohs I, Tugues S., Gagliardi A., Misljencevic N, Sutton J., 
Spörri R., Becher B., Gupta A. and van den Broek M. CSF1R-dependent monocytes are 
required for NK cell-mediated control of metastasis. 2016. Manuscript in preparation 
Bransi A., Salgado OC., Beffinger M., Milo K, Silina K., Yagita H., Becher B., Knuth A., 
van den Broek M., Rational combination of immunotherapies with clinical efficacy in mice 
with advanced cancer. Cancer Immunol Res. 3(11):1279-88. 
Skwarska A, Augustin E., Beffinger M., Wojtczyk A., Konicz S., Laskowska K., Polewska 
J., Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 
against FLT3-activated leukemia cells. Biochem Pharmacol. 2015;95(4):238-52 
Beffinger M., Skwarska A., The role of FLT3 kinase as an AML therapy target. Curr Pharm 
Des. 2012;18(19):2758-65 
 
	 125 
 
